OA18257A

OA18257A - Triazolopyrazinones as PDE 1 inhibitors.

Info

Publication number: OA18257A
Application number: OA1201700124
Authority: OA
Inventors: Jan Kehler; Mikkel JESSING; Lars Kyhn Rasmussen
Original assignee: H Lundbeck A/S
Priority date: 2014-10-10
Filing date: 2015-10-09
Publication date: 2018-09-17

Abstract

The present invention provides triazolopyrazinones as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.

Description

FIELD OF THE INVENTION

The présent invention provides compounds that are PDE1 enzyme inhibitors and their use as a médicament, in particular for the treatment of neurodegenerative disorders and psychiatrie disorders. The présent invention also provides pharmaceutical compositions comprising compounds ofthe invention and methods oftreating disorders using the compounds ofthe invention.

BACKGROUND OF THE INVENTION

Throughout this application, various publications are referenced in full. The disclosures of these publications are hereby incorporated by reference into this application to describe more fully the state ofthe art to which this invention pertains.

The second messenger cyclic Nucléotides (cNs), cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) play a major rôle in intracellular signal transduction cascade, by regulating cN-dependent protein kinases (PKA and PKG), EPACs (Exchange Protein Activated by cAMP), phosphoprotein phosphatases, and/or cN-gated cation channels. In neurons, this includes the activation of cAMP- and cGMP-dependent kinases and subséquent phosphorylation of proteins involved in acute régulation of synaptic transmission as well as in neuronal différentiation and survival. Intracellular concentrations of cAMP and cGMP are strictly regulated by the rate of biosynthesis by cyclases and by the rate of dégradation by phosphodiesterases (PDEs, EC 3.1.4.17). PDEs are bimetallic hydrolases that inactivate cAMP/cGMP by catalytic hydrolysis ofthe 3’-ester bond, forming the inactive 5’-monophosphate. Since PDEs provide the only means of degrading the cyclic nucléotides cAMP and cGMP in cells, PDEs play an essential rôle in cyclic nucléotide signalling. The catalytic activities of PDEs provide for breakdown of cNs over a spectrum of cN-concentrations in ail cells, and their varied regulatory mechanisms provide for intégration and crosstalk with myriad signalling pathways. Particular PDEs are targeted to discrète compartments within cells where they control cN level and sculpt microenvironments for a variety of cN signalosomes (Sharron H. Francis, Mitsi A. Blount, and Jackie D. Corbin. Physiol Rev 2011,91: 651-690).

On the basis of substrate specifîcity, the PDE families can be divided into three groups:

1) The cAMP-specific PDEs, which include PDE4, PDE7, and PDE8, 2) the cGMPselective enzymes PDE5 and PDE9, and 3) the dual-substrate PDEs, PDE1, PDE2, PDE3, as well as PDE10 and PDE11.

Previously named calmodulin-stimulated PDE (CaM-PDE), PDE1 is unique in that it is Ca2+-dependently regulated via calmodulin (CaM, a 16 kDa Ca2+-binding protein) complexed with four Ca2+ (for review, Sharron H. Francis, Mitsi A. Blount, and Jackie D. Corbin. Physiol Rev 2011, 91: 651-690). Thus, this family represents an interesting regulatory link between cyclic nucléotides and intracellular Ca2+. The PDE1 family is encoded by three genes: PDE1A (mapped on human chromosome 2q32), PDE1B (human chromosome location, hcl: 12q13) and PDE1C (hcl: 7p14.3). They hâve alternative promoters and give rise to a multitude of proteins by alternative splicing which differ in their regulatory properties, substrate affinities, spécifie activities, activation constants for CaM, tissue distribution and molecular weights. More than 10 human isoforms are identified. Their molecular weights vary from 58 to 86 kDa per monomer. The N-terminal regulatory domain that contains two Ca2+/CaM binding domains and two phosphorylation sites differentiate their corresponding proteins and modulate their biochemical functions. PDE1 is a dual substrate PDE and the PDE1Csubtype has equal activity towards cAMP and cGMP (Km « 1-3 μΜ), whereas the subtypes PDE1A and PDE1B has a preference for cGMP (Km for cGMP « 1-3 μΜ and for cAMP = 10-30 μΜ).

The PDE1 subtypes are highly enriched in the brain and located especially in the striatum (PDE1B), hippocampus (PDE1A) and cortex (PDE1A) and this localization is conserved across species (Amy Bernard et al. Neuron 2012, 73,1083-1099). In the cortex, PDE1A is présent mainly in deep cortical layers 5 and 6 (output layers), and used as a specifîcity marker for the deep cortical layers. PDE1 inhibitors enhance the levels ofthe second messenger cNs leading to enhanced neuronal excitability.

Thus, PDE1 is a therapeutic target for régulation of intracellular signalling pathways, preferably in the nervous system and PDE1 inhibitors can enhance the levels ofthe second messengers cAMP/cGMP leading to modulation of neuronal processes and to the expression of neuronal plasticity-related genes, neurotrophic factors, and neuroprotective molécules. These neuronal plasticity enhancement properties together with the modulation of synaptic transmission make PDE1 inhibitors good candidates as therapeutic agents in many neurological and psychiatrie conditions. The évaluation of PDE1 inhibitors in animal models (for reviews see e.g. Blokland et al. Expert Opinion on Therapeutic Patents (2012), 22(4), 349-354; and Médina, A. E. Frontiers in Neuropharmacology (2011), 5(Feb.), 21) hâve suggested the potential for the therapeutic use of PDE1 inhibitors in neurological disorders, like e.g. Alzheimer’s, Parkinson's and Huntington's Diseases and in psychiatrie disorders like e.g. Attention Déficit hyperactivity Disorder (ADHD), restless leg syndrome, dépréssion, narcolepsy, cognitive impairment and cognitive impairment associated with schizophrenia (CIAS). There hâve also been patent applications claiming that PDE1 inhibitors are useful in diseases that may be alleviated by the enhancement of progesterone-signalling such as female sexual dysfunction.

The compounds ofthe invention may offer alternatives to current marketed treatments for neurodegenerative and/or psychiatrie disorders, which are not efficacious in ail patients. Hence, there remains a need for alternative methods of treatment.

Two compounds, namely 1,2,4-Triazolo[4,3-a]pyrazin-8(7H)-one, 7-[(4chlorophenyl)methyl]-3-methyl- (CAS Registry Number: 946270-18-4) and 1,2,4Triazolo[4,3-a]pyrazin-8(7H)-one, 7-[(4-chlorophenyl)methyl]-3-propyl- (CAS Registry Number: 946237-23-6) are known in the prior art, but hâve not been disclosed as PDE1 inhibitors or for use as a médicament.

SUMMARY OF THE INVENTION

PDE1 enzymes are expressed in the Central Nervous System (CNS), making this gene family an attractive source of new targets for the treatment of psychiatrie and neurodegenerative disorders.

The objective ofthe présent invention is to provide compounds that are PDE1 inhibitors, and as such are useful to treat neurodegenerative disorders and psychiatrie disorders.

Accordingly, the présent invention relates to compounds of formula (I)

wherein n is 0 or 1;

Ri is selected from the group consisting of linear or branched CrC₈ alkyl, such as C-i to C₃ alkyl, oxetanyl, tetrahydrofuranyl, tetrathydropyranyl and saturated monocyclic C₃-C₈cycloalkyl; or

R-i is selected from the group consisting oxetanyl, tetrahydrofuranyl, tetrathydropyranyl, saturated monocyclic C₃-C₈ cycloalkyl, each substituted one or two times with methyl or hydroxy, and linear or branched CrC₈ alkyl substituted one or more times, preferably one, two or three times, with fluorine; and

R₂ is selected from the group consisting of, linear or branched CrC₈ alkyl, phenyl, saturated monocyclic C₃-C₈ cycloalkyl, saturated bicyclic C₄-C-|_O cycloalkyl, saturated tricyclic C7-C10 cycloalkyl, oxetanyl, tetrahydrofuranyl and tetrahydropyranyl; or

R₂ is selected from the group consisting of phenyl substituted with a substituent selected from the group consisting of halogen, linear or branched C-i-C₃ alkyl, difluoromethyl, trifluoromethyl and methoxy; saturated monocyclic C₃-C₈ cycloalkyl, substituted one or two times with substituents selected from the group consisting of fluorine and methyl; and oxetanyl, tetrahydrofuranyl and tetrahydropyranyl, each substituted one or two times with substituents selected from the group consisting of fluorine and methyl;

R₃ is selected from the group consisting of linear or branched C-1-C4 alkyl, phenyl, substituted phenyl, halogen, tetrahydrofuranyl, benzyl, where the phenyl ring of the benzyl can be optionally substituted with one or more substituents chosen from haliogen, methyl, alkoxy or the phenyl ring of the benzyl can be substituted with an aromatic ring og heteroaromatic ring like e.g. pyridine;

R4 is selected from the group consisting of linear or branched C1-C4 alkyl, halogen, and tetrahydrofuranyl.

Reference to Compound I includes the free base of Compound I, pharmaceutically acceptable salts of Compound I, such as acid addition salts of Compound I, racemic mixtures of Compound I, or the corresponding enantiomer and/or optical isomer of Compound I, and polymorphie and amorphic forms of Compound I as well as tautomeric forms of Compound I.

DETAILED DESCRIPTION OF THE INVENTION

EMBODIMENTS OF THE INVENTION

The following notation is applied: an embodiment ofthe invention is identified as Ei, where i is an integer indicating the number ofthe embodiment. An embodiment Ei’ specifying a spécifie embodiment of a previously listed embodiment Ei is identified as Ei’(Ei), e.g. E2(E1) means “in an embodiment E2 of embodiment ET’.

Where an embodiment is a combination of two embodiments the notation is similarly Ei”(Ei and Ei’), e.g. E3(E2 and E1) means “in an embodiment E3 of any of embodiments E2 and E1”

Where an embodiment is a combination of more than two embodiments the notation is similarly Ei”’(Ei, Ei’ and Ei”), e.g. E4(E1, E2 and E3) means “in an embodiment E4 of any of embodiments E1, E2 and E3”

In a first embodiment E1 the présent invention relates to compounds of formula (I) (Compound I):

Ri

Compound (I) wherein n is 0 or 1;

Ri is selected from the group consisting linear or branched Ci-C₈ alkyl, such as C-i to C₃alkyl, oxetanyl, tetrahydrofuranyl, tetrathydropyranyl and saturated monocyclic C3-C₈cycloalkyl; or

Ri is selected from the group consisting oxetanyl, tetrahydrofuranyl, tetrathydropyranyl, saturated monocyclic C₃-C₈ cycloalkyl, each substituted one or two times with methyl or hydroxy, and linear or branched C-i-C₈ alkyl substituted one or more times, preferably one, two or three times, with fluorine; and

R₂ is selected from the group consisting of, linear or branched Ci-C₈ alkyl, phenyl, saturated monocyclic C₃-C₈ cycloalkyl, saturated bicyclic C4-C10 cycloalkyl, saturated tricyclic C7-C10 cycloalkyl, oxetanyl, tetrahydrofuranyl and tetrahydropyranyl; or

R₂ is selected from the group consisting of phenyl substituted with a substituent selected from the group consisting of halogen, C_rC₃ alkyl, difluoromethyl, trifluoromethyl and methoxy; saturated monocyclic C₃-C₈ cycloalkyl, substituted one or two times with substituents selected from the group consisting of fluorine and methyl; and oxetanyl, tetrahydrofuranyl and tetrahydropyranyl, each substituted one or two times with substituents selected from the group consisting of fluorine and methyl;

R₃ is selected from the group consisting of linear or branched C1-C4 alkyl, phenyl, substituted phenyl, halogen and tetrahydrofuranyl; ,benzyl, where the phenyl ring ofthe benzyl can be optionally substituted with one or more substituents chosen from haliogen, methyl, alkoxy orthe phenyl ring ofthe benzyl can be substituted with an aromatic ring og heteroaromatic ring like e.g. pyridine;

R₄ is selected from the group consisting of linear or branched C_rC₄ alkyl, halogen, and tetrahydrofuranyl;

with the proviso that compound I is not 1,2,4-Triazolo[4,3-a]pyrazin-8(7H)-one, 7-[(4chlorophenyI)methyl]-3-methyl- (CAS Registry Number: 946270-18-4) or 1,2,4Triazolo[4,3-a]pyrazin-8(7H)-one, 7-[(4-chlorophenyl)methyl]-3-propyl- (CAS Registry

Number: 946237-23-6).

E2(E1) R₁ is selected from methyl, ethyl, propyl and isopropyl.

E3(E2) Ri is propyl

E4(E1) R₂ is phenyl

E5(E1 ) R₂ is substituted phenyl, wherein the substituent is selected from the group consisting of fluorine, chlorine and methoxy.

E6(E1) R₂ is substituted phenyl, wherein the substituent is selected from the group consisting of difluoromethyl and trifluoromethyl.

E7(E1) R₂ is saturated monocyclic C₅-C₇ cycloalkyl.

E8(E1, E3 and E7) Ri is propyl and R₂ is saturated monocyclic C₅-C₇ cycloalkyl.

E9(E1) R₂ is adamantyl.

E10(E1) R₂ is a saturated spirooctan.

E11(E1)nis 0.

E12(E1)n is 1.

E13(E1) R3 is methyl or ethyl.

E14(E1) R3 is substituted phenyl, wherein the substituent is selected from the group consisting of phenyl, fluorine, and methyl.

E15(E1) R3 is bromine.

E16(E1) R4 is methyl or ethyl.

E17(E1) R4 is bromine.

E18(E1), the compound of formula (I) is selected among the compounds listed in Table 1, in the form of the free base, one or more tautomers thereof or a pharmaceutically acceptable sait thereof.

E19(E1 to E18) the compound has an PDE1A, PDE1B or PDE1C IC50 value, determined as described in the section “PDE1 inhibition assay”, of 10 micro molar or less, such as 5 micro molar or less, such as 4 micro molar or less, such as 3 micro molar or less, such as 2 micro molar or less, such as 1 micro molar or less, such as 500 nM or less, such as 400 nM or less, such as 300 nM or less, such as 200 nM or less, such as 100 nM or less.

E20(E1) a compound selected from the compounds listed in Table 1 or pharmaceutically acceptable salts thereof.

E21(E1 to E20) the compound is for use as a médicament.

E22(E1 to E21 ) the compound is for use in the treatment of attentiondeficit/hyperactivity disorder (ADHD).

E23(E1 to E20) a pharmaceutical composition comprising a therapeutically effective amount of a compound of any of embodiments (E1 ) to (E15), and one or more pharmaceutically acceptable carriers, diluents and excipients.

E24(E23) the pharmaceutical composition is for the treatment of attentiondeficit/hyperactivity disorder (ADHD).

E25(E1 to E20) a method of treating a subject suffering from attentiondeficit/hyperactivity disorder (ADHD), which method comprises administering to said subject an amount of a compound of formula I effective in inhibiting PDE1.

E26 (E1 to E21) the compound is for use in the treatment of cognitive problesms in e.g. schizophrenia or Alzheimers disease.

DEFINITIONS

PDE1 ENZYMES

The PDE1 isozyme family includes numerous splice variant PDE1 isoforms. lt has three subtypes, PDE1A, PDE1B and PDE1C which divide further into various isoforms. In the context of the présent invention PDE1 and PDE1 enzymes are synonymous and refer to PDE1A, PDE1B and PDE1C enzymes as well as their isoforms unless otherwise specified.

SUBSTITUENTS

As used in the context of the présent invention, the terms “halo” and “halogen” are used interchangeably and refer to fluorine, chlorine, bromine or iodine.

A given range may interchangeably be indicated with (dash) or “to”, e.g. the term ”Cr C₃ alkyl” is équivalent to ”Ci to C₃ alkyl”.

The terms ”C-|-C₃ alkyl”, ”C-i-C₄ alkyl”, C-i-Cs alkyl”, ”CrC₆ alkyl”, ”C-i-C₇ alkyl” and ”C-iC₈ alkyl” refer to a linear (i.e. unbranched) or branched saturated hydrocarbon having from one up to eight carbon atoms, inclusive. Examples of such groups include, but are not limited to, methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-butyl, 2-methyl-2-propyl, 2methyl-1-butyl, n-hexyl, n-heptyl and n-octyl.

The term saturated monocyclic C₃ to C-io cycloalkyl refers to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl and cyclodecatyl.

Corrrespondingly, the term saturated monocyclic C₃ to C₈ cycloalkyl refers to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.

The term saturated bicyclic C₄ to Ci₀ cycloalkyl refers to bicyclic ring comprising carbon and hydrogen atoms. Saturated bicyclic C₄ to Ο™ cycloalkyl include spiro rings, fused rings and bridged rings, such as, but not limited to bicyclo[1.1.0]butanylbicyclobutanyl, bicyclo[2.1.0]pentanylbicyclopentanyl, bicyclo[2.2.0]hexanylbicyclohexanyl, bicyclo[2.2.1]heptanylbicycloheptanyl, bicyclo[2.2.2]octanylbicyclooctanyl, bicyclo[3.2.2]nonanyl and decahydronaphthalenylbicyclodecanyl.

The term saturated tricyclic C₇ to Ο_Ί0 cycloalkyl refers to tricyclic ring comprising carbon and hydrogen atoms such as, but not limited to, adamantyl.

The expression “Ci-C₃ alkoxy” refers to a linear or branched saturated alkoxy group having from one to three carbon atoms, inclusive, with the open valency on the oxygen. Examples of such groups include methoxy, ethoxy, propoxy and isopropoxy.

ISOMERIC FORMS

Where compounds ofthe présent invention contain one or more chiral centers reference to any ofthe compounds will, unless otherwise specified, coverthe enantiomerically or diastereomerically pure compound as well as mixtures ofthe enantiomers or diastereomers in any ratio.

For example reference to the compound 3-Propyl-7-((tetrahydro-2H-pyran-3-yl)methyl)- [1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one without any further spécification covers (R)- 318257

Propyl-7-((tetrahydro-2H-pyran-3-yl)methyl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one, (S)-

3-Propyl-7-((tetrahydro-2H-pyran-3-yl)methyl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one as well as mixtures ofthe enantiomers in any ratio, including the racemic mixture (±)3Propyl-7-((tetrahydro-2H-pyran-3-yl)methyi)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one.

The above also applies where compounds ofthe invention contain more than two chiral centers.

PDE1 INHIBITORS

In the context ofthe présent invention a compound is considered to be a PDE1 inhibitor ifthe amount required to reach the IC₅₀ level of any ofthe three PDE1 isoforms is 10 micro molar or less, preferably less than 9 micro molar, such as 8 micro molar or less, such as 7 micro molar or less, such as 6 micro molar or less, such as 5 micro molar or less, such as 4 micro molar or less, such as 3 micro molar or less, more preferably 2 micro molar or less, such as 1 micro molar or less, in particular 500 nM or less. In preferred embodiments the amount of PDE1 inhibitor required to reach the IC₅₀ level of PDE1B is 400n M or less, such as 300 nM or less, 200 nM or less, 100 nM or less, or even 80 nM or less, such as 50 nM or less, for example 25 nM or less.

PHARMACEUTICALLY ACCEPTABLE SALTS

The présent invention also comprises salts ofthe compounds ofthe invention, typically, pharmaceutically acceptable salts. Such salts include pharmaceutically acceptable acid addition salts. Acid addition salts include salts of inorganic acids as well as organic acids.

Représentative examples of suitable inorganic acids include hydrochloric, hydrobromic, hydroiodic, phosphoric, sulfuric, sulfamic, nitric acids and the like. Représentative examples of suitable organic acids include formic, acetic, trichloroacetic, trifluoroacetic, propionic, benzoic, cinnamic, citric, fumaric, glycolic, itaconic, lactic, methanesulfonic, maleic, malic, malonic, mandelic, oxalic, picric, pyruvic, salicylic, succinic, methane sulfonic, ethanesulfonic, tartaric, ascorbic, pamoic, bismethylene salicylic, ethanedisulfonic, gluconic, citraconic, aspartic, stearic, palmitic, EDTA, glycolic, paminobenzoic, glutamic, benzenesulfonic, p-toluenesulfonic acids, theophylline acetic acids, as well as the 8-halotheophyllines, for example 8-bromotheophylline and the like.

Further examples of pharmaceutically acceptable inorganic or organic acid addition salts include the pharmaceutically acceptable salts Iisted in Berge, S.M. et al., J. Pharm. Sci. 1977, 66, 2, the contents of which are hereby incorporated by reference.

Furthermore, the compounds of this invention may exist in unsolvated as well as in solvated forms with pharmaceutically acceptable solvents such as water, éthanol and the like. In general, the solvated forms are considered équivalent to the unsolvated forms for the purposes of this invention.

THERAPEUTICALLY EFFECTIVE AMOUNT

In the présent context, the term therapeutically effective amount of a compound means an amount sufficient to cure, alleviate or partially arrest the clinical manifestations of a given disease and its complications in a therapeutic intervention comprising the administration of said compound. An amount adéquate to accomplish this is defined as therapeutically effective amount. Effective amounts for each purpose will dépend on the severity ofthe disease or injury as well as the weight and general state of the subject. It will be understood that determining an appropriate dosage may be achieved using routine expérimentation, by constructing a matrix of values and testing different points in the matrix, which is ail within the ordinary skills of a trained physician.

In the présent context, the term treatment and treating means the management and care of a patient for the purpose of combating a condition, such as a disease or a disorder. The term is intended to include the full spectrum of treatments for a given condition from which the patient is suffering, such as administration ofthe active compound to alleviate the symptoms or complications, to delay the progression of the disease, disorder or condition, to alleviate or relief the symptoms and complications, and/or to cure or eliminate the disease, disorder or condition as well as to prevent the condition, wherein prévention is to be understood as the management and care of a patient for the purpose of combating the disease, condition, or disorder and includes the administration ofthe active compounds to prevent the onset ofthe symptoms or complications. Nonetheiess, prophylactic (préventive) and therapeutic (curative) treatments are two separate aspects ofthe invention. The patient to be treated is preferably a mammal, in particular a human being.

PHARMACEUTICAL COMPOSITIONS

The présent invention further provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) and a pharmaceutically acceptable carrier or diluent. The présent invention also provides a pharmaceutical composition comprising a therapeutically effective amount of one ofthe spécifie compounds disclosed in the Experimental Section herein and a pharmaceutically acceptable carrier or diluent.

The compounds ofthe invention may be administered alone or in combination with pharmaceutically acceptable carriers, diluents or excipients, in either single or multiple doses. The pharmaceutical compositions according to the invention may be formulated with pharmaceutically acceptable carriers or diluents as well as any other known adjuvants and excipients in accordance with conventional techniques such as those disclosed in Remington: The Science and Practice of Pharmacy, 21^st Edition, Gennaro, Ed., Mack Publishing Co., Easton, PA, 2005.

The pharmaceutical compositions may be specifically formulated for administration by any suitable route such as oral, rectal, nasal, pulmonary, topical (including buccal and sublingual), transdermal, intracisternal, intraperitoneal, vaginal and parentéral (including subeutaneous, intramuscular, intrathecal, intravenous and intradermal) routes. It will be appreciated that the route will dépend on the general condition and âge of the subject to be treated, the nature of the condition to be treated and the active ingrédient.

Pharmaceutical compositions for oral administration include solid dosage forms such as capsules, tablets, dragees, pills, lozenges, powders and granules. Where appropriate, the compositions may be prepared with coatings such as enteric coatings or they may be formulated so as to provide controlled release ofthe active ingrédient such as sustained or prolonged release according to methods well known in the art. Liquid dosage forms for oral administration include solutions, émulsions, suspensions, syrups and élixirs.

Pharmaceutical compositions for parentéral administration include stérile aqueous and nonaqueous injectable solutions, dispersions, suspensions or émulsions as well as stérile powders to be reconstituted in stérile injectable solutions or dispersions prior to use. Other suitable administration forms include, but are not limited to, suppositories, sprays, ointments, creams, gels, inhalants, dermal patches and implants.

Typical oral dosages range from about 0.001 to about 100 mg/kg body weight per day. Typical oral dosages also range from about 0.01 to about 50 mg/kg body weight per day. Typical oral dosages further range from about 0.05 to about 10 mg/kg body weight per day. Oral dosages are usually administered in one or more dosages, typically, one to three dosages per day. The exact dosage will dépend upon the frequency and mode of administration, the sex, âge, weight and general condition ofthe subjecttreated, the nature and severity ofthe condition treated and any concomitant diseases to be treated and other factors évident to those skilled in the art.

The formulations may also be presented in a unit dosage form by methods known to those skilled in the art. For illustrative purposes, a typical unit dosage form for oral administration may contain from about 0.01 to about 1000 mg, from about 0.05 to about 500 mg, or from about 0.5 mg to about 200 mg.

The présent invention also provides a process for making a pharmaceutical composition comprising mixing a therapeutically effective amount of a compound of formula (I) and at least one pharmaceutically acceptable carrier or diluent. In an embodiment, ofthe présent invention, the compound utilized in the aforementioned process is one ofthe spécifie compounds disclosed in the Experimental Section herein.

The compounds of this invention are generally utilized as the free substance or as a pharmaceutically acceptable sait thereof. One example is an acid addition sait of a compound which has the same utility as of a free base. When a compound of formula (I) contains a free base such salts are prepared in a conventional manner by treating a solution or suspension of a free base of formula (I) with a pharmaceutically acceptable acid. Représentative examples of suitable organic and inorganic acids are described above.

For parentéral administration, solutions ofthe compounds of formula (I) in stérile aqueous solution, aqueous propylene glycol, aqueous vitamin E or sesame or peanut oil may be employed. Such aqueous solutions should be suitably buffered if necessary and the liquid diluent first rendered isotonie with sufficient saline or glucose. The aqueous solutions are particularly suitable for intravenous, intramuscular, and subeutaneous administration. The compounds of formula (I) may be readily incorporated into known stérile aqueous media using standard techniques known to those skilled in the art.

Suitable pharmaceutical carriers include inert solid diluents or fillers, stérile aqueous solutions and various organic solvents. Examples of solid carriers include lactose, terra alba, sucrose, cyclodextrin, talc, gelatin, agar, pectin, acacia, magnésium stéarate, stearic acid and lower alkyl ethers of cellulose. Examples of liquid carriers include, but are not limited to, syrup, peanut oil, olive oil, phospholipids, fatty acids, fatty acid amines, polyoxyethylene and water. Similarly, the carrier or diluent may include any sustained release material known in the art, such as glyceryl monostearate or glyceryl distearate, alone or mixed with a wax. The pharmaceutical compositions formed by combining the compounds of formula (I) and a pharmaceutically acceptable carrier are then readily administered in a variety of dosage forms suitable for the disclosed routes of administration. The formulations may conveniently be presented in unit dosage form by methods known in the art of pharmacy.

Formulations ofthe présent invention suitable for oral administration may be presented as discrète units such as capsules or tablets, each containing a predetermined amount ofthe active ingrédient, and optionally a suitable excipient. Furthermore, the orally available formulations may be in the form of a powder or granules, a solution or suspension in an aqueous or non-aqueous liquid, or an oil-in-water or water-in-oil liquid émulsion.

If a solid carrier is used for oral administration, the préparation may be tabletted, placed in a hard gelatin capsule in powder or pellet form or it may be in the form of a troche or lozenge. The amount of solid carrier will vary widely but will range from about 25 mg to about 1 g per dosage unit. If a liquid carrier is used, the préparation may be in the form of a syrup, émulsion, soft gelatin capsule or stérile injectable liquid such as an aqueous or non-aqueous liquid suspension or solution.

The pharmaceutical compositions of the invention may be prepared by conventional methods in the art. For example, tablets may be prepared by mixing the active ingrédient with ordinary adjuvants and/or diluents and subsequently compressing the mixture in a conventional tableting machine préparé tablets. Examples of adjuvants or diluents comprise: corn starch, potato starch, talcum, magnésium stéarate, gelatin, lactose, gums, and the like. Any other adjuvants or additives usually used for such purposes such as colorings, flavorings, preservatives etc. may be used provided that they are compatible with the active ingrédients.

TREATMENT OF DISORDERS

As mentioned above, the compounds of formula (I) are PDE1 enzyme inhibitors and as such are useful to treat associated neurological and psychiatrie disorders.

The invention thus provides a compound of formula (I) or a pharma^ceutically acceptable acid addition sait thereof, as well as a pharmaceutical composition containing such a compound, for use in the treatment of a neurodegenerative disorder, psychiatrie disorder or drug addiction in mammals including humans; wherein the neurodegenerative disorder is selected from the group consisting of Alzheimer's disease, multi-infarct dementia, alcoholic dementia or other drug-related dementia, dementia associated with intracranial tumors or cérébral trauma, dementia associated with Huntington’s disease or Parkinson’s disease, or AIDS-related dementia; delirium; . amnestic disorder; post-traumatic stress disorder; mental retardation; a learning disorder, for example reading disorder, mathematics disorder, or a disorder of written expression; attention-deficit/hyperactivity disorder; and age-related cognitive décliné; and wherein the psychiatrie disorder is selected from the group consisting of schizophrenia, for example ofthe paranoid, disorganized, catatonie, undifferentiated, or residual type; schizophreniform disorder; schizoaffective disorder, for example ofthe delusional type or the dépressive type; delusional disorder; substance-induced psychotic disorder, for example psychosis induced by alcohol, amphétamine, cannabis, cocaïne, hallucinogens, inhalants, opioids, or phencyclidine; personality disorderofthe paranoid type; and personality disorder ofthe schizoid type; and wherein the drug addiction is an alcohol, amphétamine, cocaïne, or opiate addiction.

The compounds of formula (I) or pharmaceutically acceptable salts thereof may be used in combination with one or more other drugs in the treatment of diseases or conditions forwhich the compounds ofthe présent invention hâve utility, where the combination of the drugs together are safer or more effective than either drug alone. Additionally, the compounds of the présent invention may be used in combination with one or more other drugs that treat, prevent, control, ameliorate, or reduce the risk of side effects or toxicity ofthe compounds ofthe présent invention. Such other drugs may be administered, by a route and in an amount commonly used therefore, contemporaneously or sequentially with the compounds ofthe présent invention. Accordingly, the pharmaceutical compositions ofthe présent invention include those that contain one or more other active ingrédients, in addition to the compounds ofthe présent invention. The combinations may be administered as part of a unit dosage form combination product, or as a kit or treatment protocol wherein one or more additional drugs are administered in separate dosage forms as part of a treatment regimen.

The présent invention provides a method of treating a mammal, including a human, suffering from a neurodegenerative disorder selected from a cognition disorder or movement disorder, which method comprises administering to the subject a therapeutically effective amount of a compound of formula (I).

This invention further provides a method of treating a neurodegenerative disorder or condition in a mammal, including a human, which method comprises administering to said mammal an amount of a compound of formula (I) effective in inhibiting PDE1.

This invention also provides a method of treating a subject suffering from a psychiatrie disorder, which method comprises administering to the subject a therapeutically effective amount of a compound of formula (I). Examples of psychiatrie disorders that can be treated according to the présent invention include, but are not limited to, Attention Déficit Hyperactivity Disorder (ADHD) schizophrenia, for example ofthe paranoid, disorganized, catatonie, undifferentiated, or residual type; schizophreniform disorder; schizoaffective disorder, for example of the delusional type or the dépressive type; delusional disorder; substance-induced psychotic disorder, for example psychosis induced by alcohol, amphétamine, cannabis, cocaïne, hallucinogens, inhalants, opioids, or phencyclidine; personality disorder ofthe paranoid type; and personality disorder of the schizoid type; and the anxiety disorder is selected from panic disorder; agoraphobia; a spécifie phobia; social phobia; obsessive-compulsive disorder; post-traumatic stress disorder; acute stress disorder; and generalized anxiety disorder.

lt has been found that the compounds of formula (I) or pharmaceutically acceptable salts thereof may advantageously be administered in combination with at least one neuroleptic agent (which may be a typical or an atypical antipsychotic agent) to provide improved treatment of psychiatrie disorders such as schizophrenia. The combinations, uses and methods of treatment ofthe invention may also provide advantages in treatment of patients who fail to respond adequately or who are résistant to other known treatments.

The présent invention thus provides a method of treating a mammal suffering from a psychiatrie disorder, such as schizophrenia, which method comprises administering to the mammal a therapeutically effective amount of a compound of formula (I), either alone or as combination therapy together with at least one neuroleptic agent.

The term neuroleptic agent as used herein refers to drugs, which hâve the effect on cognition and behaviour of antipsychotic agent drugs that reduce confusion, delusions, hallucinations, and psychomotor agitation in patients with psychoses. Also known as major tranquilizers and antipsychotic drugs, neuroleptic agents include, but are not limited to: typical antipsychotic drugs, including phenothiazines, further divided into the aliphatics, piperidines, and piperazines, thioxanthenes (e.g., cisordinol), butyrophenones (e.g., haloperidol), dibenzoxazepines (e.g., loxapine), dihydroindolones (e.g., molindone), diphenylbutylpiperidines (e.g., pimozide), and atypical antipsychotic drugs, including benzisoxazoles (e.g., rispéridone), sertindole, olanzapine, quetiapine, osanetant and ziprasidone.

Particularly preferred neuroleptic agents for use in the invention are sertindole, olanzapine, rispéridone, quetiapine, aripiprazole, haloperidol, clozapine, ziprasidone and osanetant.

The présent invention further provides a method of treating a subject suffering from a cognition disorder, which method comprises administering to the subject a therapeutically effective amount of a compound of formula (I). Examples of cognition disorders that can be treated according to the présent invention include, but are not limited to, Alzheimer's disease, multi-infarct dementia, alcoholic dementia or other drugrelated dementia, dementia associated with intracranial tumors or cérébral trauma, dementia associated with Huntington's disease or Parkinson's disease, or AIDS-related dementia; delirium; amnestic disorder; post-traumatic stress disorder; mental retardation; a learning disorder, for example reading disorder, mathematics disorder, or a disorder of written expression; attention-deficit/hyperactivity disorder; and age-related cognitive décliné.

This invention also provides a method of treating a movement disorder, which method comprises administering to the subject a therapeutically effective amount of a compound of formula (I). Examples of movement disorders that can be treated according to the présent invention include, but are not limited to, Huntington's disease and dyskinesia associated with dopamine agonist therapy. This invention further provides a method of treating a movement disorder selected from Parkinson's disease and restless leg syndrome, which comprises administering to the subject a therapeutically effective amount of a compound of formula (I).

This invention also provides a method of treating a mood disorder, which method comprises administering to the subject a therapeutically effective amount of a compound of formula (I). Examples of mood disorders and mood épisodes that can be treated according to the présent invention include, but are not limited to, major dépressive épisode of the mild, moderate or severe type, a manie or mixed mood épisode, a hypomanie mood épisode; a dépressive épisode with a typical features; a dépressive épisode with melancholic features; a dépressive épisode with catatonie features; a mood épisode with postpartum onset; post-stroke dépréssion; major dépressive disorder; dysthymie disorder; minor dépressive disorder; premenstrual dysphorie disorder; post-psychotic dépressive disorder of schizophrenia; a major dépressive disorder superimposed on a psychotic disorder such as delusional disorder or schizophrenia; a bipolar disorder, for example bipolar I disorder, bipolar II disorder, and cyclothymie disorder. lt is understood that a mood disorder is a psychiatrie disorder.

This invention further provides a method of treating a disorder comprising as a symptom a deficiency in attention and/or cognition in a mammal, including a human, which method comprises administering to said mammal an amount of a compound of formula (I) effective in treating said disorder.

Other disorders that can be treated according to the présent invention are obsessive/compulsive disorders, Tourette's syndrome and other tic disorders.

As used herein, and unless otherwise indicated, a neurodegenerative disorder or condition refers to a disorder or condition that is caused by the dysfunction and/or death of neurons in the central nervous system. The treatment of these disorders and conditions can be facilitated by administration of an agent which prevents the dysfunction or death of neurons at risk in these disorders or conditions and/or enhances the function of damaged or healthy neurons in such a way as to compensate for the loss of function caused by the dysfunction or death of at-risk neurons. The term neurotrophic agent as used herein refers to a substance or agent that has some or ail of these properties.

Examples of neurodegenerative disorders and conditions that can be treated according to the présent invention include, but are not limited to, Parkinson's disease; Huntington's disease; dementia, for example Alzheimer’s disease, multi-infarct dementia, AIDSrelated dementia, and Fronto temperal Dementia; neurodegeneration associated with cérébral trauma; neurodegeneration associated with stroke, neurodegeneration associated with cérébral infarct; hypoglycemia-induced neurodegeneration;

neurodegeneration associated with epileptic seizure; neurodegeneration associated with neurotoxin poisoning; and multi-system atrophy.

In one embodiment ofthe présent invention, the neurodegenerative disorder or condition involves neurodegeneration of striatal medium spiny neurons in a mammal, including a human.

In a furtherembodiment ofthe présent invention, the neurodegenerative disorderor condition is Huntington's disease. Ail references, including publications, patent applications and patents, cited herein are hereby incorporated by reference in their entirety and to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety (to the maximum extent permitted by law).

Headings and sub-headings are used herein for convenience only, and should not be construed as limiting the invention in any way.

The use of any and ail examples, or exemplary language (including “for instance, “for example”, “e.g.”, and “as such”) in the présent spécification is intended merely to better illuminate the invention, and does not pose a limitation on the scope of invention unless otherwise indicated.

The citation and incorporation of patent documents herein is done for convenience only, and does not reflect any view ofthe validity, patentability and/or enforceability of such patent documents.

The présent invention includes ail modifications and équivalents ofthe subject-matter recited in the claims appended hereto, as permitted by applicable law.

COMPOUNDS OF THE INVENTION

Table 1: Compounds ofthe invention

Compound	PDE1C inhibition³) (nM or %)	PDE1B inhibition³) (nM or %)	PDE1A inhibition³) (nM or %)
3-Propyl-7-((tetrahydro-2H-pyran-3yl)methyl)-[l,2,4]triazolo[4,3-a]pyrazin8(7H)-one, stereoisomer 1	68%	57%	48%
3-P ro py 1-7-( (tetra hyd ro-2 H-py ra n-3yl)methyl)-[l,2,4]triazolo[4,3-a]pyrazin8(7H)-one, stereoisomer 2	48%	33%	26%
7-(Cyclohexylmethyl)-3-propyl- [l,2,4]triazolo[4,3-a]pyrazin-8(7H)-one	47 nM	81 nM	96 nM
7-(Cyclopentylmethyl)-3-propyl- [l,2,4]triazolo[4,3-a]pyrazin-8(7H)-one	95 nM	820 nM	840 nM
3-Propyl-7-((tetrahydro-2H-pyran-4- yl)methyl)-[l,2,4]triazolo[4,3-a]pyrazin- 8(7H)-one	1600 nM	47%	42%
7-lsobutyl-3-propyl-[l,2,4]triazolo[4,3- a]pyrazin-8(7H)-one	970 nM	2700 nM	3300 nM
7-(Cyclopropylmethyl)-3-propyl- [l,2,4]triazolo[4,3-a]pyrazin-8(7H)-one	1300 nM	2000 nM	3600 nM
7-Ethyl-3-propyl-[l,2,4]triazolo[4,3- a]pyrazin-8(7H)-one	52%	71%	49%

Compound	PDE1C inhibition³) (nM or %)	PDE1B inhibition ³⁾(nM or %)	PDE1A inhibition ³⁾(nM or %)
7-(Oxetan-3-ylmethyl)-3-propyl- [l_z2_z4]triazolo[4_z3-a]pyrazin-8(7H)-one	57%	46%	37%
7-(Cyc)oheptylmetbyl)-3-propyi- [l,2,4]triazolo[4,3-a]pyrazin-8(7H)-one	33 nM	28 nM	54 nM
3-Propyl-7-((tetrahydrofuran-3yl)methyl)-[l,2,4]triazolo[4,3-a]pyrazin8(7H)-one, stereisomer 1	55%	67%	35%
3-Pro py 1 -7-( (te t ra hyd rofu ra n-3yl)methyl)-[l,2,4]triazolo[4,3-a]pyrazin8(7H)-one, stereisomer 2	74%	4000 nM	60%
7-Benzyl-3-propyl-[l_z2_z4]triazolo[4,3- a]pyrazin-8(7H)-one	110 nM	400 nM	770 nM
7-(2-Fluorobenzyl)-3-propyl- [l,2,4]triazolo[4,3-a]pyrazin-8(7H)-one	130 nM	1000 nM	860 nM
7-(3-Fluorobenzyl)-3-(tetrahydro-2Hpyran-4-yl)-[l_z2_z4]triazolo[4_z3-a]pyrazin8(7H)-one	140 nM	680 nM	730 nM
7-(3-Fluorobenzyl)-3-propyl- [l,2,4]triazolo[4,3-a]pyrazin-8(7H)-one	190 nM	1200 nM	1100 nM
7-(3-Methylbenzyl)-3-propyl- [l_z2,4]triazolo[4_z3-a]pyrazin-8(7H)-one	170 nM	1600 nM	1500 nM
3-Propyl-7-(4-(trifluoromethyl)benzyl)- [l,2_z4]triazolo[4_z3-a]pyrazin-8(7H)-one	2100 nM	570 nM	1200 nM
7-(3-Fluorobenzyl)-3-((tetrahydrofuran-3- yl)methyl)-[l_z2_z4]triazolo[4_z3-a]pyrazin- 8(7H)-one	420 nM	1900 nM	1200 nM
3-Propyl-7-(2-(trifluoromethyl)benzyl)- [l_z2_z4]triazolo[4_z3-a]pyrazin-8(7H)-one	41%	46%	44%
7-(2-Chlorobenzyl)-3-propyl- [l_z2_z4]triazolo[4_z3-a]pyrazin-8(7H)-one	430 nM	2500 nM	2000 nM

Compound	PDE1C inhibition³) (nM or %)	PDE1B inhibition ^a)(nM or %)	PDE1A inhibition^a) (nM or %)
7-(4-Chlorobenzyl)-3-propyl- [l,2,4]triazolo[4,3-a]pyrazin-8(7H)-one	170 nM	83 nM	620 nM
7-(4-Chlorobenzyl)-3-(tetrahydrofuran-3yl)-[l,2,4]trïazolo[4,3-a]pyrazin-8(7H)one	750 nM	840 nM	500 nM
7-Hexyl-3-(tetrahydro-2H-pyran-4-yl)- [l,2,4]triazolo[4,3-a]pyrazin-8(7H)-one	1100 nM	1000 nM	1260 nM
7-(4-Fluorobenzyl)-3-propyl- [l,2_;4]triazolo[4_z3-a]pyrazin-8(7H)-one	360 nM	1200 nM	970 nM
7-(4-Chlorobenzyl)-3-ethyl- [l,2,4]triazolo[4,3-a]pyrazin-8(7H)-one	2400 nM	800 nM	1000 nM
7-(3-Chlorobenzyl)-3-propyl- [l_z2_z4]triazolo[4,3-a]pyrazin-8(7H)-one	160 nM	1300 nM	1400 nM
7-(4-Methylbenzyl)-3-propyl- [l,2,4]triazolo[4,3-a]pyrazin-8(7H)-one	780 nM	930 nM	1000 nM
7-(2-Methylbenzyl)-3-propyl- [l,2,4]triazolo[4,3-a]pyrazin-8(7H)-one	2400 nM	42%	53%
3-Cyclopentyl-7-(3-fluorobenzyl)- [l,2,4]triazolo[4,3-a]pyrazin-8(7H)-one	800 nM	290 nM	420 nM
7-lsopentyl-3-(tetrahydro-2H-pyran-4-yl)- [l,2,4]triazolo[4,3-a]pyrazin-8(7H)-one	1100 nM	55%	47%
3-Cyclopropyl-7-(3-fluorobenzyl)- [l,2,4]triazolo[4,3-a]pyrazin-8(7H)-one	210 nM	780 nM	500 nM
3-Cyclohexyl-7-(3-fluorobenzyl)- [l,2,4]triazolo[4,3-a]pyrazin-8(7H)-one	120 nM	590 nM	810 nM
7-(3-Fluorobenzyl)-3-(tetrahydro-2Hpyran-2-yl)-[l,2,4]triazolo[4,3-a]pyrazin8(7H)-one, stereoisomer 1	390 nM	2200 nM	3200 nM
7-(3-Fluorobenzyl)-3-(tetrahydro-2Hpyran-2-yl)-[l,2,4]triazolo[4,3-a]pyrazin8(7H)-one, stereoisomer2	470 nM	3400 nM	3200 nM

Compound	PDE1C inhibition³’ (nM or %)	PDE1B inhibition³’ (nM or %)	PDE1A inhibition³’ (nM or %)
7-(3-Fluorobenzyl)-3-(tetrahydrofuran-3- yl)-[l,2,4]triazolo[4,3-a]pyrazin-8(7H)- one, stereoisomer 1	240 nM	2100 nM	1800 nM
7-(3-Fluorobenzyl)-3-(tetrahydrofuran-3- yl)-[l,2,4]triazolo[4,3-a]pyrazin-8(7H)- one, stereoisomer 2	240 nM	1800 nM	2100 nM
7-(3-Fluorobenzyl)-3-(2-fluoroethyl)- [l,2,4]triazolo[4,3-a]pyrazin-8(7H)-one	620 nM	3000 nM	2900 nM
3-(l,l-Difluoroethyl)-7-(3-fluorobenzyl)- [l,2,4]triazolo[4,3-a]pyrazin-8(7H)-one	550 nM	2700 nM	2500 nM
7-(3-Fluorobenzyl)-3-(tetrahydro-2Hpyran-3-yl)-[l,2,4]triazolo[4,3-a]pyrazin8(7H)-one, stereoisomer 1	350 nM	2700 nM	1800 nM
7-(3-Fluorobenzyl)-3-(tetrahydro-2Hpyran-3-yl)-[l,2,4]triazolo[4_z3-a]pyrazin8(7H)-one, stereoisomer 2	200 nM	1300 nM	1800 nM
7-(3-Fluorobenzyl)-3-(tetrahydrofuran-2yl)-[l,2,4]triazolo[4,3-a]pyrazin-8(7H)one Stereoisomer 1	700 nM	4400 nM	2700 nM
7-(3-Fluorobenzyl)-3-(tetrahydrofuran-2yl)-[l,2_/4]triazolo[4,3-a]pyrazin-8(7H)one Stereoisomer 2	240 nM	660 nM	890 nM
7-(3-Fluorobenzyl)-3-((tetrahydrofuran-2- yl)methyl)-[l,2,4]triazolo[4,3-a]pyrazin- 8(7H)-one, stereoisomer 1	870 nM	3700 nM	67%
7-( 3-F1 uoro be nzy 1)-3-( (tetra hyd rofu ra n-2yl)methyl)-[l,2,4]triazolo[4,3-a]pyrazin8(7H)-one, stereoisomer 2	1200 nM	67%	49%

Compound	PDE1C inhibition³) (nM or %)	PDE1B inhibition³) (nM or %)	PDE1A inhibition³) (nM or %)
7-(3-Fluorobenzyl)-3-(2,2,2trifluoroethyl)-[l,2,4]triazolo[4,3a]pyrazin-8(7H)-one	380 nM	1400 nM	2000 nM
7-(3-Fluorobenzyl)-3-(oxetan-3-yl)- [l,2,4]triazolo[4,3-a]pyrazin-8(7H)-one	1700 nM	7200 nM	67%
7-(3-Fluorobenzyl)-3-(l-fluoroethyl)- [l,2,4]triazolo[4,3-a]pyrazin-8(7H)-one, stereoisomer2	1000 nM	4000 nM	2900 nM
7-(3-Fluorobenzyl)-3-(l-fluoroethyl)- [l,2,4]triazolo[4,3-a]pyrazin-8(7H)-one, stereoisomer 1	420 nM	2600 nM	1400 nM
7-(3-Fluorobenzyl)-3-(heptan-3-yl)- [l,2,4]triazolo[4,3-a]pyrazin-8(7H)-one,	480 nM	1600 nM	3200 nM
7-(3-Fluorobenzyl)-3-((tetrahydrofuran-3- yl)methyl)-[l,2,4]triazolo[4,3-a]pyrazin- 8(7H)-one, stereoisomer 1	720 nM	2500 nM	2500 nM
7-(3-Fluorobenzyl)-3-((tetrahydrofuran-3- yl)methyl)-[l,2,4]triazolo[4,3-a]pyrazin- 8(7H)-one, stereoisomer 2	510 nM	2000 nM	2100 nM
7-((4,4-Dimethylcyclohexyl)methyl)-3propyl-[l,2,4]triazolo[4,3-a]pyrazin8(7H)-one	110 nM	110 nM	130 nM
7-(Cycloheptylmethyl)-3-(tetrahydro-2Hpyran-4-yl)-[l,2,4]triazolo[4,3-a]pyrazin8(7H)-one	42 nM	33 nM	43 nM
7-(((3r,5r,7r)-Adamantan-l-yl)methyl)-3- propyl-[l,2,4]triazolo[4,3-a]pyrazin- 8(7H)-one	63 nM	210 nM	180 nM
7-((4-MethylcycIohexyl)methyl)-3-propyl- [l,2,4]triazolo[4,3-a]pyrazin-8(7H)-one	65 nM	53 nM	83 nM

Compound	PDE1C inhibition³) (nM or %)	PDE1B inhibition ^a)(nM or %)	PDE1A inhibition ^a)(nM or %)
7-((l-Methylcyclohexyl)methyl)-3-propyl- [l,2,4]triazolo[4,3-a]pyrazin-8(7H)-one	260 nM	950 nM	1300 nM
7-((4,4-Difluorocyclohexyl)methyl)-3propyl-[l,2,4]triazolo[4,3-a]pyrazin8(7H)-one	760 nM	420 nM	450 nM
7-(Cyclopentylmethyl)-3-(tetrahydro-2H- pyran-4-yl)-[l,2,4]triazolo[4,3-a]pyrazin- 8(7H)-one	110 nM	990 nM	1100 nM
7-(Cyclohexylmethyl)-3-(tetrahydro-2H- pyran-4-yl)-[l,2,4]triazolo[4,3-a]pyrazin- 8(7H)-one	87 nM	190 nM	220 nM
3-Propyl-7-(spiro[2.5]octan-6-ylmethyl)- [l,2,4]triazolo[4,3-a]pyrazin-8(7H)-one	92 nM	53 nM	86 nM
7-((3-Methylcyclohexyl)methyl)-3-propyl- [l,2,4]triazolo[4,3-a]pyrazin-8(7H)-one	83 nM	230 nM	320 nM
7-((2-Methylcyclohexyl)methyl)-3-propyl- [l,2,4]triazolo[4,3-a]pyrazin-8(7H)-one	240 nM	260 nM	320 nM
7-(((lr,3r,5r,7r)-Adamantan-2-yl)methyl)- 3-propyl-[l,2,4]triazolo[4,3-a]pyrazin- 8(7H)-one	63 nM	210 nM	179 nM
7-((4-Fluorocyclohexyl)methyl)-3-propyl- [l,2,4]triazolo[4,3-a]pyrazin-8(7H)-one	610 nM	560 nM	660 nM
7-(3-Fluorobenzyl)-3-((ls,4s)-4hydroxycyclohexyl)-[l,2,4]triazolo[4,3a]pyrazin-8(7H)-one	350 nM	1000 nM	1800 nM
7-(3-Fluorobenzyl)-3-((lr,4r)-4hydroxycyclohexyl)-[l,2,4]triazolo[4,3a]pyrazin-8(7H)-one	200 nM	630 nM	1000 nM
7-(((ls,4s)-4-methylcyclohexyl)methyl)-3propyl-[l,2,4]triazolo[4,3-a]pyrazin8(7H)-one	36 nM	24 nM	111 nM

Compound	PDE1C inhibition³) (nM or %)	PDE1B inhibition³) (nM or %)	PDE1A inhibition ^a)(nM or %)
7-(((lr,4r)-4-methylcyclohexyl)methyl)-3- propyl-[l,2,4]triazolo [4,3-a] pyrazin8(7H)-one	120 nM	40 nM	79 nM
6-bromo-7-(3-fluorobenzyl)-3-propyl- [l,2,4]triazolo[4,3-a]pyrazin-8(7H)-one	20 nM	99 nM	63 nM
6-bromo-7-(3-fluorobenzyl)-3- (tetrahydro-2H-pyran-4-yl)- [l,2,4]triazolo[4,3-a]pyrazin-8(7H)-one	24 nM	150 nM	114nM
6-bromo-7-(cyclopentylmethyl)-3- (tetra hydro-2H-pyran-4-yl)- [l,2,4]triazolo[4,3-a]pyrazin-8(7H)-one	6 nM	140 nM	164 nM
6-bromo-7-(cyclohexylmethyl)-3- (tetra hyd ro-2 H-py ra n-4-y I ) [l,2,4]triazolo[4,3-a]pyrazin-8(7H)-one	3 nM	17 nM	12 nM
6-bromo-7-(cycloheptylmethyl)-3- (tetra hyd ro-2 H-py ra n-4-yl)[l,2,4]triazolo[4,3-a]pyrazin-8(7H)-one	3 nM	4 nM	13 nM
6-benzyl-7-methyl-3-(tetrahydro-2Hpyran-4-yl)-[l,2,4]triazolo[4,3-a]pyrazin8(7H)-one	2800 nM	1600 nM	2000 nM
7-(4-methoxybenzyl)-6-methyl-3- (tetra hyd ro-2 H-py ra n-4-y I)[l,2,4]triazolo[4,3-a]pyrazin-8(7H)-one	37 nM	34 nM	54 nM
7-(4-methoxybenzyl)-6-methyl-3-propyl- [l,2,4]triazolo[4,3-a]pyrazin-8(7H)-one	44 nM	32 nM	66 nM
7-((4-methoxycyclohexyl)methyl)-6methyl-3-propyl-[l,2,4]triazolo[4,3a]pyrazin-8(7H)-one (cis)	n.d.	n.d.	n.d.
7-((4-methoxycyclohexyl)methyl)-6methyl-3-propyl-[l,2,4]triazolo[4,3a]pyrazin-8(7H)-one (trans)	n.d.	n.d.	n.d.

Compound	PDE1C inhibîtion^a)(nM or %)	PDE1B inhibition³) (nM or %)	PDE1A inhibition³) (nM or %)
Cis 6-methyl-7-((4- methylcyclohexyl)methyl)-3-propyl- [l,2,4]triazolo[4,3-a]pyrazin-8(7H)-one	n.d.	n.d.	n.d.
Trans 6-methyl-7-((4- methylcyclohexyl)methyl)-3-propyl- [l,2,4]triazolo[4_z3-a]pyrazin-8(7H)-one	n.d.	n.d.	n.d.
7-((4-methoxycyclohexyl)methyl)-6methy 1-3 - (t e t ra hyd ro-2 H-py ra n-4-yl)[l,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (cis)	n.d.	n.d.	n.d.
7-((4-methoxycyclohexyl)methyl)-6methyl-3-(tetrahydro-2H-pyran-4-yl)[l,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (trans)	n.d.	n.d.	n.d.
Cis 6-methyl-7-((4- methylcyclohexyl)methyl)-3-(tetrahydro2H-pyran-4-yl)-[l,2,4]triazolo[4_/3a]pyrazin-8(7H)-one	n.d.	n.d.	n.d.
Trans 6-methyl-7-((4methylcyclohexyl)methyl)-3-(tetrahydro2H-pyran-4-yl)-[l,2,4]triazolo[4,3a]pyrazin-8(7H)-one	n.d.	n.d.	n.d.
6-([l,l'-biphenyl]-4-ylmethyl)-7- (cyclohexylmethyl)-3-(tetrahydro-2Hpyran-4-yl)-[l,2,4]triazolo[4,3-a]pyrazin8(7H)-one	0.10 nM	0.17 nM	0.33 nM

Compound	PDE1C inhibition³) (nM or %)	PDE1B inhibition ^a)(nM or %)	PDE1A inhibition³) (nM or %)
7-(3-fluorobenzyl)-6-(3-methylbenzyl)-3(tetra hyd ro-2 H-py ra n-4-y 1 ) [l,2,4]triazolo[4,3-a]pyrazin-8(7H)-one	2 nM	9nM	6 nM
7-(cyclohexylmethyl)-6-(3-methylbenzyl)- 3-(tetrahydro-2H-pyran-4-yl)- [l,2,4]triazolo[4,3-a]pyrazin-8(7H)-one	1 nM	3nM	2nM
7-(cyclopentylmethyl)-6-(3methylbenzyl)-3-(tetrahydro-2H-pyran-4yl)-[l,2,4]triazolo[4,3-a]pyrazin-8(7H)one	4nM	37 nM	17 nM
7-(cycloheptylmethyl)-6-(4-fluorobenzyl)- 3-(tetra hyd ro-2 H-py ra n-4-yl)- [l,2,4]triazolo[4,3-a]pyrazin-8(7H)-one	4nM	9 nM	3nM
6-benzyl-7-(cycloheptylmethyl)-3- (tetra hyd ro-2 H-py ra n-4-yl)[l,2,4]triazolo[4,3-a]pyrazin-8(7H)-one	2nM	4nM	1 nM
6,7-bis(3-fluorobenzyl)-3-(tetrahydro-2H- pyran-4-yl)-[l,2,4]triazolo[4,3-a]pyrazin- 8(7H)-one	8 nM	40 nM	47 nM
7-(cyclohexylmethyl)-6-(3-fluorobenzyl)- 3-(tetra hyd ro-2 H-pyra n-4-yl )- [l,2,4]triazolo[4,3-a]pyrazin-8(7H)-one	6 nM	22 nM	24 nM
7-(cyclopentylmethyl)-6-(3-fluorobenzyl)- 3-(tetra hyd ro-2 H-pyra n -4-y 1 ) - [l,2,4]triazolo[4,3-a]pyrazin-8(7H)-one	27 nM	220 nM	369 nM
7-(3-fluorobenzyl)-6-(4-fluorobenzyl)-3(tetrahydro-2H-pyran-4-yl)[l,2,4]triazolo[4,3-a]pyrazin-8(7H)-one	10 nM	43 nM	46 nM
7-(cyclohexylmethyl)-6-(4-fluorobenzyl)- 3-(tetrahydro-2H-pyran-4-yl)- [l,2,4]triazolo[4,3-a]pyrazin-8(7H)-one	6nM	17 nM	12 nM

Compound	PDE1C inhibition^a) (nM or %)	PDE1B inhibition³) (nM or %)	PDE1A inhibition³) (nM or %)
7-(cyclopentylmethyl)-6-(4-fluorobenzyl)- 3-(tetra hyd ro-2 H-pyran-4-yl)- [l,2,4]triazolo[4,3-a]pyrazin-8(7H)-one	12 nM	140 nM	142 nM
7-(cycloheptylmethyl)-6-(2- methylbenzyl)-3-(tetrahydro-2H-pyran-4yl)-[l,2,4]triazolo[4,3-a]pyrazin-8(7H)one	14 nM	39 nM	25 nM
7-(cycloheptylmethyl)-6-(4- methylbenzyl)-3-(tetrahydro-2H-pyran-4yl)-[l,2,4]triazolo[4,3-a]pyrazin-8(7H)one	0.37 nM	1 nM	0.86 nM
7-(cyclohexylmethyl)-6-(4-methylbenzyl)- 3-(tetrahydro-2H-pyran-4-yl)- [l,2,4]triazolo[4,3-a]pyrazin-8(7H)-one	1 nM	2nM	1 nM
7-(cyclopentylmethyl)-6-(4- m ethyl be nzy l)-3-(tetra hyd ro-2 H-py ra n-4yl)-[l,2,4]triazolo[4,3-a]pyrazin-8(7H)one	3 nM	19 nM	21 nM
7-(cyclohexylmethyl)-6-(2-methylbenzyl)- 3-(tetra hyd ro-2 H-py ra n-4-yl)- [l,2,4]triazolo[4,3-a]pyrazin-8(7H)-one	10 nM	44 nM	41 nM
7-(cyclopentylmethyl)-6-(2methylbenzyl)-3-(tetrahydro-2H-pyran-4yl)-[l,2,4]triazolo[4,3-a]pyrazin-8(7H)one	23 nM	260 nM	251 nM
6-benzyl-7-(cyclopentylmethyl)-3- (tetra hyd ro-2 H-py ra n-4-y 1 )[l,2,4]triazolo[4,3-a]pyrazin-8(7H)-one	5 nM	46 nM	65 nM
6-benzyl-7-(cyclohexylmethyl)-3- (tetra hyd ro-2 H-pyra n-4-y 1)- [l,2,4]triazolo[4,3-a]pyrazin-8(7H)-one	4nM	11 nM	11 nM

Compound	PDE1C inhibition³’ (nM or %)	PDE1B inhibition ^a’ (nM or %)	PDE1A inhibition ^a)(nM or %)
7-(3-fluorobenzyl)-6-(4-methylbenzyl)-3(tetra hyd ro-2 H-py ra n-4-y 1 ) [l,2,4]triazolo[4,3-a]pyrazin-8(7H)-one	1 nM	6 nM	7nM
7-(3-fluorobenzyl)-6-(2-methylbenzyl)-3- (tetra hyd ro-2 H-py ra n-4-yl)[l,2,4]triazolo[4,3-a]pyrazin-8(7H)-one	17 nM	82 nM	91 nM
6-benzyl-7-(4-fluorobenzyl)-3- (tetra hyd ro-2 H-pyra n-4-yl)- [l,2_;4]triazolo[4,3-a]pyrazin-8(7H)-one	6 nM	12 nM	15 nM
(R)-7-(3-fluorobenzyl)-3-propyl-6- (tetrahydrofuran-3-yl)-[l,2,4]triazolo[4,3- a]pyrazin-8(7H)-one	290 nM	1800 nM	2976 nM
(S)-7-(3-fluorobenzyl)-3-propyl-6- (tetrahydrofuran-3-yl)-[l,2,4]triazolo[4,3- a]pyrazin-8(7H)-one	270 nM	1100 nM	1105 nM
7-(3-fluorobenzyl)-6-methyl-3-propyl- [l,2,4]triazolo[4,3-a]pyrazin-8(7H)-one	46 nM	190 nM	236 nM
7-(3-fluorobenzyl)-6-ethyl-3-propyl- [l,2,4]triazolo[4,3-a]pyrazin-8(7H)-one	50 nM	180 nM	117 nM
6-benzyl-7-(3-fluorobenzyl)-3- (tetra hyd ro-2 H-pyra n-4-y 1 )- [l,2,4]triazolo[4,3-a]pyrazin-8(7H)-one	5 nM	18 nM	32 nM
(R)-7-(3-fluorobenzyl)-3-propyl-5- (tetrahydrofuran-3-yl)-[l,2,4]triazolo[4,3- a]pyrazin-8(7H)-one	260 nM	2300 nM	1605 nM
(S)-7-(3-fluorobenzyl)-3-propyl-5- (tetrahydrofuran-3-yl)-[l,2,4]triazolo[4,3- a]pyrazin-8(7H)-one	260 nM	1000 nM	1784 nM
7-(3-fluorobenzyl)-3-propyl-5-methyl)- [l,2,4]triazolo[4,3-a]pyrazin-8(7H)-one	260 nM	1000 nM	1365 nM

Compound	PDE1C inhibition³) (nM or %)	PDE1B inhibition³) (nM or %)	PDE1A inhibition³) (nM or %)
7-(3-fluorobenzyl)-3-propyl-5-ethyl)- [l,2,4]triazolo[4,3-a]pyrazin-8(7H)-one	180 nM	510 nM	858 nM
5-bromo-7-(3-fluorobenzyl)-3-propyl- [l,2,4]triazolo[4,3-a]pyrazin-8(7H)-one	72 nM	180 nM	149 nM

n.d. means “not determined”

a) IC50 refers to the concentration (nM) ofthe compound required to reach 50% inhibition of the enzyme at the specified substrate concentration %inhib refers to the % inhibition 5 of the enzyme at a concentration of 10 micro molar of the compound.

EXPERIMENTAL SECTION

PREPARATION OF THE COMPOUNDS OF THE INVENTION

GENERAL METHODS io Analytical LC-MS data were obtained using one ofthe methods identified below.

Method 1 : A Waters Acquity UPLC-MS was used. Column: Acquity UPLC BEH C18

1.7pm; 2.1x50mm; Column température: 60 °C; Solvent system: A = water/trifluoroacetic acid (99.965:0.035) and B = acetonitrile /water/trifluoroacetic acid (94.965:5:0.035); Method: Linear gradient elution with A:B = 90:10 to 0:100 in 1.0 minutes and with a flow rate of 1.2 mL/minute.

Method 2: A Waters Acquity UPLC-MS was used. Column: Acquity UPLC BEH C18 1.7pm; 2.1x50mm; Column température: 60 °C; Solvent system: A = water/formic acid (99.9:0.1 ) and B = acetonitrile /water/formic acid (94.9:5:0.1); Method: Linear gradient elution with A:B = 90:10 to 0:100 in 1.0 minutes and with a flow rate of 1.2 mL/minute.

Method 3: An Agilent 1200 LCMS system with ELS detector was used. Column: Agilent TCC18 5 pm; 2.1x50mm; Column température: 50 °C; Solvent system: A = water/trifluoroacetic acid (99.9:0.1) and B = acetonitrile /trifluoroacetic acid (99.95:0.05); Method: Linear gradient elution with A:B = 99:1 to 0:100 in 4.0 minutes and with a flow rate of 0.8 mL/minute.

Method 4: An Agilent 1200 LCMS system with ELS detector was used. Column: XBridge ShieldRP18, 5 pm, 50x2.1mm; Column température: 40 °C; Solvent system: A = water/NH3*H2O (99.95:0.05) and B = acetonitrile; Method: Linear gradient elution with A:B = 95:5 to 0:100 in 3.4 minutes and with a flow rate of 0.8 mL/minute.

Method 5: A Waters Acquity UPLC-MS was used. Column: Acquity UPLC HSS T3 C18

1.8pm; 2.1x50mm; Column température: 60 °C; Solvent system: A = water/trifluoroacetic acid (99.965:0.035) and B = acetonitrile /water/trifluoroacetic acid (94.965:5:0.035); Method: Linear gradient elution with A:B = 98:02 to 0:100 in 1.0 minutes and with a flow rate of 1.2 mL/min.

Method 6: An Agilent 1200 LCMS system with ELS detector was used. Column: Waters XBridge ShieldRP18,2.1*50mm,5pm; Column température: 40 °C; Solvent system: A = water/ammonia (99.95:0.05) and B = acetonitrile; Method: Linear gradient elution with A:B = 95:5 to 0:100 in 4.0 minutes and with a flow rate of 0.8 mL/min.

Method 7: A Shimadzu 20 MS instrument equipped with atmospheric pressure photo ionisation ion source and a Shimadzu LC-20AB system was used. Column: MERCK, RP-18e 25-2mm; Column température: 50 °C; Solvent system: A = water/trifluoroacetic acid (99.9625:0.0375) and B = acetonitrile /trifluoroacetic acid (99.981:0.019); Method: A linear gradient elution A:B = 95:5 to A:B=5:95 in 0.7 minutes, then A:B=5:95 for 0.4 minutes, then with a linear gradient elution to A:B 95:5 for 0.4 minutes with a constant flow rate of 1.5 mL/min.

Method 8: An Agilent 1100 LCMS system with ELS detector was used. Column: YMC ODSAQ 5 pm; 2.0x50mm; Column température: 50 °C; Solvent system: A = water/trifluoroacetic acid (99.9:0.1) and B = acetonitrile /trifluoroacetic acid (99.95:0.05); Method: Linear gradient elution with A:B = 99:1 to 5:95 in 3.5 minutes and with a flow rate of 0.8 mL/min.

Method 9: An Agilent 1100 LCMS system with ELS detector was used. Column: YMC ODSAQ 5 pm; 2.0x50mm; Column température: 50 °C; Solvent system: A = water/trifluoroacetic acid (99.9:0.1) and B = acetonitrile /trifluoroacetic acid (99.95:0.05); Method: Linear gradient elution with A:B = 90:10 to 0:100 in 3.5 minutes and with a flow rate of 0.8 mL/min.

Préparative SFC was performed on a Thar 80 instrument. Exemplified conditions can be, but not limited to: Column AD 250 X 30mm with 20 pm particle size; Column température: 38 °C, Mobile phase: Supercritical CO₂/ EtOH(0.2%NH3H₂O) =45/55.

The following abbreviations hâve been used:

DME dimethoxyethane

DCM dichloromethane

TEA triethyl amine

THF tetrahydrofurane

EtOAc ethyl acetate

DMF /V,A/-dimethylformamide

DIPEA /V,A/-diisopropylethyl amine

MeOH Methanol

MTBE methyl tert-butyl ether

HATU 1 -[Bis(dimethylamino)methylene]-1 H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate

RT room température

SFC Supercritical Fluid Chromatography

Example 1

Intermediate 1 :

o

3-Propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one:

To a solution of commercial available 2-chloro-3-hydrazinylpyrazine (28 g, 0.19 mol) in dichloromethane (200 mL) was added butyraldéhyde (14.7 g, 0.20 mol) and the reaction was stirred at 50 °C for 2 hours before cooling to 0 °C. Diacetoxyiodobenzene (71.8 g, 0.223 mol) was added at 0 °C. Cooling was removed and the mixture was stirred at 20°C for 2 hours. A saturated aq. solution of Na₂CO₃ (80mL) was slowly poured into the reaction and the mixture was stirred for 10 minutes. The organic phase was separated, washed with brine (3x50 mL), dried over Na₂SO4 and concentrated under vacuum. The residue was purified by flash chromatography on silica gel using a gradient of ethyl acetate and petroleum ether to give 8-chloro-3-propyl- [1,2,4]triazolo[4,3-a]pyrazine 20 g (53%).

A mixture of 8-chloro-3-propyl-[1,2,4]triazolo[4,3-a]pyrazine (10 g, 51 mmol) and conc. aq. HCl (21 mL) in dioxane (120 mL) and H₂O (50 mL) was stirred at 100 °C for 12 hours. The solution was cooled to 20 °C and sat. aq. NaHCO₃ was added to adjust pH to 8. The mixture was concentrated under vacuum, the residue was washed with water and dried to give 3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one 8 g (88%).

Example 2

3-Propyl-7-((tetrahydro-2H-pyran-3-yl)methyl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)one:

Step 1: To a solution of (tetrahydro-2H-pyran-3-yl)methanol (300 mg, 2.58 mmol) and TEA (522 mg, 5.17mmol) in dichloromethane (10 mL) was added methanesulfonyl chloride (355 mg, 3.10 mmol) at 0 °C and the reaction was allowed to warm to 20 °C and stirred for 1 hour. The solution was washed with sat. aq. NaHCO₃ (2 mL), H₂O (3x2 mL), brine (1 mL), dried and concentrated to give (tetrahydro-2H-pyran-3-yl)methyl methanesulfonate (500 mg), which was used in the next step directly.

Step 2: To a solution of (tetrahydro-2H-pyran-3-yl)methyl methanesulfonate (500 mg,

2.58 mmol) and 3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (413 mg, 2.32 mmol) in DMF (30 mL) was added K₂CO₃ (534 mg, 3.87 mmol). The mixture was stirred at 60 °C for 4 hours. The reaction was cooled to RT and diluted with DCM (100 mL). The organic phase was washed with H₂O (2x1 OmL), dried over Na₂SO₄ and evaporated. The residue was washed with MeOH (2 mL) to give 3-propyl-7-((tetrahydro-2H-pyran-3yl)methyl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one 400 mg (56%).

The racemate of 3-propyl-7-((tetrahydro-2H-pyran-3-yl)methyl)-[1,2,4]triazolo[4,3-

a]pyrazin-8(7H)-one 400 mg was purified by SFC and the enantiomers numbered according to their order of elution.

Stereoisomer 1: 160 mg (40%), ¹H NMR (CDCI3 varian 400): δ 6.93 (d, J=6.0 Hz, 1H),

6.66 (d, J=6.0 Hz, 1H), 4.03-3.94 (m, 1H), 3.89-3.74 (m, 3H), 3.60-3.50 (m, 1H), 3.37 (dd, J=11.6, 7.6 Hz, 1H), 2.97 (t, J=7.Q Hz, 2H), 2.23-2.12 (m, 1H), 1.97-1.80 (m, 3H),

1.78-1.68 (m, 1 H), 1.62-1.53 (m, 1 H), 1.50-1.40 (m, 1 H), 1.06 (t, J=7.4 Hz, 3H). LCMS (MH+): m/z = 277.2, t_R (minutes, Method 3) = 1.99 [a]_D ²⁰ = - 11.33 (c = 0.10, MeOH).

Stereoisomer 2: 170 mg (42%), ¹H NMR (CDCI3 varian 400): δ 6.94 (d, J=6.0 Hz, 1 H),

6.66 (d, J=6.4 Hz, 1H), 4.01-3.94 (m, 1H), 3.89-3.74 (m, 3H), 3.60-3.51 (m, 1H), 3.37 (dd, J=11.6, 7.6 Hz, 1H), 2.97 (t, J=7.6 Hz, 2H), 2.23-2.12 (m, 1H), 1.97-1.80 (m, 3H),

1.78-1.68 (m, 1 H), 1.62-1.53 (m, 1 H), 1.50-1.40 (m, 1 H), 1.06 (t, J=7.4 Hz, 3H). LCMS (MH+): m/z = 277.2, t_R (minutes, Method 3) = 1.99 [a]_D ²⁰ = + 12.33 (c = 0.10, MeOH).

Example 3

7-(Cyclohexylmethyl)-3-propyl-[1,2,4]triazoIo[4,3-a]pyrazin-8(7H)-one:

To a solution of 3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (200 mg, 1.1 mmol) and (bromomethyl)cyclohexane (239 mg, 1.35 mmol) in DMF (2 mL) was added K₂CO₃(310 mg, 2.2 mmol). The reaction was stirred at 60 °C for 4 hours and then cooled to RT. DCM (20 mL) was added and the organic phase was washed with water (2x5 mL). The organic layer was dried over Na₂SO₄ and evaporated. The residue was washed with

MeOH (2 mL) to give 7-(cyclohexylmethyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)one 190 mg (61%). ¹H NMR (CDCI₃, 400 MHz TMS): δ 6.90 (d, J=5.6 Hz, 1H), 6.62 (d, J=5.6 Hz, 1H), 3.79 (d, J=7.2 Hz, 2H), 2.96 (t, J=7.6 Hz, 2H), 1.93-1.88 (m, 3H), 1.75-

1.61 (m, 5H), 1.21-1.18 (m, 3H), 1.08-1.01 (m, 5H). LCMS (MH+): m/z = 275.2, t_R(minutes, Method 3) = 2.57

Example 4

7-(Cyclopentylmethyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one:

To a solution of 3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (200 mg, 1.1 mmol) and (bromomethyl)cyclopentane (283 mg, 1.35 mmol) in DMF (2 mL) was added K2CO3 (310 mg, 2.2 mmol). The reaction was stirred at 60 °C for 4 hours and then cooled to RT. The mixture was diluted with DCM (20 mL) and washed with water (2x5 mL). The organic layer was dried over Na₂SO₄ and evaporated. The crude product was washed with MeOH (2 mL)to give 7-(cyclopentylmethyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin8(7H)-one 120 mg (41%). ¹H NMR(CDCI₃, 400 MHz TMS): δ 6.91 (d, J=5.6 Hz, 1H),

6.66 (d, J=5.6 Hz, 1H), 3.89 (d, J=8.0 Hz, 2H), 2.94 (t, J=7.6 Hz, 2H), 2.37-2.31 (m, 1H), 1.92-1.86 (m, 2H), 1.73-1.68 (m, 4H), 1.63-1.56 (m, 2H), 1.32-1.27 (m, 2H), 1.04 (t, J=7.4 Hz, 3H). LCMS (MH+): m/z = 261.1, t_R (minutes, Method 3) = 2.41

Example 5

3-Propyl-7-((tetrahydro-2H-pyran-4-yl)methyl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H) one:

To a solution of 3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (200 mg, 1.1 mmol) and

4-(bromomethyl)tetrahydro-2H-pyran (241 mg, 1.35 mmol) in DMF (2 mL) was added K2CO3 (310 mg, 2.2 mmol). The mixture was stirred at 60 °C for 4 hours and then cooled to RT. The reaction mixture was diluted with DCM (20 mL) and washed with water (2x5 mL). The organic phase was dried over Na₂SO4 and evaporated. The crude product was washed with MeOH (2 mL) to give 3-propyI-7-((tetrahydro-2H-pyran-4yl)methyl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one 120 mg (54%). ¹H NMR (CDCI₃, 400 MHz TMS): δ 6.91 (d, J=6.0 Hz, 1H), 6.62 (d, J=6.0 Hz, 1H), 3.96 (dd, J=11.6, 3.2 Hz, 2H), 3.82 (d, J=7.6 Hz, 2H), 3.34 (td, J=11.6, 1.6 Hz, 2H), 2.94 (t, J=7.6 Hz, 2H), 2.20-

2.10 (m, 1H), 1.91-1.86 (m, 2H), 1.61-1.58 (m, 2H), 1.40 (dq, J=4.0, 12.0 Hz, 2H), 1.04 (t, J=7.6 Hz, 3H). LCMS (MH+): m/z = 277.1, t_R (minutes, Method 3) = 1.93

Example 6

7-lsobutyI-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one:

1-bromo-2-methylpropane (231 mg, 1.68 mmol) in DMF (2 mL) was added K₂CO₃(185 mg, 1.34 mmol). The mixture was stirred at 60 °C for 12 hours and then cooled to RT. The reaction mixture was diluted with DCM (20 mL) and washed with water (2x5 mL). The organic phase was dried over Na₂SO₄ and evaporated. The residue was washed with MeOH (2 mL) to give 7-isobutyl-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one 160 mg (61%). ¹H NMR (CDCI3, 400 MHz TMS): δ 6.93 (d, J=6.0 Hz, 1H), 6.65 (d, J=6.0 Hz, 1H), 3.78 (d, J=7.6 Hz, 2H), 2.96 (t, J=7.6 Hz, 2H), 2.20-2.14 (m, 1H), 1.95-

1.88 (m, 2H), 1.06 (t, J=7.4 Hz, 3H), 0.98 (d, J=6.6 Hz, 6H). LCMS (MH+): m/z = 235.2, t_R (minutes, Method 3) = 2.16

Example 7

Ο

7-(Cyclopropylmethyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one:

Το a solution of 3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (200 mg, 1.1 mmol) and (bromomethyl)cyclopropane (227 mg, 1.68 mmol) in DMF (2 mL) was added K2CO3 (186 mg, 1.35 mmol). The mixture was stirred at 60 °C for 12 hours and then cooled to RT. To the reaction mixture was added DCM (20 mL) and it was washed with water (2x5 mL). The organic layer was dried over Na₂SO4 and evaporated. The residue was washed with MeOH (2 mL) to give 7-(cyclopropylmethyl)-3-propyl-[1,2,4]triazolo[4,3-

a]pyrazin-8(7H)-one 60 mg (23%). ¹H NMR (CDCI3, 400 MHzTMS): δ 6.97 (d, J=6.0 Hz, 1H), 6.82 (d, J=5.6 Hz, 1H), 3.85 (d, J=7.2 Hz, 2H), 2.97 (t, J=7.6 Hz, 2H), 1.94-

1.87 (m, 2H), 1.15-1.27 (m, 1 H), 1.06 (t, J=7.4 Hz, 3H), 0.60-0.68 (m, 2H), 0.45-0.42 (m, 2H). LCMS (MH+): m/z = 233.2, t_R (minutes, Method 3) = 2.06

Example 8 o

7-Ethyl-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one:

To a solution of 3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (200 mg, 1.1 mmol) and iodoethane (262 mg, 1.68 mmol) in DMF (2 mL) was added K₂CO₃(186 mg, 1.34 mmol). The mixture was stirred at 60 °C for 12 hours and then cooled to RT. The reaction mixture was diluted with DCM (20 mL) and washed with H₂O (2x5 mL). The organic layer was dried over Na₂SO4 and evaporated. The residue was washed with MeOH (2 mL) to give 7-ethyl-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one 60 mg (26%). ¹H NMR (CDCI3, 400 MHz TMS): δ 6.96 (d, J=5.8 Hz, 1 H), 6.69 (d, J=5.8 Hz, 1H), 4.03 (q, J=7.1 Hz, 2H), 2.96 (t, J=7.6 Hz, 2H), 1.95-1.86 (m, 2H), 1.38 (t, J=7.2 Hz, 3H), 1.06 (t, J=7.4 Hz, 3H). LCMS (MH+): m/z = 207.1, t_R (minutes, Method 3) = 1.81

Example 9

Ο

7-(Oxetan-3-ylmethyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one:

Step 1: To a solution of oxetan-3-ylmethanol (500 mg, 5.67 mmol) and Et₃N (1.15 g,

11.4 mmol) in DCM (20 mL) was added methanesulfonyl chloride (780 mg, 6.81 mmol) at 0°C. Cooling was removed and the mixture was stirred at 20°C for 1 hour. The reaction mixture was diluted with 2 M NaHCO₃ (5 mL) then brine (5 mL). The organic layer was dried over Na₂SO₄ and evaporated to give oxetan-3-ylmethyl methanesulfonate 920 mg (97%).

Step 2: To a solution of 3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (200 mg, 1.1 mmol) and oxetan-3-ylmethyl methanesulfonate (249 mg, 1.35 mmol) in DMF (2 mL) was added K₂CO₃ (310 mg, 2.20 mmol). The mixture was stirred at 60 °C for 4 hours and then cooled to RT. The reaction mixture was diluted with DCM (20 mL) and washed with water (2x5 mL). The organic phase was dried over Na₂SO₄ and evaporated. The residue was washed with ethyl acetate (4 mL) to give 7-(oxetan-3-ylmethyl)-3-propyl- [1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one 40 mg (14%). ¹H NMR(CDCI₃, 400 MHzTMS): δ

6.88 (d, J=6.0 Hz, 1H), 6.62 (d, J=6.0 Hz, 1H), 4.75 (t, J=7.2 Hz, 2H), 4.46 (t, J=6.4 Hz, 2H), 4.22 (d, J=7.2 Hz, 2H), 3.50-3.40 (m, 1H), 2.89 (t, J=7.6 Hz, 2H), 1.89-1.79 (m, 2H), 0.99 (t, J=7.6 Hz, 3H). LCMS (MH+): m/z = 249.1, t_R (minutes, Method 3) = 1.38

Example 10 o

7-(Cycloheptylmethyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one:

Step 1 : To a solution of cycloheptanecarboxylic acid (200 mg, 1.41 mmol) in THF (15 mL) was added 1 M BH₃-THF (2.8 mL, 2.8 mmol) at 0°C and it was then heated to 70°C and stirred for 12 hours. The solution was cooled to 20 °C and MeOH (4 mL) was added. the reaction was stirred at 65°C for 2 hours before it was cooled to RT and concentrated in vacuo. The residue was purified by flash chromatography on silica gel using a gradient of ethyl acetate petroleum ether to give cycloheptylmethanol 150 mg (83%).

Step 2: To a solution of cycloheptylmethanol (150 mg, 1.17 mmol) and TEA (236 mg,

2.34 mmol) in DCM (5 mL) was added methanesulfonyl chloride (201 mg, 2.75 mmol) at 0 °C and it was allowed to warm to 20 °C and stirred for 0.5 hour. The solution was washed with sat. aq. NaHCO₃ (2 mL), H₂O (3x2 mL), brine (1 mL), dried over Na₂SO₄and concentrated to give cycloheptylmethyl methanesulfonate (250 mg), which was used in the next step directly.

Step 3: To a solution of cycloheptylmethyl methanesulfonate (250 mg ) and 3-propyl- [1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (187 mg, 1.05 mmol) in DMF (5 mL) was added K₂CO₃ (241 mg, 1.75 mmol). The mixture was stirred at 60°C for 12 hours. The reaction mixture was diluted with DCM (20 mL) and washed with water (2x5 mL). The organic phase was dried over Na₂SO₄ and evaporated. The residue was washed with MeOH (2 mL)to give 7-(cycloheptylmethyl)-3-propyI-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one 100 mg (33%). ¹H NMR (CDCI₃₎ 400 MHzTMS): δ 6.91 (d, J=6.0 Hz, 1H), 6.64 (d, J=6.0 Hz, 1H), 3.79 (d, J=7.2 Hz, 2H), 2.96 (t, J=7.6 Hz, 2H), 2.08-2.00 (m, 1H), 1.96-1.87 (m, 2H), 1.71-1.65 (m, 4H), 1.61-1.38 (m, 6H), 1.30-1.21 (m, 2H), 1.07 (t, J=7.4 Hz, 3H). LCMS (MH+): m/z = 289.1, îr (minutes, Method 3) = 2.31

Example 11

O

3-Propyl-7-((tetrahydrofuran-3-yl)methyl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one:

Step 1: To a solution of tetrahydrofuran-3-carboxylic acid (600 mg, 5.17 mmol) in THF (15 mL) was added a solution of 1 M BH₃-THF in THF (10.3 mL, 10.3 mmol) at 0 °C. The reaction was heated to 65 °C and stirred for 12 hours. The solution was then cooled to 20 °C and MeOH (4 mL) was added. The reaction was then stirred at 65 °C for 2 hours before cooling to RT and concentrated in vacuo. The residue was purified by flash chromatography on siiica gel using a gradient of ethyl acetate and petroleum ether to give (tetrahydrofuran-3-yl)methanol 200 mg (38%).

Step 2: To a solution of (tetrahydrofuran-3-yl)methanol (200 mg, 1.96 mmol) and TEA (396 mg, 3.92 mmol) in DCM (15 mL) was added methanesulfonyl chloride (448 mg,

3.92 mmol) at 0 °C. The reaction was heated at 20 °C and stirred for 1 hour. The solution was washed with sat. aq. NaHCO₃ (2 mL), H2O (3^2 mL), brine (1 mL) dried and concentrated to give (tetrahydrofuran-3-yl)methyl methanesulfonate (400 mg), which was used in the next step directly.

Step 3: To a solution of (tetrahydrofuran-3-yl)methyl methanesulfonate (400 mg) and 3propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (348 mg, 1.95 mmol) in DMF (10 mL) was added K₂CO₃(539 mg, 3.91 mmol). The mixture was stirred at 60 °C for 12 hours. The mixture was diluted with DCM (100mL) and washed with H₂O (2x1 OmL). The organic layer was dried over Na₂SC>4 and evaporated. The residue was washed with MeOH (2 mL) to give 3-propyl-7-((tetrahydrofuran-3-yl)methyl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)one 200 mg (39%).

The racemate of 3-propyl-7-((tetrahydrofuran-3-yl)methyl)-[1,2,4]triazolo[4,3-a]pyrazin8(7H)-one 200 mg was purified by SFC and the enantiomers numbered according to their order of elution.

Stereoisomer 1: 160 mg (40%), ¹H NMR (CDCI₃ varian 400 MHz): δ 6.95 (d, J=5.9 Hz,

1H), 6.68 (d, J=6.1 Hz, 1H), 4.08 (dd, J=13.5, 7.3 Hz, 1H), 4.00-3.94 (m, 1H), 3.86-3.74 (m, 3H), 3.63 (dd, J=9.1,4.9 Hz, 1H), 2.97 (t, J=7.6 Hz, 2H), 2.91-2.80 (m, 1H), 2.132.02 (m, 1H), 1.96-1.87 (m, 2H), 1.77-1.69 (m, 1H), 1.06 (t, J=7.6 Hz, 3H). LCMS (MH+): m/z = 263.1, t_R (minutes, Method 3) = 1.85 [a]_D ²⁰ = + 9.33° (c = 0.10, MeOH).

Stereoisomer 2: 170 mg (43%), ¹H NMR (CDCh varian 400 MHz): δ 6.94 (d, J=6.0 Hz, 1H), 6.68 (d, J=6.0 Hz, 1H), 4.09 (dd, J=13.5, 7.3 Hz, 1H), 4.00-3.94 (m, 1H), 3.86-3.74 (m, 3H), 3.63 (dd, J=9.1,4.9 Hz, 1H), 2.97 (t, J=7.6 Hz, 2H), 2.91-2.80 (m, 1H), 2.132.02 (m, 1 H), 1.96-1.87 (m, 2H), 1.77-1.69 (m, 1 H), 1.06 (t, J=7.4 Hz, 3H). LCMS (MH+): m/z = 263.1, t_R (minutes, Method 3) = 1.86 [ct]_D ²⁰ = - 7.67° (c = 0.10, MeOH).

Example 12

7- Benzyl-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one:

8- Chloro-3-propyl-[1,2,4]triazolo[4,3-a]pyrazine (101 mg, 0.514 mmol) and phenylmethanol (100 mg, 0.925 mmol) were dissolved in dimethoxyethane (3 mL), NaH 60% in minerai oil (41 mg, 1.0 mmol) was added, and the mixture was stirred at RT for 1 hour. Sodium iodide (154 mg, 1.03 mmol) was added and the reaction was heated at 200°C for 20 min under microwave irridiation. The reaction was filtered and concentrated in vacuo. The crude product was purified by column chromatography using a gradient of (petroleum ether: EtOAc: 5%Et3N/10%MeOH/85%EtOAc = 1:0:0 to 0:1:0 to 0:0:1) to afford 7-benzyl-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one 65 mg (45%). %), ¹H NMR (CDCI3 500 MHz): δ 7.38 (m, 5 H), 6.92 (d, J=6.0 Hz, 1 H), 6.68 (d, J=6.0 Hz, 1 H), 5.17 (s, 2 H), 2.97 (t, J=7.6 Hz, 2 H), 1.96-1.87 (m, 2 H), 1.06 (t, J=7.4 Hz, 3 H). LCMS (MH+): m/z = 269.2, t_R (minutes, Method 1) = 0.50

Example 13

7-(2-Fluorobenzyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one:

8-Chloro-3-propyl-[1,2,4]triazolo[4,3-a]pyrazine (116 mg, 0.590 mmol), (2-fluorophenyl) methanol (134 mg, 1.06 mmol) were dissolved in dimethoxyethane (3.5 ml), NaH 60% in minerai oil (43 mg, 1.1 mmol) was added and the reaction was stirred at RT for 2 hours. Sodium iodide (177 mg, 1.18 mmol) was added and the reaction was heated at 200°C for 20 minutes under microwave irridiation. The reaction was filtered and concentrated in vacuo. The crude product was purified by column chromatography using a gradient of (petroleum ether: EtOAc: 5%Et₃N/10%MeOH/85%EtOAc = 1:0:0 to 0:1:0 to 0:0:1) to afford 7-(2-fluorobenzyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)one 8 mg (9%). %), ¹H NMR (CDCI₃ 500 MHz): δ 7.56 (m, 1 H), 7.35 (m, 1 H), 7.17 (m, 1 H), 7.12 (m, 1 H), 6.92 (d, J=6.0 Hz, 1 H), 6.82 (d, J=6.0 Hz, 1 H), 5.22 (s, 2 H), 2.94 (t, J=7.6 Hz, 2 H), 1.92 (m, 2 H), 1.06 (t, J=7.4 Hz, 3 H). LCMS (MH+): m/z = 287.2, t_R(minutes, Method 1) = 0.51

Example 14

Intermediate 2:

1-(3-Fluorobenzyl)-3-hydrazinylpyrazin-2(1H)-one:

Step 1: To a solution of (3-fluorophenyl)methanamine (10.0 g, 80.0 mmol) in THF (40 mL) was slowly added ethyl 2-chloro-2-oxoacetate (9.78 mL, 87.9 mmol) at 0°C. Then the mixture was stirred at RT for 30 minutes. Then a solution of 2,2-dimethoxyethan-lamine (10. 5 mL, 95.9 mmol) and DIPEA (41.8 mL, 239 mmol) in ethylacetate (40 mL) was added to the mixture. The reaction mixture was heated at reflux overnight and then cooled to RT. To the reaction mixture was added sat. aq. NaHCOs (50 mL) and it was extracted with ethyl acetate (50 mL). The organic phase was dried over Na2SO4, filtered, concentrated in vacuo and purified by column chromatography on silica gel using a gradient of DCM and methanol (DCM/MeOH=100/1 to 20/1) to give Δ/1 -(2,2dimethoxyethyl)-A/2-(3-fluorobenzyl)oxalamide 15 g (66%).

Step 2: To a solution of A/1-(2,2-dimethoxyethyl)-A/2-(3-fluorobenzyl)oxalamide (1.00 g,

3.52 mmol) in acetic acid (20 mL) was added trifluoroacetic acid (0.3 mL). Then the reaction was heated at 140°C for 2 hours and cooled to RT. The crude mixture was concentrated and the residue was added to MTBE (50 mL) and sat. aq. NaHCC>3 (50 mL). The resulting precipitate was collected by filtration, washed with H₂O (50 mL) and MTBE (50 mL) to give 1-(3-fluorobenzyl)-1,4-dihydropyrazine-2,3-dione 500 mg (64%).

LCMS (MH+): m/z = 221.1, îr (minutes, Method 3) = 1.95

Step 3: 1-(3-Fluorobenzyl)-1,4-dihydropyrazine-2,3-dione (8.0 g, 36 mmol) was slowly added to POCI3 (35 mL). The mixture was heated at 80°C for 1 hour and then cooled to RT. The crude reaction mixture was poured onto ice-water (100 mL), pH was adjusted around 7 by addition of sat. aq. NaHCO₃ (1 L). The mixture was extracted with DCM (2x500 mL). The combined organic phases were dried over Na₂SO₄, filtered, concentrated and purified by column chromatography silica gel using a gradient of ethyl actetate and DCM (DCM/EtOAc=100/1 to 30/1) to give 3-chloro-1-(3fluorobenzyl)pyrazin-2(1H)-one 6 g (69%).

Step 4: To a solution of 3-chloro-1-(3-fluorobenzyl)pyrazin-2(1H)-one (1 g, 4.19 mmol) in EtOH (30 mL) was added NH₂NH₂-H₂O (1 mL). The mixture was stirred at 40 °C overnight and then cooled to 0 °C. The precipitate was filtered off and washed with water (20 mL), cold EtOH (20 mL) and dried to give 1-(3-fluorobenzyl)-3hydrazinylpyrazin-2(1 H)-one 800 mg (81 %).

Example 15

O

7-(3-Fluorobenzyl)-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)one:

Step 1: To a cooled (0°C) solution of 1-(3-fluorobenzyl)-3-hydrazinyIpyrazin-2(1H)-one (300 mg, 1.28 mmol) in DCM (8 mL) was added dropwise a solution of tetrahydro-2H18257 pyran-4-carbonyl chloride (209 mg, 1.41 mmol) in DCM (2 mL). The mixture was warmed to room température and stirred for 1 h. To the mixture was added H₂O (5 mL). The organic layer was washed with water (10 mL), dried over Na₂SO₄ and concentrated to give crude A/'-(4-(3-fluorobenzyl)-3-oxo-3,4-dihydropyrazin-2-yl)tetrahydro-2H-pyran-

4-carbohydrazide 400 mg (90%) used for the next reaction without further purification.

Step 2: To a solution of /V'-(4-(3-fluorobenzyl)-3-oxo-3,4-dihydropyrazin-2-yl)tetrahydro2H-pyran-4-carbohydrazide (400 mg, 1.16 mmol) in dioxane (10 mL) was added POCI₃(884 mg, 5.78 mmol). The mixture was heated at reflux for 1.5 h and then cooled to room température. The reaction was concentrated in vacuo and the residue was adjusted to pH=7-8 by addition of sat. aq. NaHCO₃. The mixture was extracted with ethyl acetate (3x30 mL). The combined organic phases were washed with brine, dried over Na₂SO₄, filtered, concentrated in vacuo and purified by flash chromatography using a gradient of DCM/methanol (DCM/MeOH=50/1 to 20/1) to give 7-(3fluorobenzyl)-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one 122 mg (32%). ¹H NMR (DMSO-d₆ varian 400): δ 7.69 (d, J=5.6 Hz, 1 H), 7.41 - 7.36 (m, 1 H), 7.28 (d, J=6.0 Hz, 1 H), 7.21 - 7.12 (m, 3 H), 5.11 (s, 2 H), 3.94 (d, J=11.6 Hz, 2 H),

3.52 - 3.46 (m, 2 H), 1.87 - 1.81 (m, 4 H). LCMS (MH+): m/z = 329.1, t_R (minutes, Method 3) = 1.68

Example 16 o

7-(3-Fluorobenzyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one:

Step 1: To a solution of 2-((3-fluorobenzyl)oxy)-3-hydrazinylpyrazine (1.5 g, 6.4 mmol) in chloroform (20 ml) was added butyraldéhyde (0.508 g7.04 mmol) and the mixture was stirred for 6 hours at RT and subsequently cooled on an icebath. lodobenzene diacetate (2.27 g, 7.04 mmol) was added and cooling removed. The reaction was stirred at RT for 16 hours. The crude reaction was concentrated onto celite and purified by flash chromatography using a gradient of ethyl acetate and heptane to yield 8-((3fluorobenzyl)oxy)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazine 1.5 g (82%).

Step 2: To a solution of 8-((3-fluorobenzyl)oxy)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazine (1.43 g, 4.99 mmol) in DME (30 ml) was added sodium iodide (1.5 g, 1.0 mmol) and the reaction was heated at 200°C for 20 minutes under microwave irradiation. To the reaction was added with H₂O (50 mL) and it was extracted with DCM (3x60 mL). The combined organic phases were washed with brine, dried over MgSO₄, concentrated in vacuo and purified by flash chromatography using a gradient of ethyl acetate and heptane to yield 7-(3-fluorobenzyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one 1.14 g (80 %). ¹H NMR (CDCh 500 MHz): δ 7.38 (m, 1 H), 7.15 (m, 1 H), 7.08 (m, 2 H), 6.92 (d, J=6.0 Hz, 1 H), 6.66 (d, J=6.0 Hz, 1 H), 5.18 (s, 2 H), 2.96 (t, J=7.6 Hz, 2 H), 1.91 (m, 2 H), 1.08 (t, J=7.4 Hz, 3 H). LCMS (MH+): m/z = 287.1, t_R (minutes, Method 1) = 0.52

Example 17 o

7-(3-Methylbenzyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one:

To a solution of 8-chloro-3-propyl-[1,2,4]triazolo[4,3-a]pyrazine (94 mg, 0.48 mmol) and m-tolylmethanol (105 mg, 0.860 mmol) in DME (3 ml) was added NaH 60% in minerai oil (34 mg, 0.86 mmol) at RT and the reaction was stirred for 1 hour.

Sodium iodide (143 mg, 0.956 mmol) was added and the reaction was heated at 200°C for 20 minutes under microwave irradiation. The crude reaction mixture was concentrated in vacuo and purified by flash chromatography using a gradient of (petroleum ether: EtOAc: 5%Et₃N/10%MeOH/85%EtOAc = 1:0:0 to 0:1:0 to 0:0:1) to yield 44 mg 7-(3-methylbenzyl)-3-propyI-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (33%). ¹H NMR (CDCh 500 MHz): δ 7.25 (m, 1 H), 7.13 (m, 3 H), 6.89 (d, J=6.0 Hz, 1 H), 6.64 (d, J=6.0 Hz, 1 H), 5.11 (s, 2 H), 2.92 (t, J=7.5 Hz, 2 H), 2.33 (s, 3 H), 1.89 (m, 2 H), 1.02 (t, J=7.4 Hz, 3 H). LCMS (MH+): m/z = 283.3, t_R (minutes, Method 1) = 0.57

Example 18

Ο

3-Propyl-7-(4-(trifluoromethyl)benzyl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one:

To a solution of 8-chloro-3-propyl-[1,2,4]triazolo[4,3-a]pyrazine (82 mg, 0.42 mmol) and (4-(trifluoromethyl)phenyl)methanol (114 mg, 0.646 mmol) in DME (3.5 ml) was added NaH 60% in minerai oil (47 mg, 1.2 mmol) at RT and the mixture was stirred for 2 hours. Sodium iodide (140 mg, 0.932 mmol) was added and the reaction was heated at 200°C for 20 minutes under microwave irradiation. The crude reaction mixture was concentrated in vacuo and purified by flash chromatography using a gradient of (petroleum ether: EtOAc: 5%Et₃N/10%MeOH/85%EtOAc = 1:0:0 to 0:1:0 to 0:0:1) to yield 31 mg 3-propyl-7-(4-(trifluoromethyl)benzyl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (19%). ¹H NMR (CDCIs 500 MHz): δ 7.65 (m, 2 H), 7.50 (m, 2 H), 6.94 (d, J=6.0 Hz, 1 H), 6.65 (d, J=6.0 Hz, 1 H), 5.21 (s, 2 H), 2.97 (t, J=7.6 Hz, 2 H), 1.91 (m, 2 H), 1.07 (t, J=7.4 Hz, 3 H). LCMS (MH⁺): m/z = 337.2, t_R (minutes, Method 1) = 0.62

Example 19 o

7-(3-Fluorobenzyl)-3-((tetrahydrofuran-3-yl)methyl)-[1,2,4]triazolo[4,3-a]pyrazin8(7H)-one:

Step 1: To a mixture of 2-(tetrahydrofuran-3-yl)acetic acid (1.00 g, 7.68 mmol) and SOCI₂ (10 ml) was added one drop of DMF and the reaction mixture was stirred at RT for 45 minutes.

The température was brought to 85 °C and stirred for 4 hours before being concentrated in vacuo.

The crude product was used for next step without further purification

Step 2: To an ice-cold solution of 2-chloro-3-hydrazinylpyrazine (1.1 g, 7.7 mmol) and DIPEA (2.98 g, 23.1 mmol) in DCM (30 ml) was added 2-(tetrahydrofuran-3-yI)acetyl chloride (1.1 g, 7.7 mmol) in DCM (8.0 ml). The reaction was then allowed to warm to RT and stirred overnight.

The reaction mixture was poured into H₂O (100 mL) and extracted with DCM (3^50 mL). The combined organic phases were washed with brine, dried over MgSO₄ and concentrated in vacuo. The crude product was purified by flash chromatography using a gradient of ethyl acetate and heptane to yield /V-(3-chloropyrazin-2-yl)-2(tetrahydrofuran-3-yl)acetohydrazide 714 mg (36%).

Step 3: A mixture of A/'-(3-chloropyrazin-2-yl)-2-(tetrahydrofuran-3-yl)acetohydrazide (200 mg, 0.779 mmol) and POCI₃ (597 mg, 3.90 mmol) in acetonitrile (4.5 ml) was heated for 60 min at 100 °C under microwave irradiation. To the reaction was carefully added sat. aq. K₂CO₃ (15 mL) and then H₂O (20mL). The mixture was extracted with ethyl acetate (3x30 mL). The combined organic phases were washed with brine, dried over MgSO₄ and concentrated in vacuo. The crude product was purified by flash chromatography using a gradient of ethyl acetate and heptane to yield 8-chloro-3((tetrahydrofuran-3-yl)methyI)-[1,2,4]triazolo[4,3-a]pyrazine 73 mg, (39%).

Step 4: To a solution of 8-chIoro-3-((tetrahydrofuran-3-yl)methyl)-[1,2,4]triazolo[4,3ajpyrazine (72 mg, 0.30 mmol) and (3-fluorophenyl)methanol (46 mg, 0.36 mmol) dissolved in DME (2 ml) was added NaH 60% in minerai oil (22 mg, 0.54 mmol) at 0°C. The mixture was allowed to warm to RT and stirred for 3 hours. Sodium iodide (90 mg, 0.60 mmol) was added and the reaction was heated at 200 °C for 20 min under microwave irradiation. The reaction mixture was poured into H₂O (25 mL) and extracted with ethyl acetate (3x25mL). The combined organic phases were washed with brine, dried over MgSO₄, concentrated in vacuo and purified by flash chromatography using a gradient of ethyl acetate and heptane to yield 26 mg (26%) 7-(3-fluorobenzyl)-3((tetrahydrofuran-3-yl)methyl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one. ¹H NMR (CDCI₃600 MHz): δ 7.32 (m, 1 H), 7.13 (m, 1 H), 7.06 (m, 2 H), 7.00 (d, J=6.0 Hz, 1 H), 6.72 (d, J=6.0 Hz, 1 H), 5.14 (s, 2 H), 3.93 (m, 2 H), 3.79 (m, 1 H), 3.54 (m, 1 H), 3.02 (m, 2 H),

2.91 (m, 1 H), 2.18 (m, 1 H), 1.72 (m, 1 H). LCMS (MH⁺): m/z = 329.0, t_R (minutes,

Method 2) = 0.47

Example 20

3-Propyl-7-(2-(trifluoromethyl)benzyl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one:

To a solution of 8-chloro-3-propyl-[1,2,4]triazolo[4,3-a]pyrazine (88 mg, 0.45 mmol) and (2-(trifluoromethyl)phenyl)methanol (111 mg, 0.629 mmol) in dimethoxyethane (3.5 ml) was added NaH 60% in minerai oil (35 mg, 0.88 mmol) at RT and the reaction was stirred for 2 hours. Sodium iodide (110 mg, 0.734 mmol) was added and the reaction was heated at 200 °C for 20 min under microwave irradiation. The reaction mixture was concentrated in vacuo and purified by flash chromatography using a gradient of (petroleum ether: EtOAc: 5%Et₃N/10%MeOH/85%EtOAc = 1:0:0 to 0:1:0 to 0:0:1) to yield 31 mg (17%) 3-propyl-7-(2-(trifluoromethyl)benzyl)-[1,2,4]triazolo[4,3-a]pyrazin8(7H)-one. ¹H NMR (CDCI3 500 MHz): δ 7.76 (m, 1 H), 7.56 (m, 1 H), 7.45 (m ,1 H), 7.40 (m, 1 H), 6.93 (d, J=6.0 Hz, 1 H), 6.60 (d, J=6.0 Hz, 1 H), 5.40 (s, 2 H), 2.98 (t, J=7.6 Hz, 2 H), 1.92 (m, 2 H), 1.09 (t, J=7.4 Hz, 3 H). LCMS (MH⁺): m/z = 337.2, tR (minutes, Method 1) = 0.60.

Example 21

Cl o

7-(2-ChlorobenzyI)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one:

To a solution of 8-chloro-3-propyl-[1,2,4]triazolo[4,3-a]pyrazine (108 mg, 0.549 mmol) and (2-chlorophenyl)methanol (153 mg, 1.07 mmol) in dimethoxyethane (3 ml) was added NaH 60% in minerai oil (40 mg, 0.99 mmol) at RT. The reaction was stirred for 2 hours. Sodium iodide (165 mg, 1.10 mmol) was added and the reaction was heated at 200°C for 20 min under microwave irradiation.The crude mixture was concentrated in vacuo and purified by flash chromatography using a gradient of (petroleum ether: EtOAc: 5%Et₃N/10%MeOH/85%EtOAc = 1:0:0 to 0:1:0 to 0:0:1) to yield 15 mg (9%) 7(2-chlorobenzyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one. ¹H NMR (CDCI3 500 MHz): δ 7.44 (m, 2 H), 7.28 (m, 2 H), 6.90 (d, J=6.0 Hz, 1 H), 6.76 (d, J=6.0 Hz, 1 H), 5.30 (s, 2 H), 2.94 (t, J=7.6 Hz, 2 H), 1.88 (p, J=7.5 Hz, 2 H), 1.03 (t, J=7.4 Hz, 3 H). LCMS (MH⁺): m/z = 303.2, tR (minutes, Method 1) = 0.56

Example 22

O

Cl

7-(4-Chlorobenzyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one:

To an ice-cold solution of 3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (201 mg, 1.13 mmol) in DMF (0.8 mL) was added sodium hydride 60% in minerai oil (122 mg, 3.05 mmol). Cooling was removed and stirring was continued for 1 hour. To the reaction was added 1-(bromomethyl)-4-chlorobenzene (624 mg, 3.04 mmol) and stirring was continued for another 3½ hours. The reaction was quenched by addition of sat. aq. NH4CI (2mL) dropwise. It was then poured into H2O (20 mL) and extracted with ethyl acetate (3x20 mL). The combined organic phases were washed with brine, dried over MgSO₄ and concentrated in vacuo. The crude product was purified by flash chromatography using a gradient of ethyl acetate and heptane to yield 13 mg (4%) 7-(4chlorobenzyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one. ¹H NMR (CDCI3 600 MHz): δ 7.35 (m, 2 H), 7.32 (m, 2 H), 6.91 (d, J=6.0 Hz, 1 H), 6.61 (d, J=6.0 Hz, 1 H), 5.12 (s, 2 H), 2.93 (t, J=7.6 Hz, 2 H), 1.89 (m, 2 H), 1.04 (t, J=7.4 Hz, 3 H). LCMS (MH⁺): m/z = 303.2 tR (minutes, Method 1) = 0.59

Example 23

7-HexyI-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one:

A solution of 3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one hydrochloride (100 mg, 0.390 mmol), 1-bromohexane (148 mg, 0.898 mmol), K2CO3 (193 mg, 1.40 mmol) and Nal (5.84 mg, 0.039 mmol) in DMF (1.5 ml) was stirred at 80°C over night. The reaction mixture was poured into H₂O (20 mL) and extracted with ethyl acetate (3x20 ml). The combined organic phases were wahed with brine, dried over MgSO₄ and concentrated in vacuo . The residue was purified by flash chromatography on silica using a gradient of heptane, ethyl acetate and ethyl acetate+20% MeOH (Heptane/EtOAc/EtOAc + 20%MeOH 1:0:0 to 0:1:0 to 0:0:1 ) to yield 26 mg (22%) 7-hexyl-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3-a]pyrazin8(7H)-one. ¹H NMR (CDCI3 500 MHz): δ 7.02 (d, J=6.0 Hz, 1 H), 6.71 (d, J=6.0 Hz, 1 H), 4.13 (m, 2 H), 3.96 (m, 2 H), 3,61 (m, 2 H), 3.23 (m, 1 H), 2.21 (m, 2 H), 1.96 (m, 2 H), 1.77 (m, 2 H), 1.35 (m, 6 H), 0.91 (m, 3 H). LC-MS: m/z = 305.2 [M + H]⁺, tR (minutes, Method 1) = 0.55 ,.

Example 24

7-(4-Chlorobenzyl)-3-(tetrahydrofuran-3-yl)-['l,2,4]triazolo[4,3-a]pyrazin-8(7H)-one:

Step 1: To a solution of tetrahydrofuran-3-carboxylic acid (1.0 g, 8.6 mmol) in DMF (15 ml) was added HATU (3.60 g, 9.47 mmol), DIPEA (1.22 g, 1.66 ml, 9.47 mmol) and finally 2-chloro-3-hydrazinylpyrazine (1.37 g, 9.47 mmol). The mixture was stirred for 3 hours at RT. The reaction mixture was poured into sat. aq. Na₂CO₃ (20 mL) and extracted with ethyl acetate (3x20 mL). The combined organic phases were washed with brine (3x25 mL), dried over MgSO4 and concentrated in vacuo. The crude product was purified by flash chromatography using a gradient of ethyl acetate and heptane to yield 1.1 g (53%) A/'-(3-chloropyrazin-2-yl)tetrahydrofuran-3-carbohydrazide.

Step 2: A mixture of A/'-(3-chIoropyrazin-2-yi)tetrahydrofuran-3-carbohydrazide (1.1 g,

4.5 mmol) and POCI₃ (20 ml) was heated at reflux for 2 hours. The reaction mixture was concentrated in vacuo and diluted with DCM (50 mL). The solution was poured onto icewater (50 mL) and pH adjusted to basic. The phases were separated and the water phase extracted with DCM (2x50 mL). The combined organic phases were washed with brine, dried over MgSO4, concentrated in vacuo and purified by flash chromatography using a gradient of ethyl acetate and heptane to yield 285 mg (28%) 8-chloro-3(tetrahydrofuran-3-yl)-[1,2,4]triazolo[4,3-a]pyrazine.

Step 3: To a solution of 8-chloro-3-(tetrahydrofuran-3-yl)-[1,2,4]triazoIo[4,3-a]pyrazine (80 mg, 0.36 mmol) and (4-chlorophenyl)methanol (91 mg, 0.64 mmol) dissolved in dimethoxyethane (2.2 mL) was added NaH 60% in minerai oil (26 mg, 0.64 mmol) at RT. The reaction was stirred at RT for 2 hours. Sodium iodide (107 mg, 0.712 mmol) was added and the reaction was heated at 200°C for 20 min under microwave irradiation. The crude reaction was poured into H₂O (25 mL) and extracted with ethyl acetate (3x25mL). The combined organic phases were washed with brine, dried over MgSÜ4 and concentrated in vacuo. The crude product was purified by flash chromatography using a gradient of ethyl acetate and heptane to yield 22 mg (19%) 7(4-chlorobenzyl)-3-(tetrahydrofuran-3-yl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one. ¹H NMR (CDCI3 600 MHz): δ 7.35 (m, 2 H), 7.32 (m, 2 H), 7.11 (d, J=6.0 Hz, 1 H), 6.61 (d, J=6.0 Hz, 1 H), 5.12 (m, 2 H), 4.13 (m, 3 H), 3.89 (m, 2 H), 2.48 (m, 1 H), 2.42 (m, 1 H). LCMS (MH⁺): m/z = 331.2 tR (minutes, Method 1 ) = 0.53.

Example 25

O

7-(4-Fluorobenzyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one:

To a solution of 8-chloro-3-propyl-[1,2,4]triazolo[4,3-a]pyrazine (112 mg, 0.570 mmol) and (4-fluorophenyl)methanol (129 mg, 1.03 mmol) in dimethoxyethane (3.5 ml) was added NaH 60% in minerai oil (41 mg, 1.0 mmol) at RT and the mixture was stirred for 2 hours. Tothe reaction was added sodium iodide (171 mg, 1.14 mmol) and the reaction was heated at 200°C for 20 min under microwave irradiation. The crude reaction was concentrated in vacuo and purified by flash chromatography using a gradient of (petroleum ether: EtOAc: 5%Et₃N/10%MeOH/85%EtOAc = 1:0:0 to 0:1:0 to 0:0:1) to yield 28 mg (16%) 7-(4-fluorobenzyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin8(7H)-one. 4-chlorobenzyl)-3-(tetrahydrofuran-3-yl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)one. ¹H NMR (CDCI₃ 500 MHz): 5 7.39 (m, 2 H), 7.08 (m, 2 H), 6.91 (d, J=6.0 Hz, 1 H),

6.63 (d, <7=6.0 Hz, 1 H), 5.13 (s, 2 H), ), 2.94 (t, J=7.6 Hz, 2 H), 1.91 (m, 2 H), 1.07 (t, J=7.4 Hz, 3 H), (t, J= . LCMS (MH+): m/z = 287.2, t_R (minutes, Method 1) = 0.52

Example 26

Cl o

7-(4-Chlorobenzyl)-3-ethyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one:

Step 1: To a solution 2-chloro-3-hydrazinylpyrazine (2.00 g, 13.8 mmol) in DCM (73 ml) was added propionaldéhyde (0.804 g, 13.8 mmol) and mixture was heated at reflux for 1 hour and then cooled on an ice bath.

To the cold solution was added iodobenzene diacetate (5.12 g, 15.9 mmol) and it was allowed to warm to RT overnight. The reaction was washed with H₂O (25 mL), then brine (25 mL) and concentrated in vacuo. The crude product was purified by flash chromatography using a gradient of ethyl acetate and heptane to yield 1.84 g (73%) 8chloro-3-ethyl-[1,2,4]triazolo[4,3-a]pyrazine.

Step 2: To a solution of 8-chloro-3-ethyl-[1,2,4]triazolo[4,3-a]pyrazine (101 mg, 0.553 mmol) and (4-chlorophenyl)methanol (142 mg, 0.996 mmol) in dimethoxyethane (4.5 mL) was added NaH 60% in minerai oil (40 mg, 1.0 mmol) at RT and the mixtrure was stirred for 2 hours.To the reaction was added sodium iodide (107 mg, 0.712 mmol) and the reaction was heated at 200°C for 20 minutes under microwave irradiation. The reaction mixture was poured into H2O (25 mL) and extracted with ethyl acetate (3x25mL). The combined organic phases were washed with brine, dried over MgSO₄and concentrated in vacuo. The crude product was purified by flash chromatography using a gradient of ethyl acetate and ethyl acetate + 10% methanol to yield 21 mg (13%) yield) 7-(4-chlorobenzyl)-3-ethyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one. ¹H NMR (CDCI3 600 MHz): δ 7.36 (m, 2 H), 7.31 (m, 2 H), 6.91 (d, J=6.0 Hz, 1 H), 6.62 (d, J=6.0 Hz, 1 H), 5.13 (s, 2 H), ), 2.96 (t, J=7.6 Hz, 2 H), 1.46 (t, J=7.4 Hz, 3 H). LCMS (MH⁺): m/z = 389.1, tR (minutes, Method 1 ) = 0.53

Example 27 o

Cl

7-(3-Chlorobenzyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one:

To a solution of 8-chloro-3-propyl-[1,2,4]triazolo[4,3-a]pyrazine (97 mg, 0.49 mmol) and (3-chlorophenyl)methanol (127 mg, 0.888 mmol) in dimethoxyethane (3 ml) was added NaH 60% in minerai oil (40 mg, 1.0 mmol) at RT and the mixture was stirred for 2 hours. To the solution was added sodium iodide (148 mg, 0.987 mmol) and the reaction was heated at 200°C for 20 min under microwave irradiation. The crude reaction was concentrated in vacuo and purified by flash chromatography using a gradient of (petroleum ether: EtOAc: 5%Et₃N/10%MeOH/85%EtOAc = 1:0:0 to 0:1:0 to 0:0:1) to yield 30 mg (20%) of 7-(3-chlorobenzyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one. ¹H NMR (CDCI3 500 MHz): δ 7.32 (m, 3 H), 7.22 (m, 1 H), 6.92 (d, J=6.0 Hz, 1 H), 6.64 (d, J=6.0 Hz, 1 H), 5.11 (s, 2 H), ), 2.93 (t, J=7.6 Hz, 2 H), 1.89 (m, 2 H), 1.04 (t, J=7.4 Hz, 3 H). LCMS (MH⁺): m/z = 303.2, t_R (minutes, Method 1) = 0.58

Example 28 o

7-(4-Methylbenzyl)-3-propyl-['1₅2_J4]triazolo[4,3-a]pyrazin-8(7H)-one

A solution of 8-chloro-3-propyl-[1 ,2,4]triazolo[4,3-a]pyrazine (106 mg, 0.539 mmol) and

1-(bromomethyl)-4-methylbenzene (100 mg, 0.539 mmol) in DMF (2 ml) was heated at 200°C for 20 min under microwave irradiation. The crude reaction was poured into sat. aq. NaHCO₃ and extracted with ethyl acetate (3x15 mL). The combined organic phases were washed with brine, dried over Na₂SO₄ and concentrated in vacuo. The crude product was purified by flash chromatography using a gradient of (petroleum ether: EtOAc: 5%Et₃N/10%MeOH/85%EtOAc = 1:0:0 to 0:0:1) to yield 24 mg (13%) 7-(4methylbenzyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one. ¹H NMR (CDCI₃ 500 MHz): 5 7.24 (m, 2 H), 7.17 (m, 2 H), 6.93 (d, J=6.0 Hz, 1 H), 6.70 (d, J=6.0 Hz, 1 H),

5.11 (s, 2 H), ), 2.91 (t, J=7.6 Hz, 2 H), 1.85 (m, 2 H), 1.02 (t, J=7.4 Hz, 3 H). LCMS (MH⁺): m/z = 283.3, t_R (minutes, Method 1) = 0.58

Example 29

7-(2-Methylbenzyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one:

A solution of 8-chloro-3-propyl-[1,2,4]triazolo[4,3-a]pyrazine (105 mg, 0.534 mmol) and

1-(bromomethyl)-2-methylbenzene (104 mg, 0.562 mmol) in DMF (2 ml), washeated at 200°C for 20 min under microwave irradiation. The crude reaction was poured into sat. aq. NaHCO₃ and extracted with ethyl acetate (3x10 mL). The combined organic phases were washed with brine, dried over Na₂SO₄ and concentrated in vacuo. The crude product was purified by column chromatography using a gradient of (heptane: ethyl acetate: 5%Et₃N/10%MeOH/85%EtOAc = 1:0:0 to 0:1:0 to 0:0:1 ) to yield 1.4 mg (1 %) 7(2-methylbenzyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one. ¹H NMR (CDCI3 600 MHz): 5 7.25 (m, 3 H), 7.19 (m, 1 H), 6.86 (d, J=6.0 Hz, 1 H), 6.49 (d, J=6.0 Hz, 1 H), 5.19 (s, 2 H), ), 2.92 (t, J=7.6 Hz, 2 H), 1.89 (m, 2 H), 1.04 (t, J=7.4 Hz, 3 H). LCMS (MH⁺): m/z = 283.3, tR (minutes, Method 1) = 0.56

Example 30

7-isopentyl-3-(tetrahydro-2H-pyran-4-yI)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one:

A solution of 3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one hydrochloride (100 mg, 0.390 mmol), 1-bromo-3-methylbutane (136 mg, 112 pi, 0.898 mmol), K₂CO₃ (192 mg, 1.389 mmol) and Nal (5.84 mg, 0.039 mmol) in in DMF (1.5 ml) was stirred at 80°C over night. The reaction mixture was poured into H2O and extracted with ethyl acetate (3x20 ml). The combined organic phases were washed with brine, dried over MgSCU and concentrated in vacuo. The residue was purified by flash chromatography on silica using (Heptane/EtOAc/EtOAc + 20%MeOH 1:0:0 to 0:1:0 to 0:0:1) to yield 31 mg (27%) 7-isopentyl-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3-

a]pyrazin-8(7H)-one. ¹H NMR (CDCI3 500 MHz): δ 7.01 (d, J= 6 Hz, 1 H), 6.69 (d, J= 6 Hz, 1 H), 4.16 (d, J=7.6 Hz, 2 H), 4.01 (m, 2 H), 3.61 (m, 2 H), 3.22 (m, 1 H), 2.21 (m, 2 H), 1.98 (m, 2 H), 1.65 (m, 3 H), 1.00 (m, 6 H). LC-MS m/z = 291.2 [M + H]⁺: tR (minutes, Method 5) = 0.58 .

Example 31 o

6-bromo-7-(cyclopentylmethyl)-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3-

a]pyrazin-8(7H)-one:

Step 1: To a solution of 5-bromo-3-chloro-2-hydrazinylpyrazine (44.50 g, 199.14 mmol) in DCM (500 mL) was added tetrahydro-2H-pyran-4-carbaldehyde (23.87 g, 209.10 mmol). The mixture was stirred at 30°C for 1.5 h. LCMS showed the reaction was completed. The mixture was directly used for the next step as a brown liquid. Then it was cooled to 0°C, Phl(OAc)2 (73.76 g, 229.01 mmol) was added in portions. After addition, the mixture was stirred at 30°C for 2 h. LCMS showed the reaction was completed. Sat. aq. K2CO3 (100 mL) was added to the mixture slowly and it was stirred for 10 min. The organic phase was separated and washed with brine, dried over Na₂SO4, filtered and concentrated to give the crude product. The crude product was washed with MTBE (100 mL) and DCM (200 mL) to give 6-bromo-8-chloro-3(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3-a]pyrazine (48.00 g, 75.90% yield).

Step 2: To a solution of 6-bromo-8-chloro-3-(tetrahydro-2H-pyran-4-yl)- [1.2.4] triazolo[4,3-a]pyrazine (20.0 g, 62.98 mmol) in THF (300 mL) and H₂O (60 mL) was added NaOH (5.04 g, 125.96 mmol). The mixture was heated at 70°C for 2 h. LCMS showed the reaction was completed. The mixture was cooled to 28°C and acidified to pH 5-6 by 1 N HCl. The mixture was filtered and the filter cake was washed with water (200 mL) and dried in vacuo to give 6-bromo-3-(tetrahydro-2H-pyran-4-yl)- [1.2.4] triazoio[4,3-a]pyrazin-8-ol (15.00 g, 79.62% yield).

Step 3: To a suspension of 6-bromo-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3-

a]pyrazin-8-oI (4.0 g, 13.37 mmol) in DMF (40 mL) was added (bromomethyl)cyclopentane (2.62 g, 16.04 mmol) and K₂CO₃ ((217 g, 20.06 mmol). The mixture was heated at 80°C for 24 h. The mixture was concentrated and the residue was dissolved in DCM (50 mL) and H₂O (50 mL). The organic layer was washed with H₂O (50 mL), dried over Na₂SO4, filtered and concentrated to give the crude product. The residue was purified by re-crystallization from DCM (50 mL) and EA (30 mL) to give 6-bromo-7-(cyclopentylmethyl)-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3-

a]pyrazin-8(7H)-one (1.20 g, 23.54% yield). ¹H NMR (CDCI3 400MHz): δ 7.20 (s, 1H),

4.24 (d, J=7.6 Hz, 2H), 4.16-4.12 (m, 2H), 3.63-3.57 (m, 2H), 3.19-3.10 (m, 1H), 2.45-

2.35 (m, 1H), 2.21-2.18 (m, 2H), 1.98-1.95 (m, 2H), 1.73-1.70 (m, 4H), 1.62-1.55 (m, 2H), 1.44-1.31 (m, 2H). LC-MS: t_R = 2.54 min (METHOD 3), m/z = 381.0 [M + H]⁺.

Example 32

6-bromo-7-(cyclohexylmethyl)-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3-

a]pyrazin-8(7H)-one:

To a suspension of 6-bromo-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3-a]pyrazin-8ol (5.0 g, 16.72 mmol) in DMSO (50 mL) was added (bromomethyl)cyclohexane (3.55 g, 20.06 mmol) and K₂CO₃ (3.47 g, 25.07 mmol). The mixture was heated at 80°C for 12 h. LCMS showed 40% of desired product. The mixture was cooled to 28°C and water (50 mL) was added. The aqueous layer was extracted with DCM (100 mL, two times). The combined organics were washed with water (100 mL, two times, two times), dried over Na₂SO4, filtered, concentrated and purified by flash chromatography on silica gel (DCM/MeOH=100/1-20/1 ) to give 6-bromo-7-(cyclohexylmethyl)-3-(tetrahydro-2Hpyran-4-yl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (1.90 g, 28.75% yield). ¹H NMR (CDCIs 400MHz): 5 7.19 (s, 1H), 4.17-4.10 (m, 4H), 3.63-3.57 (m, 2H), 3.19-3.16 (m, 1 H), 2.22-2.18 (m, 2H), 1.98-1.94 (m, 2H), 1.90-1.82 (m, 1H), 1.73-1.70 (m, 2H), 1.66-

1.61 (m, 3H), 1.19-1.10(m, 5H). LC-MS: t_R = 2.66 min (METHOD 3), m/z = 395.1 [M + H]⁺.

6-bromo-7-(cycloheptylmethyl)-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3

a]pyrazin-8(7H)-one:

Step 1: BH₃.THF (1 Μ, 98.45 mL, 98.45 mmol) was added dropwise to a solution of cycloheptanecarboxylic acid (7.0 g, 49.23 mmol) in THF (50 mL) at 0°C. Then the mixture was heated at 70°C for 12 h. The reaction was checked by TLC. The mixture was cooled to 0°C and MeOH (50 mL) was added dropwise to the mixture. The mixture was concentrated and the residue was purified by flash chromatography on silica gel (PE/EA=20/1~3/1) to give cycloheptylmethanol (6.0 g, 95.06% yield).

Step 2: To a cooled (0°C) solution of cycloheptylmethanol (4.00 g, 31.20 mmol) in DCM (40 mL) was added TEA (6.31 g, 62.40 mmol) and methane sulfonylchloride (9.28 g, 81.01 mmol) dropwise. The mixture was stirred at 0°C for 1 h. TLC showed the reaction was completed. Water (20 mL) was added to the mixture. The organic layer was dried over NazSO4, filtered and concentrated to give cycloheptylmethyl methanesulfonate (6.00 g, 93.22% yield).

a]pyrazin-8-ol (5.0 g, 16.72 mmol) in anhydrous DMF (50 mL) was added cycloheptylmethyl methanesulfonate (4.48 g, 21.74 mmol) and CsF (5.08 g, 33.44 mmol). The mixture was heated at 80°C for 12 h. LCMS showed 21% of desired product. The mixture was concentrated and the residue was dissolved in DCM (50 mL) and H₂O (30 mL). The aqueous layer was extracted with DCM (50 mL). The organic layer was washed with H₂O (30 mL), dried over Na₂SO₄, filtered, concentrated and purified by flash chromatography on silica gel (DCM/MeOH=100/1-20/1) and further purified by préparative HPLC (base) to give 6-bromo-7-(cycloheptylmethyl)-3(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (465.00 mg, 6.79% yield). ¹H NMR (CDCI3 400MHz): δ 7.20 (s, 1 H), 4.15-4.09 (m, 4H), 3.63-3.57 (m, 2H), 3.19-3.17 (m, 1H), 2.21-2.02 (m, 3H), 1.97-1.94 (m, 2H), 1.75-1.65 (m, 4H), 1.60-1.45 (m, 4H), 1.44-1.27 (m, 4H). LC-MS: f_R = 2.81 min (METHOD 3), m/z = 409.1 [M + H]⁺.

6-bromo-7-(3-fluorobenzyl)-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]trïazolo[4,3-

a]pyrazin-8(7H)-one:

To a suspension of 6-bromo-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazoio[4,3-a]pyrazin-8ol (5.00 g, 16.72 mmol) in DMF (2 mL) was added 1-(bromomethyl)-3-fluorobenzene (3.79 g, 20.06 mmol) and K₂CO₃ (3.47 g, 25.07 mmol). The mixture was heated at 60°C for 12 h. The mixture was concentrated and the residue was dissolved in DCM (50 mL) and H₂O (50 mL). The organic layer was washed with H₂O (50 mL), dried over Na₂SO4, filtered and concentrated and purified by flash chromatography on silica gel (DCM/MeOH=100/1-20/1 ) to give 6-bromo-7-(3-fluorobenzyl)-3-(tetrahydro-2H-pyran-4yl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (3.90 g, 57.28% yield). ¹H NMR (CDCI3 varian 400): δ 7.30-7.26 (m, 1H), 7.22 (s, 1H), 7.13 (d, J=8.0 Hz, 1 H),7.04-6.99 (m, 2H),

5.45 (s, 2H), 4.14-4.11 (m, 2H), 3.61-3.55 (m, 2H), 3.21-3.16 (m, 1H), 2.22-2.13 (m, 2H), 1.96-1.93 (m, 2H). LC-MS: t_R = 2.42 min (METHOD 3), m/z = 407.0 [M + H]⁺.

6-bromo-7-(3-fluorobenzyl)-3-propyl-[1,2,4]trïazolo[4,3-a]pyrazin-8(7H)-one :

Step 1: To a solution of 2,3-dichloropyrazine (150 g, 1.01 mol) in EtOH (700 mL) was added hydrazine monohydrate (124.53g, 2.11 mmol, 85% in water). The reaction mixture was heated under reflux overnight. The reaction mixture was cooled and the precipitate was filtered. The resulting solid was washed with water (100 mL, two times), then cold EtOH (150 ml, two times) and dried under reduced pressure to give the 218257 chloro-3-hydrazinylpyrazine (140 g, yield 96%).

Step 2: To a suspension of 2-chloro-3-hydrazinylpyrazine (156.5 g, 1.05 mol) in THF (1.2 L) cooled at 0°C was added dropwise a solution of TFAA (295.6 g, 1.41 mol) in THF (0.3 L). The reaction mixture was stirred at room température overnight and then poured into H₂O (500 mL). The organic phase was separated and the aqueous phase was extracted with EtOAc (500 mL*3). The combined organic phases were washed with brine, dried over MgSO4 and concentrated under reduced pressure to give the N'-(3chloropyrazin-2-yI)-2,2,2-trifluoroacetohydrazide (300 g, purity 85%, yield 98%).

Step 3: To a suspension of N'-(3-chloropyrazin-2-yl)-2,2,2-trifluoroacetohydrazide (150 g, purity 85%, 0.53 mol) in DCM (1.5 L) was added NBS (141.5 g, 0.79 mol) in portions. After the addition, the mixture was stirred at room température for 2 hr. The reaction mixture was concentrated under vacuum. The residue was purified by flash chromatography on silica gel (PE/EtOAc=5/1-3/1) to give the N'-(5-bromo-3chloropyrazin-2-yl)-2,2,2-trifluoroacetohydrazide (80 g, purity 75%, yield 94%) as a black solid.

Step 4: To a solution of N'-(5-bromo-3-chloropyrazin-2-yl)-2,2,2-trifluoroacetohydrazide (150 g, purity 75%, 0.35 mol) in EtOH (1.2 L) was added 12N HCl (100 mL) dropwise. The solution was stirred under reflux for 6h. The solution was cooled to room température and concentrated under reduced pressure. Water (300 mL) was added to the flask and it was treated with sat. NaHCO3 until pH = 8 (slow addition). The solution was extracted with EtOAc (500 mL*3). The combined organic phases were dried over Na₂SO4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE/EA=2:1) to give 5-bromo-3-chloro-2-hydrazinylpyrazine (75 g, 95% yield) as a tan powder. ¹H NMR (DMSO-d6 varian 400 MHz): δ 8.55 (s, 1 H),

8.24 (s, 1H), 4.40 (s, 2H). LC-MS: f_R = 1.74 min (METHOD 3), m/z = 224.9 [M + H]⁺

Step 5: To a mixture of 5-bromo-3-chloro-2-hydrazinylpyrazine (25.0 g, 0.11 mol) in

DCM (600 mL) was added butanal (8.47 g, 0.12 mol) in one portion at room température. The mixture was stirred at room température for 1.5 h. Then it was cooled to 0°C, Phl(OAc)₂ (37.9 g, 0.12 mol) was added in portions. After the addition, the reaction mixture was stirred at room température for another 1.5 h. Sat K₂CO₃(aq) (50 mL) was poured into the reaction mixture and stirred for 10 min. The organic phase was separated and washed with brine, dried over Na₂SO₄, filtered and evaporated. The residue was purified by silica gel chromatography (PE/EA=2:1) to afford 6-bromo-8chloro-3-propyl-[1,2,4]triazolo[4,3-a]pyrazine (22.00 g, 71% yield).

Step 6: To a mixture of 6-bromo-8-chloro-3-propyl-[1,2,4]triazolo[4,3-a]pyrazine (12.0 g,

43.6 mmol) in THF (150 mL) and H₂O (30 mL), was added NaOH (3.5 g, 87.1 mmol) in one portion at room température. The mixture was stirred at 70°C for 2.5 h. The mixture was adjusted to pH=5-6 by 1N HCI(aq), and concentrated under reduced pressure. The residue was dissolved in MeOH (20 mL) and filtered. The filtrate was concentrated in vacuo to afford 6-bromo-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8-ol (11.0 g, 98% yield).

Step 7: To a suspension of 6-bromo-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8-ol (550 mg,

2.1 mmol) and 1-(bromomethyl)-3-fluoro-benzene (485 mg, 2.57 mmol) in DMF (8 mL), was added K₂CO₃ (443.6 mg, 3.2 mmol) in one portion at room température. The mixture was stirred at 60°C for 3h. And then the mixture was concentrated under reduced pressure. The residue diluted with water (30 mL) and extracted with DCM (70 mL, two times). The combined organic phase was washed with saturated brine, dried over anhydrous Na₂SO₄, filtered and concentrated in vacuo. The residue was purified by silica gel chromatography (PE/EA=1:1-1:3) to afford 6-bromo-7-(3-fluorobenzyl)-3propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (380.00 mg, 49% yield) as yellow solid. ¹H NMR(DMSO-d6 varian 400 MHz): δ 8.09 (s, 1H), 7.42-7.37 (m, 1H), 7.19-7.10 (m, 3H),

5.38 (s, 2H), 2.97 (t, J=7.Q Hz, 2H), 1.79-1.73 (m, 2H), 0.98 (t, J=7.2 Hz, 3H). LC-MS: t_R= 2.62 min (METHOD 3), m/z = 365.0 [M + H]⁺.

7-(3-fluorobenzyl)-6-methyl-3-propyI-[1_J2,4]triazolo[4,3-a]pyrazin-8(7H)-one:

To a mixture of 6-bromo-7-(3-fluorobenzyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)one (300 mg, 0.82 mmol) and [trifluoro(methyl)-boranyl]potassium(1+) (501 mg, 4.1 mmol) in dioxane (5 mL), was added 1,T-Bis(diphenylphosphino)ferrocenepalladium(ll)dichloride (60 mg, 0.08 mmol) and K2CO3 (681 mg, 4.9 mmol) at room température under N₂. The mixture was stirred at 80°C for 12 h. The mixture was concentrated and diluted with water, extracted EtOAc (30 mL, two times, two times). The combined organic layer was washed with brine, concentrated in vacuo and the residue was purified by préparative HPLC to give 7-(3-fluorobenzyl)-6-methyl-3-propyl- [1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (20 mg, 8% yield) as a gray solid. ¹H NMR (CDCI3 varian 400 MHz): δ 7.26-7.19 (m, 1 H), 6.94-6.83 (m, 3H), 6.70 (s, 1 H), 5.24 (s, 2H), 2.88 (t, J=8.0 Hz, 2H), 2.18 (s, 3H), 1.89-1.80 (m, 2H), 0.99 (t, J=7.2 Hz, 3H). LCMS: t_R = 2.47 min (METHOD 3), m/z = 301.1 [M + H]⁺.

Example 37 o

6-ethyl-7-(3-fluorobenzyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one:

Step 1: To a mixture of 6-bromo-7-(3-fluorobenzyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin8(7H)-one (300 mg, 0.82 mmol) and 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane (190 mg, 1.2 mmol) in THF (5 mL) was added K₂CO₃ (227 mg, 1.64 mmol) and 1 ,TBis(diphenylphosphino)ferrocene-palladium(II)dichloride (60 mg, 82.2 micromol) in at room température under N₂. The mixture was stirred at 70°C for 12 h. Then the mixture was cooled and water (10 mL) was added. Then it was extracted with EtOAc (30 mL, two times). The combined organic layer was washed with brine (20 mL), dried over Na₂SO₄ and concentrated in vacuo. The residue was purified by silica gel chromatography (petroleums ether: ethylaacetate =1:1-1:2) to afford 7-(3-fluorobenzyl)-

3-propyl-6-vinyI-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (150 mg, 57% yield).

Step 2: To a solution of 7-(3-fluorobenzyl)-3-propyl-6-vinyl-[1,2,4]triazolo[4,3-a]pyrazin8(7H)-one (150 mg, 0.48 mmol) in MeOH (4 mL) was added Pd/C (wet, 10% Pd with

50% water, 0.1 g). The suspension was degassed under vacuum and purged with H₂ several times. The mixture was stirred under H₂ (15psi) at room température for 10 min.

The reaction mixture was filtered and the filtrate was concentrated. The crude product was purified by silica gel chromatography (DCM/MeOH=50:1) to give 6-ethyl-7-(3fluorobenzyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (80 mg, 53% yield). ¹H NMR (CDCI₃ varian 400 MHz): δ 7.29-7.26 (m, 1 H), 6.97-6.86 (m, 3H), 6.72 (s, 1 H), 5.32 (s, 2H), 2.96 (t, J=7.6 Hz, 2H), 2.60-2.54 (m, 2H), 1.95-1.88 (m, 2H), 1.26 (t, J=6.8 Hz, 3H), 1.07 (t, J=7.2 Hz, 3H). LC-MS: f_R = 2.60 min (METHOD 3), m/z = 315.1 [M + H]⁺.

Example 38

7-(3-fluorobenzyl)-6-(3-hydroxytetrahydrofuran-3-yl)-3-propyl-[1,2,4]triazolo[4,3-

a]pyrazin-8(7H)-one, stereoisomer 1 and 2:

Step 1: To a suspension of 6-bromo-8-chloro-3-propyl-[1,2,4]triazolo[4,3-a]pyrazine (9.0 g, 32.7 mmol) in MeOH (100 mL) was added sodium methoxide (3.53 g, 65.3 mmol) in one portion at room température under N₂. The mixture was stirred at 60°C for 4 hr. The mixture was concentrated under reduced pressure. The residue was suspended in DCM (100mL), washed with water (20 mL), saturated brine (20 mL), dried with anhydrous Na₂SO₄ and conncentrated in vacuo. The residue was purified by silica gel chromatography (eluent Petroleum ether/Ethyl acetate=3:1) to afford 6-bromo-8methoxy-3-propyl-[1,2,4]triazolo[4,3-a]pyrazine (7.40 g, 84% yield).

Step 2: To a light yellow solution of 6-bromo-8-methoxy-3-propyl-[1,2,4]triazolo[4,3ajpyrazine (2.0 g, 7.4 mmol) in THF (20 mL), was added i-PrMgCI-LiCI (17.02 mL, 22.1 mmol, 1.3 M) dropwise at 0°C under N₂. After the addition, the red solution was stirred at 0°C for 30 min. Then dihydrofuran-3(2H)-one (1.91 g, 22.1 mmol) was added as a solution in THF (2 mL) and stirred for 1 hr at 0°C. The mixture was quenched with sat NH₄CI(aq) and extracted with EtOAc twice. The combined organic layer was washed with brine and concentrated, the residue was purified by silica gel chromatography (PE:EA=1:1-1:5) to afford 3-(8-methoxy-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-618257 yl)tetrahydrofuran-3-ol (250 mg, 12% yield).

Step 3: To a solution of 3-(8-methoxy-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-6yl)tetrahydrofuran-3-ol (440 mg, 1.6 mmol) in MeOH (8 mL), was added 2 M HCI(aq) (8 mL) in one portion at room température. The solution was stirred at 50°C for 20 hr. The mixture was concentrated under reduced pressure at 50°C. The residue was purified by silica gel chromatography (DCM:MeOH=10:1) to give 6-(3-hydroxytetrahydrofuran-3-yl)-

3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8-ol (270 mg, 65% yield) as yellow solid.

Step 4: To a solution of 6-(3-hydroxytetrahydrofuran-3-yl)-3-propyl-[1,2,4]triazolo[4,3-

a]pyrazin-8-ol (250 mg, 0.95 mmol) and 1-(bromomethyl)-3-fluoro-benzene (214.6 mg, 1.14 mmol) in DMF (2 mL), was added K₂CO₃ (261 mg, 1.89 mmol) in one portion. The suspension was stirred at 60°C for 4 hr. The mixture was concentrated under reduced pressure. The residue was diluted with EtOAc (20mL), washed with water (10mL), saturated brine (5 mL), dried with anhydrous Na₂SO4, filtered and concentrated in vacuum. The residue was purified by préparative HPLC to afford 7-(3-fluorobenzyl)-6(3-hydroxytetrahydrofuran-3-yl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (40 mg, 11% yield).

Step 5: 7-(3-fluorobenzyl)-6-(3-hydroxytetrahydrofuran-3-yl)-3-propyl-[1,2,4]triazolo[4,3-

a]pyrazin-8(7H)-one (50 mg, 134.3 micromol) was purified by SFC to afford 7-(3fluorobenzyl)-6-(3-hydroxytetrahydrofuran-3-yl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin8(7H)-one, stereoisomer 1 (27 mg, 54 % yield). ¹H NMR (CDCI3 varian 400): δ 7.75 (s, 1H), 7.28-7.15 (m, 3H), 6.97-6.95 (m, 1H), 5.53 (s, 2H), 4.17-4.13 (m, 1H), 4.07-4.04 (m, 1H), 3.93 (d, J=9.6Hz, 1H), 3.76 (d, J=9.6Hz, 1H), 2.98 (t, J=7.6Hz, 2H), 2.68 (brs, 1H), 2.53-2.50 (m, 1H), 2.08-2.05 (m, 1H), 1.88-1.82 (m, 2H), 0.99 (t, J=7.2Hz, 3H). LCMS: fR = 2.48 min (METHOD 3), m/z = 373.1 [M + H]⁺. SFC-MS: fR = 8.05 min, ee% = 100.00%, [a]_D ²⁰ =-58.67° (c=0.10, MeOH).

And 7-(3-fluorobenzyl)-6-(3-hydroxytetrahydrofuran-3-yl)-3-propyl-[1,2,4]triazolo[4,3-

a]pyrazin-8(7H)-one, stereoisomer 2 (17 mg, 34% yield) as white solid. ¹H NMR (CDCI₃varian 400): 5 7.82 (s, 1H), 7.33-7.23 (m, 3H), 7.21-7.00 (m, 1H), 5.58 (s, 2H), 4.22-4.19 (m, 1H), 4.12-4.09 (m, 1H), 3.99 (d, J=9.6Hz, 1H), 3.82 (d, J=9.6Hz, 1H), 3.04 (t,

J=7.6Hz, 2H), 2.83 (s, 1H), 2.58-2.55 (m, 1H), 2.08-2.05 (m, 1H), 1.93-1.88 (m, 2H),

1.04 (t, J=7.2Hz, 3H). LC-MS: t_R = 2.47 min (METHOD 3), m/z = 373.1 [M + H]⁺. SFCMS: t_R = 8.39 min, ee% = 92.28%, [o]_D ²⁰ = +52.67 (c=0.10, MeOH).

Example 39

7-(3-fluorobenzyl)-3-propyI-6-(tetrahydrofuran-3-yl)-[1,2,4]triazolo[4,3-a]pyrazin8(7H)-one, stereoisomer 1 and 2:

Step 1 : To a mixture of 6-bromo-7-(3-fluorobenzyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin8(7H)-one (300 mg, 821.5 micromol) and 2-(2,5-dihydrofuran-3-yl)-4,4,5,5-tetramethyl-

1,3,2-dioxaborolane (242 mg, 1.23 mmol) in dioxane (4 mL) and H₂O (2 mL), was added K₂CO₃ (227mg, 1.64 mmol) and 1,T-Bis(diphenylphosphino)ferrocenepalladium(ll)dichloride (60 mg, 82.2 micromol) in one portion. The mixture was stirred at 70-80°C for 16h. The mixture was concentrated under reduced pressure. The residue was diluted with EtOAc (20 mL), washed with water (10 mL), saturated brine (10 mL), dried over anhydrous Na₂SO4, filtered and concentrated in vacuum. The residue was purified by silica gel chromatography (DCM/MeOH=20/1) to afford 6-(2,5-dihydrofuran-

3-yl)-7-(3-fluorobenzyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (260 mg, 76% yield, 85% purity) as yellow solid.

Step 2: To a solution of 6-(2,5-dihydrofuran-3-yl)-7-(3-fluorobenzyl)-3-propyl- [1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (340 mg, 959.4 micromol) in MeOH (2 mL), was added Pd/C (50 mg, wet, 10% Pd with 50% of water) in one portion .The mixture was stirred at room température for 1 hr. The mixture was filtered and the filtrate was concentrated in vacuum. The residue was purified by préparative HPLC to afford 7-(3fluorobenzyl)-3-propyl-6-(tetrahydrofuran-3-yl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (60 mg, 17% yield).

Step 3: 7-(3-fluorobenzyl)-3-propyl-6-(tetrahydrofuran-3-yl)-[1,2,4]triazolo[4,3-a]pyrazin8(7H)-one (60 mg, 168.34 micromol) was purified by Chiral SFC to afford 7-(3fluorobenzyl)-3-propyl-6-(tetrahydrofuran-3-yl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one, stereoisomer 1 (10 mg, 17% yield). ¹H NMR (CDCI3varian 400): δ 7.26-7.20 (m, 1H), 6.93-6.87 (m, 3H), 6.80 (d, J=9.6Hz, 1H), 5.54 (d, J=13.6Hz, 1H), 5.10 (d, J=14.4Hz, 1H), 3.96-3.94 (m, 1H), 3.86-3.76 (m, 3H), 3.28-3.24 (m, 1H), 2.89 (t, J=7.6Hz, 2H), 2.26-2.21 (m, 1 H), 1.88-1.83 (m, 3H), 1.01 (t, J=7.6Hz, 3H). LC-MS: fR = 2.44 min (METHOD 3), m/z = 357.1 [M + H]⁺. SFC-MS: tR = 7.91 min, ee% = 100%.

And 7-(3-fluorobenzyl)-3-propyl-6-(tetrahydrofuran-3-yl)-[1,2,4]triazolo[4,3-a]pyrazin8(7H)-one, stereoisomer 2 (9 mg, 14% yield) as white solid. ¹H NMR (CDCI3 varian 400): δ 7.33-7.30 (m, 1 H), 7.01 -6.87 (m, 4H), 5.70-5.55 (brs, 1 H), 5.25-5.10 (brs, 1 H), 4.03-4.02 (m, 1H), 3.93-3.84 (m, 3H), 3.33 (brs, 1H), 2.97 (t, J=7.6Hz, 2H), 2.33-2.28 (m, 1 H), 1.95-1.92 (m, 3H), 1.08 (t, J=7.6Hz, 3H). LC-MS: tR = 2.43 min (METHOD 3), m/z = 357.1 [M + H]⁺. SFC-MS: tR = 8.46 min, ee% = 97.35%.

Example 40 o

6-benzyl-7-(cyclopentylmethyl)-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3-

a]pyrazin-8(7H)-one:

Step 1: To a suspension of 6-bromo-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3-

a]pyrazin-8(7H)-one (500 mg, 1.67 mmol) in dioxane (10 mL) and H₂O (5 mL) was added 2-benzyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (547 mg, 2.51 mmol), Cs₂CO₃(1.09 g, 3.34 mmol) and 1,T-Bis(diphenylphosphino)ferrocene-palladium(ll)dichloride (122 mg, 167.16 micromol,). The mixture was degassed with N₂ and heated at 100°C for 12 h under N₂. LCMS showed the reaction was completed. The mixture was cooled to 25°C and extracted with EA (20 mL, two times, two times). The organic layer was washed with water (20 mL), dried over Na₂SO4, filtered, concentrated and purified by flash chromatography on silica gel (DCM/MeOH=100/1-20/1 ) to give 6-benzyI-3(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (230 mg, 41.05% yield).

Step 2: To a suspension of 6-benzyl-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3a]pyrazin-8(7H)-one (50 mg, 161.11 micromol) in DMF (2 mL) was added (bromomethyl)cyclopentane (32 mg, 193.33 micromol) and K2CO3 (33 mg, 241.67 micromol). The mixture was heated at 60°C for 12 h. LCMS showed the reaction was completed. The mixture was concentrated and the residue was dissolved in DCM (20 mL) and H₂O (20 mL). The organic layer was washed with H₂O (20 mL), dried over Na₂SO4, filtered, concentrated and purified by préparative HPLC to give 6-benzyl-7(cyclopentylmethyl)-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (9.7 mg, 15% yield). ¹H NMR (CDCI₃ 400MHz): δ 7.41-7.34 (m, 3H), 7.18 (d, J=6.8 Hz, 2H), 6.64 (s, 1H), 4.13-4.10 (m, 2H), 3.97 (s, 2H), 3.90 (d, J=7.6 Hz, 2H), 3.58-3.52 (m, 2H), 3.12-3.10 (m, 1H), 2.30-2.18 (m, 1H), 2.16-2.15 (m, 2H), 1.94-1.91 (m, 2H), 1.711.68 (m, 4H), 1.56-1.55 (m, 2H), 1.32-1.31 (m, 2H). LC-MS: fo = 2.83 min (METHOD 3), m/z = 393.2 [M + H]⁺

Example 41 o

6-benzyl-7-(cycIohexylmethyl)-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3a]pyrazin-8(7H)-one:

To a suspension of 6-benzyl-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3-a]pyrazin8(7H)-one (70 mg, 225.55 micromol) in DMF (2 mL) was added (bromomethyl)cyclohexane (48 mg, 270.66 micromol) and K₂CO₃ (47 mg, 338.33 micromol). The mixture was heated at 60°C for 12 h. LCMS showed the reaction was completed. The mixture was concentrated and the residue was dissolved in DCM (20 mL) and H₂O (20 mL). The organic layer was washed with H₂O (20 mL), dried over Na₂SO₄, filtered, concentrated and purified by préparative HPLC (base) to give 6benzyl-7-(cyclohexylmethyl)-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3-a]pyrazin8(7H)-one (5.50 mg, 5.83% yield). ¹H NMR (CDCI₃ 400MHz): δ 7.41-7.34 (m, 3H), 7.17 (d, J=6.8 Hz, 2H), 6.65 (s, 1H), 4.13-4.10 (m, 2H), 3.95 (s, 2H), 3.78 (d, J=6.8 Hz, 2H),

3.58-3.53 (m, 2H), 3.12-3.10 (m, 1H), 2.20-2.15 (m, 2H), 1.94-1.91 (m, 2H), 1.75-1.66 (m, 3H), 1.63-1.58 (m, 4H), 1.17-1.03 (m, 4H). LC-MS: t_R = 2.46 min (METHOD 6), m/z = 407.2 [M + H]⁺

Example 42 o

6-benzyl-7-(cycloheptylmethyl)-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3a]pyrazin-8(7H)-one:

To a suspension of 6-benzyl-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3-a]pyrazin8(7H)-one (200 mg, 644.43 micromol) in anhydrous DMF (5 mL) was added cycloheptylmethyl methanesulfonate (173 mg, 837.76 micromol) and K2CO3 (134 mg, 966.65 micromol). The mixture was heated at 60°C for 24 h. LCMS showed 26% of desired product. The mixture was concentrated and the residue was dissolved in DCM (30 mL) and H₂O (30 mL). The organic layer was washed with H₂O (30 mL), dried over Na₂SO₄, filtered, concentrated and purified by préparative HPLC (base) to give 6benzyl-7-(cycloheptylmethyl)-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3-a]pyrazin8(7H)-one (22.60 mg, 8.27% yield). ¹H NMR (CDCI₃ 400MHz): δ 7.40-7.34 (m, 3H), 7.17-7.15 (m, 2H), 6.65 (s, 1H), 4.13-4.10 (m, 2H), 3.94 (s, 2H), 3.77 (d, J=7.6 Hz, 2H),

3.58-3.53 (m, 2H), 3.12-3.10 (m, 1H), 2.19-2.12 (m, 2H), 2.05-1.94 (m, 1H), 1.92-1.85 (m, 2H), 1.67-1.64 (m, 4H), 1.57-1.54 (m, 4H), 1.45-1.30 (m, 2H), 1.23-1.20 (m, 2H). LC-MS: t_R = 2.66 min (METHOD 4), m/z = 421.3 [M + H]⁺

6-benzyl-7-(3-fluorobenzyI)-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3a]pyrazin-8(7H)-one:

To a suspension of 6-bromo-7-(3-fluorobenzyl)-3-(tetrahydro-2H-pyran-4-yl)- [1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (100 mg, 245.56 micromol) in H₂O (0.5 mL) and THF (1 mL) was added 2-benzyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (80 mg, 368.33 micromol), K₂CO₃ (68 mg, 491.11 micromol) and 1,1’Bis(diphenylphosphino)ferrocene-palladium(ll)dichloride (18 mg, 24.56 micromol). The mixture was degassed with N₂ and heated at 80°C for 12 h under N₂. LCMS showed the reaction was completed. The mixture was cooled to 25°C and extracted with ethyl acetate (10 mL, two times). The combined organic layer was washed with water (10 mL), dried over Na₂SO₄, filtered, concentrated and purified by préparative TLC (DCM/MeOH=10/1) to give the crude product which was purified by préparative HPLC to give 6-benzyl-7-(3-fluorobenzyl)-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3a]pyrazin-8(7H)-one (5.90 mg, 5.74% yield). ¹H NMR (CDCI₃ varian 400): δ 7.39-7.36 (m, 3H), 7.31-7.30 (m, 1H), 7.13 (d, J=7.2 Hz, 2H), 6.99-6.95 (m, 1H), 6.94 (d, J=8.0 Hz, 1H), 6.85-6.80 (m, 1H), 6.74 (s, 1H), 5.15 (s, 2H), 4.13 (d, J=12.0 Hz, 2H), 3.79 (s, 2H),

3.58 (t, J=10.0 Hz, 2H), 3.19-3.13 (m, 1H), 2.24-2.15 (m, 2H), 1.96-1.93 (m, 2H). LCMS: t_R = 2.70 min (METHOD 3), m/z = 419.2 [M + H]⁺

7-(cyclopentylmethyl)-6-(2-methylbenzyl)-3-(tetrahydro-2H-pyran-4-yl)- [1.2.4] tnazolo[4,3-a]pyrazin-8(7H)-one:

Step 1: To a suspension of 6-bromo-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3a]pyrazin-8(7H)-one (1.20 g, 4.01 mmol) in H₂O (10 mL) and dioxane (20 mL) was added 4,4,5,5-tetramethyl-2-(2-methylbenzyl)-1,3,2-dioxaborolane (1.40 g, 6.02 mmol), 1,T-Bis(diphenylphosphino)ferrocene-palladium(ll)dichloride (294 mg, 401.00 micromol) and CS2CO3 (2.61 g, 8.02 mmol). The mixture was degassed with N₂ and heated at 100°C for 12 h under N₂. TLC showed the reaction was completed. The mixture was concentrated and the residue was dissolved in DCM (20 mL) and H₂O (10 mL). The aqueous layer was extracted with DCM (20 mL). The organics were washed with water (20 mL), dried over Na₂SO4, filtered, concentrated and purified by flash chromatography on silica gel (DCM/MeOH=100/1~20/1) to give 6-(2-methylbenzyl)-3(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (500 mg, 20. % yield).

Step 2: To a suspension of 6-(2-methylbenzyl)-3-(tetrahydro-2H-pyran-4-yl)- [1.2.4] triazolo[4,3-a]pyrazin-8(7H)-one (150 mg, 462.42 micromol) in anhydrous DMF (5 mL) was added (bromomethyl)cyclopentane (91 mg, 554.90 micromol) and K₂CO₃ (96 mg, 693.63 micromol). The mixture was heated at 60°C for 12 h. LCMS showed 45% of desired product. The mixture was concentrated and the residue was dissolved in DCM (20 mL) and H₂O (20 mL). The aqueous layer was extracted with DCM (20 mL). The combined organics were washed with H₂O (20 mL), dried over Na₂SO4, filtered, concentrated and purified by préparative HPLC (base) to give 7-(cyclopentylmethyl)-6(2-methylbenzyl)-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (26.94 mg, 13% yield). ¹H NMR (CDCI₃ 400MHz): δ 7.29-7.28 (m, 2H), 7.23-7.19 (m, 1H), 6.99 (d, J=7.6 Hz, 1H), 6.37 (s, 1H), 4.08-4.06 (m, 2H), 3.95 (d, J=7.2 Hz, 2H), 3.91 (s, 2H), 3.52-3.46 (m, 2H), 3.05-2.95 (m, 1H), 2.36-2.33 (m, 4H), 2.11-2.08 (m, 2H), 1.85-1.82 (m, 2H), 1.73-1.71 (m, 4H), 1.57-1.56 (m, 2H), 1.40-1.31 (m, 2H). LCMS: t_R = 2.92 min (METHOD 3), m/z = 407.2 [M + H]⁺

Example 45

7-(cyclohexylmethyl)-6-(2-methylbenzyl)-3-(tetrahydro-2H-pyran-4-yl)- [1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one:

To a suspension of 6-(2-methylbenzyl)-3-(tetrahydro-2H-pyran-4-yI)-[1,2,4]triazolo[4,3a]pyrazin-8(7H)-one (150 mg, 462.42 micromol) in anhydrous DMF (5 mL) was added (bromomethyl)cyclohexane (98 mg, 554.90 micromol and K₂CO₃ (96 mg, 693.63 micromol). The mixture was heated at 60°C for 12 hr. LCMS showed 26% of desired product The mixture was concentrated and the residue was dissolved in DCM (20 mL) 10 and H₂O (20 mL). The organic layer was washed with H₂O (20 mL), dried over Na₂SO₄, filtered, concentrated and purified by préparative HPLC to give 7-(cyclohexylmethyl)-6(2-methylbenzyl)-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (21.94 mg, 11% yield). ¹H NMR (CDCI₃ 400MHz): δ 7.29-7.27 (m, 2H), 7.23-7.19 (m, 1H), 6.99 (d, J=7.2 Hz, 1H), 6.36 (s, 1H), 4.08-4.04 (m, 2H), 3.88 (s, 2H), 3.79-3.75 (m, 15 2H), 3.52-3.46 (m, 2H), 3.00-2.99 (m, 1 H), 2.33 (s, 3H), 2.12-2.08 (m, 2H), 1.86-1.82 (m, 2H), 1.73-1.67 (m, 6H), 1.19-1.17 (m, 3H), 1.09-1.06 (m, 2H). LC-MS: t_R = 3.02 min (METHOD 3), m/z = 421.2 [M + H]⁺

7-(cycloheptylmethyl)-6-(2-methylbenzyI)-3-(tetrahydro-2H-pyran-4-yl)- [1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one:

To a suspension of 6-(2-methylbenzyl)-3-(tetrahydro-2H-pyran-4-yI)-[1,2,4]triazolo[4,3a]pyrazin-8(7H)-one (150 mg, 462.42 micromol) in anhydrous DMF (5 mL) was added cycloheptylmethyl methanesulfonate (124 mg, 601.15 micromol) and K2CO3 (96 mg,

693.63 micromol). The mixture was heated at 60°C for 12 h. LCMS showed 22% of desired product. The mixture was concentrated and the residue was dissolved in DCM (20 mL) and H₂O (20 mL). The organic layer was washed with H₂O (20 mL), dried over Na₂SO4, filtered, concentrated and purified by préparative HPLC (base) to give 7(cycloheptylmethyl)-6-(2-methylbenzyl)-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3a]pyrazin-8(7H)-one (10.5 mg, 5.22% yield). ¹H NMR (CDCI₃ 400MHz): δ 7.29-7.27 (m, 2H), 7.23-7.19 (m, 1H), 6.99 (d, J=7.2 Hz, 1H), 6.35 (s, 1H), 4.08-4.06 (m, 2H), 3.88 (s, 2H), 3.80-3.79 (m, 2H), 3.52-3.46 (m, 2H), 3.00-2.99 (m, 1H), 2.33 (s, 3H), 2.11-2.08 (m, 3H), 1.85-1.83 (m, 2H), 1.69-1.67 (m, 4H), 1.57-1.52 (m, 4H), 1.45-1.30 (m, 2H), 1.27-1.24 (m, 2H). LC-MS: t_R = 3.11 min (METHOD 3), m/z = 435.2 [M + H]⁺

7-(3-fluorobenzyl)-6-(2-methylbenzyl)-3-(tetrahydro-2H-pyran-4-yl)- [1.2.4] triazolo[4,3-a]pyrazin-8(7H)-one:

To a suspension of 6-bromo-7-(3-fluorobenzyl)-3-(tetrahydro-2H-pyran-4-yl)- [1.2.4] triazolo[4,3-a]pyrazin-8(7H)-one (200 mg, 491.11 micromol) in dioxane (4 mL) and H₂O (2.00 mL) was added 4,4,5,5-tetramethyl-2-(2-methylbenzyl)-1,3,2dioxaborolane (171 mg, 736.67 micromol), K₂CO₃ (136 mg, 982.22 micromol) and 1,TBis(diphenylphosphino)ferrocene-palladium(ll)dichloride (36 mg, 49.11 micromol). The mixture was degassed with N₂ and heated at 80°C for 12 h under N₂. LCMS showed the reaction was completed. The mixture was cooled to 25°C and extracted with EA (20 mL, two times). The organic layer was washed with water (10 mL), dried over Na₂SO4, filtered, concentrated and purified by prep-TLC (DCM/MeOH=20/1) to give the crude product which was purified by préparative HPLC (base) to give 7-(3-fluorobenzyl)-6-(2methylbenzyl)-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (13.75 mg, 6.47% yield). ¹H NMR (CDCI3 400MHz): δ 7.33-7.30 (m, 1 H), 7.26-7.25 (m, 3H), 7.01-6.99 (m, 3H), 6.97-6.90 (m, 1H), 6.41 (s, 1H), 5.27 (s, 2H), 4.10-4.06 (m, 2H), 3.76 (s, 2H), 3.52-3.46(m, 2H), 3.02-2.99 (m, 1H), 2.15-2.09 (m, 5H),1.87-1.84 (m, 2H). LC-MS: t_R = 2.84 min (METHOD 3), m/z = 433.2 [M + H]⁺

Example 48 o

7-(cyclopentylmethyl)-6-(3-methylbenzyl)-3-(tetrahydro-2H-pyran-4-yl)- [1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one:

Step 1: To a solution of 1-(chloromethyl)-3-methylbenzene (2.00 g, 14.22 mmol) in anhydrous dioxane (20 mL) was added 4,4,4^,,4',5,5,5',5^,-octamethyl-2,2'bi(1,3,2-dioxaborolane) (5.42 g, 21.34 mmol), KOAc (4.19 g, 42.67 mmol) and 1,TBis(diphenylphosphino)ferrocene-palladium(ll)dichloride (1.04 g, 1.42 mmol). The mixture was degassed with N₂ and heated at 80°C for 1 h under N₂. The mixture was concentrated and the residue was diluted with MTBE (100 mL) and filtered through a pad of silica gel. The filtrate was concentrated to give 4,4,5,5-tetramethyl-2-(3methylbenzyl)-1,3,2-dioxaborolane (4.00 g, crude). The crude was used for the next step without further purification.

Step 2: To a suspension of 6-bromo-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3a]pyrazin-8(7H)-one (1.50 g, 5.01 mmol) in H₂O (10 mL) and dioxane (20 mL) was added 4,4,5,5-tetramethyl-2-(3-methylbenzyl)-1,3,2-dioxaborolane (3.00 g, crude), 1,1'Bis(diphenylphosphino)ferrocene-palladium(ll)dichloride (367 mg, 501.00 micromol) and K₂CO₃ (1.38 g, 10.02 mmol). The mixture was degassed with N₂ and heated at 100°C for 12 h under N₂. The mixture was concentrated and the residue was dissolved in DCM (30 mL) and H₂O (30 mL). The aqueous layer was extracted with DCM (30 mL). The organics were washed with water (30 mL), dried over Na₂SO₄, filtered, concentrated and purified by flash chromatography on silica gel (DCM/MeOH=100/1~20/1) to give 6-(3-methylbenzyl)-3-(tetrahydro-2H-pyran-4-yl)- [1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (800 mg, 31.50% yield).

Step 3: To a suspension of 6-(3-methylbenzyl)-3-(tetrahydro-2H-pyran-4-yl)- [1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (150 mg, 462.42 micromol) in anhydrous DMF (5 mL) was added (bromomethyl)cyclopentane (90 mg, 554.90 micromol) and K₂CO₃ (96 mg, 693.63 micromol). The mixture was heated at 60°C for 12 h. LCMS showed 35% of desired product. The mixture was concentrated and the residue was dissolved in DCM (20 mL) and H₂O (20 mL). The aqueous layer was extracted with DCM (20 mL). The combined organics were washed with H₂O (20 mL), dried over Na2SO₄, filtered, concentrated and purified by préparative HPLC to give 7-(cyclopentylmethyl)-6-(3methylbenzyl)-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (25.60 mg, 13.62% yield). ¹H NMR(CDCI3 400MHz): δ 7.28-7.24 (m, 1H), 7.15 (d, J=7.6 Hz, 1H), 6.96-6.94 (m, 2H), 6.68 (s, 1H), 4.13-4.09 (m, 2H), 3.92-3.88 (m, 4H),

3.59-3.53 (m, 2H), 3.14-3.13 (m, 1H), 2.35 (s, 3H), 2.17-2.10 (m, 3H), 1.95-1.90 (m, 2H), 1.71-1.67 (m, 4H), 1.55-1.54 (m, 2H), 1.31-1.30 (m, 2H). LC-MS: t_R = 3.10 min (METHOD 3), m/z = 407.2 [M + H]⁺

Example 49 o

7-(cyclohexylmethyl)-6-(3-methylbenzyl)-3-(tetrahydro-2H-pyran-4-yl)18257 [1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one:

To a suspension of 6-(3-methylbenzyl)-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3a]pyrazin-8(7H)-one (150 mg, 462.42 micromol) in anhydrous DMF (5 mL) was added (bromomethyl)cyclohexane (98 mg, 554.90 micromol) and K₂CO₃ (96mg, 693.63 micromol). The mixture was heated at 60°C for 12 h. LCMS showed 32% of desired product. The mixture was concentrated and the residue was dissolved in DCM (20 mL) and H₂O (20 mL). The aqueous layer was extracted with DCM (20 mL). The combined organics were washed with H₂O (20 mL), dried over Na₂SO₄, filtered, concentrated and purified by préparative HPLC (base) to give 7-(cyclohexylmethyl)-6-(3-methylbenzyl)-3(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (12.60 mg, 6.48% yield). ¹H NMR (CDCI₃ 400MHz): δ 7.28-7.24 (m, 1H), 7.14 (d, J=7.6 Hz, 1H), 6.96-6.94 (m, 2H), 6.68 (s, 1H), 4.13-4.10 (m, 2H), 3.91 (s, 2H), 3.77-3.75 (m, 2H), 3.59-3.53 (m, 2H), 3.14-3.12 (m, 1H), 2.35 (s, 3H), 2.20-2.14 (m, 2H), 1.95-1.92 (m, 2H), 1.73-1.72 (m, 2H), 1.65-1.60 (m, 5H), 1.17-1.15 (m, 2H), 1.08-1.02 (m, 2H). LC-MS: t_R = 3.21 min (METHOD 3), m/z = 421.2 [M + H]⁺

Example 50 o

7-benzyl-6-(3-methylbenzyl)-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3a]pyrazin-8(7H)-one:

To a suspension of 6-(3-methylbenzyl)-3-(tetrahydro-2H-pyran-4-yi)-[1,2,4]triazolo[4,3a]pyrazin-8(7H)-one (150 mg, 462.42 micromol) in anhydrous DMF (5 mL) was added

1-(bromomethyl)-3-fluorobenzene (105 mg, 554.90 micromol) and K₂CO₃ (96 mg,

693.63 micromol). The mixture was heated at 60°C for 12 h. The mixture was concentrated and the residue was dissolved in DCM (20 mL) and H₂O (20 mL). The aqueous layer was extracted with DCM (20 mL). The combined organics were washed with H₂O (20 mL), dried over Na₂SO₄, filtered, concentrated and purified by préparative HPLC (base) to give 7-benzyl-6-(3-methylbenzyl)-3-(tetrahydro-2H-pyran-4-yl)18257 [1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (46.0 mg, 23.00% yield). ¹H NMR (CDCI₃400MHz): δ 7.33-7.29 (m, 1H), 7.26-7.25 (m, 1H), 7.15 (d, J=7.6 Hz, 1H), 6.99-6.95 (m, 1H), 6.94-6.87 (m, 3H), 6.85-6.81 (m, 1H), 6.80 (s, 1H), 5.15 (s, 2H), 4.15-4.12 (m, 2H), 3.76 (s, 2H), 3.60-3.54 (m, 2H), 3.22-3.18 (m, 1H), 2.34 (s, 3H), 2.23-2.17 (m, 2H),1.98-

1.95 (m, 2H). LC-MS: f_R = 3.01 min (METHOD 3), m/z = 433.1 [M + H]⁺

7-(cyclopentylmethyl)-6-(4-methylbenzyl)-3-(tetrahydro-2H-pyran-4-yl)- [1.2.4] triazolo[4,3-a]pyrazin-8(7H)-one:

Step 1: To a suspension of 6-bromo-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3a]pyrazin-8(7H)-one (1.00 g, 3.34 mmol) in H₂O (10 mL) and dioxane (20 mL) was added 4,4,5,5-tetramethyl-2-(4-methylbenzyl)-1,3,2-dioxaborolane (1.16 g, 5.01 mmol), 1,T-Bis(diphenylphosphino)ferrocene-palladium(ll)dichloride (245 mg, 334.31 micromol) and Cs₂CO₃ (2.18 g, 6.69 mmol). The mixture was degassed with N₂ and heated at 100°C for 12 h under N₂. LCMS showed the reaction was completed. The mixture was cooled to 25°C and extracted with EA (20 mL, two times). The organic layer was washed with water (20 mL), dried over Na₂SO₄, filtered, concentrated and purified by flash chromatography on silica gel (DCM/MeOH=100/1-20/1 ) to give 6-(4methylbenzyl)-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (500 mg, 38.62% yield).

Step 2: To a suspension of 6-(4-methylbenzyl)-3-(tetrahydro-2H-pyran-4-yl)- [1.2.4] triazolo[4,3-a]pyrazin-8(7H)-one (150 mg, 462.42 micromol) in anhydrous DMF (5 mL) was added (bromomethyl)cyclopentane (91 mg, 554.90 micromol) and K₂CO₃ (96 mg, 693.63 micromol). The mixture was heated at 60°C for 12 h. LCMS showed 44% of desired product. The mixture was concentrated and the residue was dissolved in DCM (20 mL) and H₂O (20 mL). The aqueous layer was extracted with DCM (20 mL). The combined organics were washed with H₂O (20 mL), dried over Na₂SO₄, filtered, concentrated and purified by préparative HPLC (base) to give 7-(cyclopentylmethyl)-6 (4-methylbenzyl)-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (47.00 mg, 24.74% yield). ¹H NMR (CDCI₃ varian 400): δ 7.17 (d, J=7.Q Hz, 2H), 7.03 (d, J=8.0 Hz, 2H), 6.65 (s, 1H), 4.11-4.08 (m, 2H), 3.90-3.86 (m, 4H), 3.56-3.51 (m, 2H),

3.12-3.09 (m, 1H), 2.34 (s, 3H), 2.35-2.25 (m, 1H), 2.16-2.13 (m, 2H), 1.92-1.89 (m, 2H), 1.67-1.63 (m, 4H), 1.53-1.51 (m, 2H), 1.31-1.26 (m, 2H). LC-MS: f_R = 2.95 min (METHOD 3), m/z = 407.2 [M + H]⁺

Example 52

7-(cyclohexylmethyl)-6-(4-methylbenzyl)-3-(tetrahydro-2H-pyran-4-yl)- [1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one:

To a suspension of 6-(4-methylbenzyl)-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3a]pyrazin-8(7H)-one (150 mg, 462.42 micromol) in anhydrous DMF (5 mL) was added (bromomethyl)cyclohexane (98 mg, 554.90 micromol) and K₂CO₃ (96 mg, 693.63 micromol). The mixture was heated at 60°C for 12 h. LCMS showed 32% of desired product. The mixture was concentrated and the residue was dissolved in DCM (20 mL) and H₂O (20 mL). The aqueous layer was extracted with DCM (20 mL). The combined organics were washed with H₂O (20 mL), dried over Na₂SO₄, filtered, concentrated and purified by préparative HPLC (base) to give 7-(cyclohexylmethyl)-6-(4-methylbenzyI)-3(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (23.90 mg, 12.29% yield). ¹H NMR (CDCI3 400MHz): δ 7.19 (d, J=8.0 Hz, 2H), 7.05 (d, J=8.0 Hz, 2H), 6.67 (s, 1H), 4.13-4.10 (m, 2H), 3.90 (s, 2H), 3.77-3.75 (m, 2H), 3.59-3.53 (m, 2H), 3.14-3.11 (m, 1H), 2.36 (s, 3H), 2.20-2.15 (m, 2H), 1.94-1.92 (m, 2H), 1.74-1.72 (m, 2H), 1.65-

1.62 (m, 5H), 1.17-1.15(m, 2H), 1.06-1.02 (m, 2H). LC-MS: t_R = 3.04 min (METHOD 3), m/z = 421.3 [M + H]⁺

Example 53

Ο

7-(cycloheptylmethyl)-6-(4-methylbenzyl)-3-(tetrahydro-2H-pyran-4-yl)- [1,2,4]triazolo[4₅3-a]pyrazin-8(7H)-one:

To a suspension of 6-(4-methylbenzyl)-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3a]pyrazin-8(7H)-one (200 mg, 616.56 micromol) in anhydrous DMF (10 mL) was added cycloheptylmethyl methanesulfonate (165 mg, 801.53 micromol) and K₂CO₃ (128 mg, 924.84 micromol). The mixture was heated at 60°C for 12 h. LCMS showed 26% of desired product. The mixture was concentrated and the residue was dissolved in DCM (20 mL) and H₂O (20 mL). The aqueous layer was extracted with DCM (20 mL). The combined organics were washed with H₂O (20 mL), dried over Na₂SO4, filtered, concentrated and purified by préparative HPLC (base) to give 7-(cycloheptylmethyl)-6(4-methylbenzyl)-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (26.50 mg, 9.89% yield). ¹H NMR (CDCI₃ varian 400): δ 7.17 (d, J=8.0 Hz, 2H), 7.02 (d, J=8.0 Hz, 2H), 6.65 (s, 1H), 4.11-4.09 (m, 2H), 3.87 (s, 2H), 3.74-3.72 (m, 2H), 3.57-

3.52 (m, 2H), 3.15-3.11 (m, 1H), 2.34 (s, 3H), 2.18-2.14 (m, 2H), 2.05-1.90 (m, 3H),

1.63-1.60 (m, 4H), 1.53-1.47 (m, 4H), 1.37-1.34 (m, 2H), 1.21 -1.18 (m, 2H). LC-MS: t_R = 2.82 min (METHOD 4), m/z = 435.3 [M + H]⁺

Example 54

O

7-(3-fluorobenzyl)-6-(4-methylbenzyl)-3-(tetrahydro-2H-pyran-4-yl)[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one:

To a suspension of 6-bromo-7-(3-fluorobenzyl)-3-(tetrahydro-2H-pyran-4-yl)- [1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (100 mg, 245.56 micromol) in dioxane (2 mL) and H₂O (1 mL) was added 4,4,5,5-tetramethyl-2-(4-methylbenzyl)-1,3,2dioxaborolane (86 mg, 368.33 micromol), K₂CO₃ (68 mg, 491.11 micromol) and 1,TBis(diphenylphosphino)ferrocene-palladium(ll)dichloride (18 mg, 24.56 micromol). The mixture was degassed with N₂ and heated at 80°C for 12 h under N₂. LCMS showed the reaction was completed. The mixture was cooled to 25°C and extracted with EA (10 mL, two times). The organic layer was washed with water (10 mL), dried over Na₂SO₄, filtered, concentrated and purified by prep-TLC (DCM/MeOH=20/1 ) to give the crude product which was purified by préparative HPLC (base) to give 7-(3-fluorobenzyl)-6-(4methylbenzyl)-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (8.89 mg, 8.04% yield). ¹H NMR (CDCI₃ 400MHz): δ 7.32-7.30 (m, 1H), 7.20 (d, J=7.6 Hz, 2H), 7.02-6.99 (m, 3H), 6.94-6.92 (m, 1H), 6.85-6.80 (m, 1H), 6.77 (s, 1H), 5.15 (s, 2H), 4.16-4.12 (m, 2H), 3.75 (s, 2H), 3.61-3.54 (m, 2H), 3.18-3.17 (m, 1H), 2.37 (s, 3H), 2.23-2.19 (m, 2H),1.98-1.94 (m, 2H). LC-MS: f_R = 2.43 min (METHOD 6), m/z = 433.2 [M + H]⁺

Example 55 o

7-(cyclopentylmethyl)-6-(3-fluorobenzyl)-3-(tetrahydro-2H-pyran-4-yl)- [1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one :

Step 1: To a suspension of 6-bromo-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3a]pyrazin-8(7H)-one (1.50 g, 5.01 mmol) in H₂O (4 mL) and dioxane (10 mL) was added

2-(3-fluorobenzyl)-4,4,5,5-tetramethyi-1,3,2-dioxaborolane (1.78 g, 7.52 mmol), 1,TBis(diphenylphosphino)ferrocene-palladium(ll)dichloride (734 mg, 1.0 mmol) and Cs₂CO₃ (3.27 g, 10.03 mmol). The mixture was degassed with N₂ and heated at 100°C for 16h under N₂. The mixture was concentrated and the residue was dissolved in DCM (20 mL) and H₂O (10 mL). The aqueous layer was extracted with DCM (20 mL). The organics were washed with water (20 mL), dried over Na₂SO₄, filtered, concentrated and purified by flash chromatography on silica gel (DCM/MeOH=100/1-20/1 ) to give 618257 (3-fluorobenzyl)-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (190 mg, 11.6% yield) as a black solid.

Step 2: To a suspension of 6-(3-fluorobenzyl)-3-(tetrahydro-2H-pyran-4-yl)- [1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (70 mg, 213.2 micromol) in anhydrous DMF (3 mL) was added (bromomethyl)cyclopentane (42 mg, 255.8 micromol) and K2CO3 (44 mg, 320 micromol). The mixture was heated at 60°C for 36 h. The mixture was cooled and filtered. The filtrate was purified by préparative HPLC to give 7-(cyclopentylmethyl)6-(3-fluorobenzyl)-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (15 mg, 17% yield). ¹H NMR(CDCI₃ 400MHz): δ 7.37-7.34 (m, 1H), 7.06-7.03 (m, 1H), 6.96 (d, J=8.0 Hz, 1H), 6.88 (d, J=9.2 Hz, 1H), 6.71 (s, 1H), 4.14-4.11 (m, 1H), 3.97 (s, 2H), 3.88 (d, J=7.2 Hz, 2H), 3.59-3.53 (m, 2H), 3.16-3.12 (m, 1H), 2.28-2.16 (m, 3H), 1.95-1.92 (m, 2H), 1.70-1.54 (m, 6H), 1.31-1.30 (m, 2H). LC-MS: t_R = 2.82 min (METHOD 3), m/z = 411.2 [M + H]⁺.

Example 56

7-(cyclohexylmethyl)-6-(3-fluorobenzyl)-3-(tetrahydro-2H-pyran-4-yl)- [1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one:

To a suspension of 6-(3-fluorobenzyl)-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3a]pyrazin-8(7H)-one (70 mg, 213.2 micromol) in anhydrous DMF (3 mL) was added (bromomethyl)cyclohexane (45 mg, 255.8 micromol) and K₂CO₃ (44 mg, 320 micromol). The mixture was heated at 60°C for 36 h. The mixture was cooled and filtered. The filtrate was purified by préparative HPLC to give 7-(cyclohexylmethyl)-6-(3fluorobenzyl)-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (18 mg, 19% yield). ¹H NMR (CDCI₃ 400MHz): δ 7.37-7.34 (m, 1 H), 7.06-7.03 (m, 1 H), 6.95 (d, J=7.6 Hz, 1H), 6.88 (d, J=9.6 Hz, 1H), 6.71 (s, 1H), 4.14-4.11 (m, 1H), 3.95 (s, 2H), 3.74 (d, J=7.2 Hz, 2H), 3.59-3.54 (m, 2H), 3.18-3.13 (m, 1H), 2.23-2.14 (m, 2H), 1.9618257

1.93 (m, 2H), 1.74-1.60 (m, 7H), 1.75-1.03 (m, 4H). LC-MS: t_R = 2.92 min (METHOD 3), m/z = 425.2 [M + H]⁺.

Example 57 o

6,7-bis(3-fluorobenzyl)-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3-a]pyrazin8(7H)-one:

To a suspension of 6-(3-fluorobenzyl)-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3a]pyrazin-8(7H)-one (70 mg, 213.2 micromol) in anhydrous DMF (3 mL) was added 1(bromomethyl)-3-fluorobenzene (48 mg, 255.8 micromol) and K₂CO₃ (44 mg, 320 micromol). The mixture was heated at 60°C for 16 h. The mixture was cooled and diluted with water (5 mL), extracted with DCM (5mL, two times). The organic layer was washed with brine, dried and concentrated in vacuo. The residue was purified by prepTLC (DCM/MeOH=10/1) to give 6,7-bis(3-fluorobenzyl)-3-(tetrahydro-2H-pyran-4-yl)- [1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (5 mg, 5% yield). ¹H NMR (CDCI₃ 400MHz): δ 7.38-7.32 (m, 2H), 7.05-7.00 (m, 2H), 6.94-6.92 (m, 2H), 6.86-6.84 (m, 2H), 6.85-6.80 (m, 1H), 6.79 (s, 2H), 5.15 (s, 2H), 4.16-4.13 (m, 2H), 3.80 (s, 2H), 3.61-3.55 (m, 2H), 3.22-3.16 (m, 1H), 2.28-2.17 (m, 2H), 1.98-1.95 (m, 2H). LC-MS: t_R = 2.46 min (METHOD 3), m/z = 437.2 [M + H],

Example 58 o

7-(cyclopentylmethyl)-6-(4-fluorobenzyl)-3-(tetrahydro-2H-pyran-4-yl)- [1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one:

Step 1: To a suspension of 6-bromo-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3a]pyrazin-8(7H)-one (1.50 g, 5.01 mmol) in H₂O (10 mL) and dioxane (20 mL) was added 2-(4-fluorobenzyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (1.78 g, 7.52 mmol), 1,r-Bis(diphenylphosphino)ferrocene-palladium(ll)dichloride (367 mg, 501.47 micromol) and Cs₂CO₃ (3.27 g, 10.03 mmol). The mixture was degassed with N₂ and heated at 100°C for 12 h under N₂. LCMS showed the reaction was completed. The mixture was concentrated and the residue was dissolved in DCM (20 mL) and H₂O (10 mL). The aqueous layer was extracted with DCM (20 mL). The organics were washed with water (20 mL), dried over Na₂SO₄, filtered, concentrated and purified by flash chromatography on silica gel (DCM/MeOH=100/1-20/1 ) to give 6-(4-fluorobenzyl)-3(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (600 mg, 24.80% yield).

Step 2: To a suspension of 6-(4-fluorobenzyl)-3-(tetrahydro-2H-pyran-4-yl)- [1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (150 mg, 456.84 micromol) in anhydrous DMF (5 mL) was added (bromomethyl)cyclopentane (89. mg, 548.21 micromol) and K₂CO₃ (95 mg, 685.27 micromol). The mixture was heated at 60°C for 12 h. LCMS showed 23% TM. The mixture was concentrated and the residue was dissolved in DCM (20 mL) and H₂O (20 mL). The aqueous layer was extracted with DCM (20 mL). The combined organics were washed with H₂O (20 mL), dried over Na₂SO₄, filtered, concentrated and purified by prep-TLC (DCM/MeOH=50/1 ) to give 7-(cyclopentylmethyl)-6-(4fluorobenzyl)-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (25.90 mg, 13.67% yield). ¹H NMR(CDCI3 400MHz): δ 7.17-7.13 (m, 2H), 7.11-7.06 (m, 2H), 6.64 (s, 1H), 4.13-4.10 (m, 2H), 3.94 (s, 2H), 3.90 (d, J=7.2 Hz, 2H), 3.59-3.53 (m, 2H),

3.13-3.12 (m, 1H), 2.28-2.10 (m, 1H), 2.19-2.16 (m, 2H), 1.94-1.91 (m, 2H), 1.71-1.68 (m, 4H), 1.54-1.45 (m, 2H), 1.33-1.28 (m, 2H). LC-MS: f_R = 2.84 min (METHOD 3), m/z = 411.2 [M + H]⁺

Example 59

7-(cyclohexylmethyl)-6-(4-fluorobenzyl)-3-(tetrahydro-2H-pyran-4-yl)- [1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one:

To a suspension of 6-(4-fluorobenzyl)-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3a]pyrazin-8(7H)-one (150 mg, 456.84 micromol) in anhydrous DMF (5 mL) was added (bromomethyl)cyclohexane (97 mg, 548.21 micromol) and K2CO3 (95 mg, 685.27 micromol). The mixture was heated at 60°C for 12 h. LCMS showed 36% of desired product. The mixture was concentrated and the residue was dissolved in DCM (20 mL) and H2O (20 mL). The aqueous layer was extracted with DCM (20 mL). The combined organics were washed with H₂O (20 mL), dried over Na₂SO₄, filtered, concentrated and purified by prep-TLC (DCM/MeOH=50/1) to give 7-(cyclohexylmethyl)-6-(4fluorobenzyl)-3-(tetrahydro-2H-pyran-4-yI)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (23.50 mg, 12.00% yield). ¹H NMR (CDCI3 400MHz): δ 7.17-7.06 (m, 4H), 6.65 (s, 1H), 4.134.10 (m, 2H), 3.92 (s, 2H), 3.76-3.74 (m, 2H), 3.59-3.54 (m, 2H), 3.13-3.12 (m, 1H), 2.20-2.16 (m, 2H), 1.94-1.91 (m, 2H), 1.77-1.72 (m, 3H), 1.65-1.60 (m, 4H), 1.181.15(m, 2H), 1.06-1.03 (m, 2H). LC-MS: f_R = 2.92 min (METHOD 3), m/z = 425.2 [M + H]⁺

7-(cycloheptylmethyl)-6-(4-fluorobenzyl)-3-(tetrahydro-2H-pyran-4-yl)- [1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one:

To a suspension of 6-(4-fluorobenzyl)-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3a]pyrazin-8(7H)-one (150 mg, 456.84 micromol) in anhydrous DMF (5 mL) was added cycloheptylmethyl methanesulfonate (122 mg, 593.90 micromol) and K₂CO₃ (95 mg, 685.27 micromol). The mixture was heated at 60°C for 12 h. LCMS showed 21% of desired product. The mixture was concentrated and the residue was dissolved in DCM (20 mL) and H₂O (20 mL). The aqueous layer was extracted with DCM (20 mL). The combined organics were washed with H₂O (20 mL), dried over Na₂SO4, filtered, concentrated and purified by préparative HPLC (base) to give 7-(cycloheptylmethyl)-6(4-fluorobenzyl)-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (6.00 mg, 2.96% yield). ¹H NMR (CDCI3 400MHz): δ 7.16-7.06 (m, 4H), 6.65 (s, 1 H),

4.13-4.10 (m, 2H), 3.92 (s, 2H), 3.74-3.72 (m, 2H), 3.59-3.54 (m, 2H), 3.13-3.10 (m, 1H), 2.19-2.16 (m, 2H), 2.05-1.95 (m, 1H), 1.94-1.91 (m, 2H), 1.67-1.65 (m, 4H), 1.561.51 (m, 4H), 1.40-1.30 (m, 2H), 1.23-1.20 (m, 2H). LC-MS: f_R = 2.67 min (METHOD 4), m/z = 439.2 [M + H]⁺

Example 61 o

7-(3-fluorobenzyl)-6-(4-fluorobenzyl)-3-(tetrahydro-2H-pyran-4-yl)- [1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one:

To a suspension of 6-(4-fluorobenzyl)-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3a]pyrazin-8(7H)-one (150 mg, 456.84 micromol) in anhydrous DMF (5 mL) was added

1-(bromomethyl)-3-fluorobenzene (104 mg, 548.21 micromol) and K₂CO₃ (95 mg,

685.27 micromol). The mixture was heated at 60°C for 12 h. LCMS showed 35% of desired product. The mixture was concentrated and the residue was dissolved in DCM (20 mL) and H₂O (20 mL). The aqueous layer was extracted with DCM (20 mL). The combined organics were washed with H₂O (20 mL), dried over Na₂SO₄, filtered, concentrated and purified by préparative HPLC (base) to give 7-(3-fluorobenzyl)-6-(4fluorobenzyl)-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (37.90 mg, 19.01% yield). ¹H NMR(CDCI₃ 400MHz): δ 7.33-7.30 (m, 1H), 7.11-7.08 (m, 4H), 7.00-6.95 (m, 1H), 6.93-6.92 (m, 1H), 6.85-6.80 (m, 1H), 6.74 (s, 1H), 5.16 (s, 2H), 4.16-4.11 (m, 2H), 3.78 (s, 2H), 3.60-3.54 (m, 2H), 3.17-3.14 (m, 1H), 2.25-2.16 (m, 2H),1.97-1.93 (m, 2H). LC-MS: t_R = 2.75 min (METHOD 3), m/z = 437.2 [M + H]⁺

Example 62

5-bromo-7-(3-fluorobenzyl)-3-propyl-[1,2,4]triazoIo[4,3-a]pyrazin-8(7H)-one:

Step 1: A solution of 3,5-dibromopyrazin-2-amine (40 g, 158.17 mmol), isopentyl nitrite (56 g, 474.51 mmol) and HCI/MeOH (8 mL, 1 M) in MeOH (400 mL) was stirred at 60°C for 3h. The solution was concentrated under vacuum. The residue was diluted with DCM (150 mL), washed with NaHCO₃(aq.) until pH = 7, dried over Na₂SO₄ and concentrated under vacuum. The residue was purified by flash chromatography on siiica gel (ethyl acetate/petroleums ether =0/1-1/20) to give 3,5-dibromo-2-methoxypyrazine (46 g, Yield: 96.4%) as a yellow liquid.

Step 2: A solution of 3,5-dibromo-2-methoxypyrazine (45 g, 0.167 mol) and NH₂NH₂.H₂O (15.7g, 0.252mol, 80%) in EtOH (250 mL) was stirred at 70°C for 5 hours. The mixture was concentrated under vacuum, the residue was washed with water, filtered and dried to give 5-bromo-3-hydrazinyl-2-methoxypyrazine (32 g, Yield: 86.9%).

Step 3: A solution of 5-bromo-3-hydrazinyl-2-methoxypyrazine (5 g, 22.83 mmol) and butyraldéhyde (1.73 g, 23.97 mmol) in DCM (60 mL) was stirred at 50 °C for 2 hours. The solution was cooled to 0°C and iodobenzene diacetate (8.45 g, 26.23mmol) was portionwise added and the reaction mixture was stirred at 30 °C for 2 hours. Then Na₂CO₃ (20 mL, sat. aq.) was slowly poured into the reaction mixture and stirred for 30 min. The organic phase was separated and washed with brine, dried over Na₂SO₄ and evaporated under reduced pressure. The crude was purified by flash chromatography on silica gel (EA/PE=1/10-1/1) to give 5-bromo-8-methoxy-3-propyl-[1,2,4]triazolo[4,3a]pyrazine (2 g, Yield: 32.4%).

Step 4: A solution of 5-bromo-8-methoxy-3-propyl-[1,2,4]triazolo[4,3-a]pyrazine (3.7 g,

13.6 mmol) in DCM (260 mL) was added BBr₃(17.1g, 68.2 mmol, 80%) at 0°C and stirred at 20°C for 12 hours. The solution was quenched with water (100mL) and stirred at 20°C for 0.5 hour. NaHCO₃ (sat. aq.) was added until pH = 8. It was filtered and the filtrate was concentrated under vacuum. The residue was diluted with DCM (200 mL), filtered and concentrated under vacuum to give 5-bromo-3-propyl-[1,2,4]triazolo[4,3a]pyrazin-8(7H)-one (2.6 g, Yield: 74%).

Step 5: A mixture of 5-bromo-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (2.0 g, 7.78 mmol), 1-(bromomethyl)-3-fluorobenzene (1.47 g, 7.78 mmol) and K₂CO₃ (2.15 g,

15.56 mmol) in DMF (60 mL) was stirred at 60°C for 5 hours. The mixture was diluted with water (80 mL) and extracted with EA (50 mL*3). The combined organic layers were dried over Na₂SO₄ and evaporated. The residue was washed with MTBE (2, two timesO mL) to give 5-bromo-7-(3-fluorobenzyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (2 g, yield: 71.4%). ¹H NMR (CDCI3, 400 MHz TMS): δ 7.39 - 7.34 (m, 1H), 7.15 - 7.13 (m, 1H), 7.09 - 7.05 (m, 2H), 6.67 (s, 1H), 5.11 (s, 2H), 3.30 (t, J= 7.6 Hz, 2H), 1.99 -

1.89 (m, 2H), 1.08 (t, J = 7.6 Hz, 3H). LC-MS: f_R = 2.069 min (METHOD 3), m!z = 365.0 [M + H]⁺

Example 63 o

5-ethyl-7-(3-fluorobenzyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one:

Step 1: A mixture of 5-bromo-7-(3-fluorobenzyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin8(7H)-one (150 mg, 410.73 micromol), 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane (127 mg, 821.47 micromol) and K₂CO₃ (170 mg, 1.23 mmol) in THF/H₂O (2 mL/1 mL) was stirred at 80°C for 12 hours. The mixture was cooled to 20°C, and concentrated in reduced pressure at 30°C. The residue was poured into water (10 mL) and stirred for 20 min. The aqueous phase was extracted with EA (10 mL*3). The combined organic phase was washed with saturated brine (5 mL), dried with anhydrous Na2SO₄, filtered and concentrated in vacuum to afford 7-(3-fluorobenzyl)-3-propyl-5-vinyl- [1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (110 mg, 85.74% yield). LC-MS: t_R = 0.693 min (Method 7), m/z = 312.9 [M + H]⁺.

Step 2: To a solution of 7-(3-fiuorobenzyl)-3-propyl-5-vinyl-[1,2,4]triazolo[4,3-a]pyrazin8(7H)-one (100 mg, 320.16 micromol) in MeOH (5 mL) was added Pd/C (10 mg, 10% Pd, 50% water) under N₂. The suspension was degassed under vacuum and purged with H₂ several times. The mixture was stirred under H₂ (balloon) at 20°C for 10 min. The mixture filtered and concentrated in reduced pressure at 30 °C. The residue was purified by prep-TLC (DCM/MeOH=12/1) to afford 5-ethyl-7-(3-fluorobenzyl)-3propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (24.3 mg, 23% yield). ¹H NMR (CDCI₃, 400 MHz TMS): δ 7.37 - 7.31 (m, 1 H), 7.14 - 7.11 (m, 1 H), 7.05 - 7.01 (m, 2H), 6.20 (s, 1 H), 5.11 (s, 2H), 3.12 (t, J = 7.6 Hz, 2H), 2.89 - 2.83 (m, 2H), 2.01 -1.92 (m, 2H), 1.27 (t, J = 7.2 Hz, 3H), 1.08 (t, J = 7.2 Hz, 3H). LC-MS: t_R = 2.595 min (METHOD 3), m/z =

315.1 [M + H]⁺

Example 64 o

7-(3-fluorobenzyl)-5-methyl-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one:

A mixture of 5-bromo-7-(3-fluorobenzyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (200 mg, 547.65 micromol) and trifluoro(methyl)-borane, potassium sait (200 mg, 1.64 mmol,) in Dioxane/H₂O (10 mL/3 mL), was added 1,1’Bis(diphenylphosphino)ferrocene-pailadium(ll)dichloride (40 mg, 54.76 micromol). The brownness solution was stirred at 90°C for 12 hours. The mixture was concentrated under vacuum, the residue was purified by column chromatography (column height: 250 mm, diameter: 100 mm, 100-200 mesh silica gel, Petroleum ether/Ethyl acetate =10/1,

3/1) and followed by prep- HPLC to afford 7-(3-fiuorobenzyl)-5-methyl-3-propyl- [1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (25.5 mg, 15% yield). ¹H NMR (CDCI₃, 400 MHz TMS): δ. 7.35-7.31 (m, 1H), 7.13-7.12 (m, 1H), 7.05-7.02 (m, 2H), 6.23 (s, 1H), 5.09 (s, 2H), 3.14 (t, J = 7.6 Hz, 2H), 2.49 (s, 3H), 1.99 -1.90 (m, 2H), 1.08 (t, J = 7.2 Hz, 3H). LC-MS: t_R = 2.448 min (METHOD 3), m/z = 301.1 [M + H]⁺

Example 65

7-(3-fluorobenzyl)-3-propyl-5-(tetrahydrofuran-3-yl)-[1,2,4]triazolo[4,3-a]pyrazin8(7H)-one, stereoisomer 1 and 2:

Step 1 : A mixture of 5-bromo-7-(3-fluorobenzyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin8(7H)-one (400 mg, 1.10 mmol) and 2-(2,5-dihydrofuran-3-yl)-4,4,5,5-tetramethyl-1,3,2dioxaborolane (237 mg, 1.21 mmol) in Dioxane/H₂O (5 mL/1 mL), was added 1,1’Bis(diphenylphosphino)ferrocene-palladium(ll)dichloride (80 mg, 109.53 micromol) and stirred at 70°C for 5 hours. The mixture was concentrated under vacuum. The residue was purified by silica gel chromatography (column height: 250 mm, diameter: 100 mm, 100-200 mesh silica gel, Petroleum ether/Ethyl acetate=10/1, 1/1) and followed by préparative HPLC to afford 5-(2,5-dihydrofuran-3-yl)-7-(3-fluorobenzyl)-3-propyl- [1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (100 mg, 25.65% yield) as white solid.

Step 2: To a solution of 5-(2,5-dihydrofuran-3-yl)-7-(3-fluorobenzyl)-3-propyl- [1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (90 mg, 253.96 micromol) in MeOH (6 mL) was added Pd/C (10 mg, 10% Pd, 50% water) under N₂. The suspension was degassed under vacuum and purged with H₂ several times. The mixture was stirred under H₂(balloon) at 20°C for 1 hour. The mixture was filtered and concentrated in reduced pressure at 30 °C. The residue was purified by prep-TLC (EA/PE=1/0) to afford 7-(3fluorobenzyI)-3-propyl-5-(tetrahydrofuran-3-yl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (60 mg, 65% yield) as white solid. LC-MS: t_R = 0.659min (Method 7), m/z = 356.9 [M + H]⁺.

Step 3: 7-(3-fluorobenzyI)-3-propyl-5-(tetrahydrofuran-3-yl)-[1,2,4]triazolo[4,3-a]pyrazin

8(7H)-one (60 mg, 168.35 micromol) was purified by SFC to give 7-(3-fluorobenzyl)-3propyl-5-(tetrahydrofuran-3-yl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one, stereoisomer 1 (15.10 mg, 25% yield) ¹H NMR (CDCI₃ varian 400): δ 7.37 - 7.31 (m, 1H), 7.13-7.11 (m, 1H), 7.05 - 7.01 (m, 2H), 6.47 (s, 1H), 5.16 - 5.06 (m, 2H), 3.93 - 3.89 (m, 4H), 3.68 -3.71 (m, 1H), 3.18-3.06 (m, 2H), 2.44 - 2.39 (m, 1H), 2.03 -1.96 (m, 3H), 1.10 (t, J =

7.6 Hz, 3H). LC-MS: t_R = 2.423 min (METHOD 3), m/z = 357.2 [M + H]⁺. SFC: tR = 10.2 min, ee% = 100%. [a]D²⁰ = +81.67° (c = 0.10, CHCI3).

And 7-(3-fluorobenzyl)-3-propyl-5-(tetrahydrofuran-3-yl)-[1,2,4]triazolo[4,3-a]pyrazin8(7H)-one , stereoisomer 2_10 (18.70 mg, 30% yield) ¹H NMR (CDCI3 varian 400): δ 7.37 - 7.31 (m, 1 H), 7.13 - 7.11 (m, 1 H), 7.05 - 7.01 (m, 2H), 6.47 (s, 1H), 5.16 - 5.06 (m, 2H), 4.00 - 3.95 (m, 4H), 3.81 - 3.69 (m, 1H), 3.18 - 3.08 (m, 2H), 2.44 - 2.39 (m, 1H), 2.03 -1.96 (m, 3H), 1.10 (t, J = 7.6 Hz, 3H). LC-MS: tR = 2.424 min (METHOD 3), m/z = 357.1 [M + H]⁺. SFC: tR = 10.76 min, ee% = 97.89%. [oc]_D ²⁰ = -81.67 (c = 0.10, CHCI₃).

Example 66 o

3- propyl-7-((tetrahydro-2H-pyran-4-yl)methyl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)one:

To a solution of 3-propyI-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (200 mg, 1.1 mmol) and

4- (bromomethyl)tetrahydro-2H-pyran (241 mg, 1.35 mmol) in DMF (2 mL) was added K₂CO₃ (310 mg, 2.2 mmol). The mixture was stirred at 60°C for 4 hours. The mixture was diluted with DCM (20 mL) and washed with water (5 mL, two times). The organic layer was dried over Na₂SO₄ and evaporated. The residue was washed with MeOH (2 mL) to give 3-propyl-7-((tetrahydro-2H-pyran-4-yl)methyl)-[1,2,4]triazolo[4,3-a]pyrazin8(7H)-one (120 mg, yield: 54%) . ¹H NMR (CDCI₃, 400 MHz TMS): δ 6.91 (d, J=6.0 Hz, 1H), 6.62 (d, J=6.0 Hz, 1H), 3.96 (dd, J=11.6, 3.2 Hz, 2H), 3.82 (d, J=7.6 Hz, 2H), 3.34 (td, J=11.6, 1.6 Hz, 2H), 2.94 (t, J=7.6 Hz, 2H), 2.20-2.10 (m, 1H), 1.91-1.86 (m, 2H), 1.61-1.58 (m, 2H), 1.40 (dq, J=4.0, 12.0 Hz, 2H), 1.04 (t, J=7.6 Hz, 3H). LC-MS: t_R =

1.93 min (METHOD 3), m/z = 277.1 [M + H]⁺.

3-propyl-7-((tetrahydro-2H-pyran-3-yl)methyl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)one, stereoîsomer 1 and 2:

Step 1: To a solution of (tetrahydro-2H-pyran-3-yl)methanol (300 mg, 2.58 mmol) and TEA(522 mg, 5.17mmol) in DCM (10 mL) was added MsCI (355 mg, 3.10 mmol) at 0°C and it was stirred at 20°C for 1 hours. The solution was washed with NaHCO₃ (aq. 2mL), water (three times 2mL), brine (1 time 1mL) dried and concentrated to give (tetrahydro-2H-pyran-3-yl)methyl methanesulfonate (500 mg), which was used in the next step directly.

2.58 mmol) and 3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (413 mg, 2.32 mmol) in DMF (30 mL) was added K₂CO₃ (534 mg, 3.87 mmol). The mixture was stirred at 60°C for 4 hours. The mixture was diluted with DCM (100mL) and washed with water (2 times 10mL). The organic layer was dried over Na₂SO₄ and evaporated. The residue was washed with MeOH (2 mL) to give 3-propyl-7-((tetrahydro-2H-pyran-3-yl)methyl)- [1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (400 mg, yield: 56%).

Step 3: 3-propyl-7-((tetrahydro-2H-pyran-3-yl)methyl)-[1,2,4]triazolo[4,3-a]pyrazin8(7H)-one (400 mg, 1.45mmol) was purified by SFC to afford 3-propyl-7-((tetrahydro2H-pyran-3-yl)methyl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one, stereoîsomer 1(160 mg, yield: 40.0%), ¹H NMR (CDCl₃ varian 400): δ 6.93 (d, J=6.0 Hz, 1H), 6.66 (d, J=6.0 Hz, 1 H), 4.03-3.94 (m, 1 H), 3.89-3.74 (m, 3H), 3.60-3.50 (m, 1 H), 3.37 (dd, J=11.6, 7.6 Hz, 1H), 2.97 (t, J=7.6 Hz, 2H), 2.23-2.12 (m, 1H), 1.97-1.80 (m, 3H), 1.78-1.68 (m, 1H),

I. 62-1.53 (m, 1 H), 1.50-1.40 (m, 1 H), 1.06 (t, J=7.4 Hz, 3H). LC-MS: f_R = 1.99 min (METHOD 3), m/z = 277.2 [M + H]⁺. SFC-MS: t_R = 9.60 min, ee% = 99.68%. [ct]_D ²⁰ = -

II. 33 (c = 0.10, MeOH).

And 3-propyl-7-((tetrahydro-2H-pyran-3-yl)methyl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)one, stereoisomer 2 (170 mg, yield: 42.5%). ¹H NMR (CDCI3 varian 400): δ 6.94 (d, J=6.0 Hz, 1H), 6.66 (d, J=6.4 Hz, 1H), 4.01-3.94 (m, 1H), 3.89-3.74 (m, 3H), 3.60-3.51 (m, 1H), 3.37 (dd, J=11.6, 7.6 Hz, 1H), 2.97 (t, J=7.6 Hz, 2H), 2.23-2.12 (m, 1H), 1.971.80 (m, 3H), 1.78-1.68 (m, 1 H), 1.62-1.53 (m, 1 H), 1.50-1.40 (m, 1 H), 1.06 (t, J=7.4 Hz, 3H). LC-MS: tR = 1.99 min (METHOD 3), m/z = 277.2 [M + H]⁺. SFC-MS: fR = 10.81 min, ee% = 99.50%.[a]_D ²⁰ = + 12.33° (c = 0.10, MeOH).

Example 68 o

7-(((1 r,3r,5r, 7r)-adamantan-2-yl)methyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin8(7H)-one:

Step 1: Borane-tetrahydrofurane complex (1 M, 4.44 mL, 2.00 Eq) was added dropwise to a solution of (1r,3r,5r,7r)-adamantane-2-carboxylic acid (400 mg, 2.22 mmol, 1.00 Eq) in THF (15 mL) at 0°C. Then the mixture was heated at 60°C for 12 h. The mixture was cooled to 0°C and MeOH (3 mL) was added dropwise to the mixture. The mixture was concentrated and the residue was purified by flash chromatography on silica gel (DCM/MeOH=100/1-20/1 ) to give ((1r,3r,5r,7r)-adamantan-2-yl)methanol (250.00 mg,

1.35 mmol, 60.96% yield, 90% purity).

Step 2: To a cooled (0°C) solution of ((1r,3r,5r,7r)-adamantan-2-yI)methanol (250 mg, 1.50 mmol, 1.00 Eq) in DCM (10 mL) was added Et₃N (304 mg, 3.01 mmol, 2.00 Eq) and MsCI (207 mg, 1.80 mmol, 1.20 Eq). The mixture was stirred at 0°C for 1 h. The reaction was checked by TLC. Water (5 mL) was added to the mixture. The organic layer was dried over Na₂SO₄, filtered and concentrated to give ((1r,3r,5r,7r)-adamantan-

2-yl)methyl methanesulfonate (350 mg, 95.49% yield) as a light yellow oil.

Step 3: To a suspension of 3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (200 mg,

1.12 mmol, 1.00 Eq) in DMF (10 mL) was added ((1r,3r,5r,7r)-adamantan-2-yl)methyl methanesulfonate (328 mg, 1.34 mmol, 1.20 Eq) and K₂CO₃ (310 mg, 2.24 mmol, 2.00

Eq). The mixture was heated at 70°C for 48 h. The reaction was checked by LCMS. The mixture was concentrated and the residue was dissolved in DCM (10 mL) and H₂O (10 mL). The organic layer was dried over Na₂SO4, filtered and concentrated and purified by prep. TLC (DCM/MeOH=50/1) to give 7-(((1 r,3r,5r,7r)-adamantan-2-yl)methyl)-3-propyl- [1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (9.00 mg, 2.46% yield). ¹H NMR (CDCI3 400MHz): δ 6.90 (d, J=6.0 Hz, 1 H), 6.64 (d, J=6.0 Hz, 1 H), 4.10 (d, J=8.0 Hz, 2 H), 2.95 (t, J=7.2 Hz, 2 H), 2.17 - 2.10 (m, 1 H), 2.05 - 2.00 (m, 2 H), 1.93 - 1.84 (m, 6 H), 1.75 - 1.64 (m, 6 H), 1.61 -1.59 (m, 2 H), 1.06 (t, J=7.2 Hz, 3 H). LC-MS: t_R = 2.26 min (METHOD 4), m/z = 327.2 [M + H]⁺.

Example 69

7-(((3r,5r,7r)-adamantan-1-yl)methyl)-3-propyl-[1 ^^triazolo^S-aJpyrazin-SiyHJone:

Step 1: To a cooled (0°C) solution of ((3r,5r,7r)-adamantan-1-yl)methanol (250 mg, 1.50 mmol) in DCM (10 mL) was added Et₃N (304 mg, 3.01 mmol) and MsCI (207 mg, 1.80 mmol). The mixture was stirred at 0°C for 1 h. The reaction was checked by TLC. Water (5 mL) was added to the mixture. The organic layer was dried over Na₂SO4, filtered and concentrated to give ((3r,5r,7r)-adamantan-1-yl)methyl methanesulfonate (350 mg, 95.49% yield).

Step 2: To a suspension of 3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (160 mg, 897.92 micromol) in DMF (5 mL) was added ((3r,5r,7r)-adamantan-1-yl)methyl methanesulfonate (263 mg, 1.08 mmol) and K₂CO₃ (248 mg, 1.80 mmol). The mixture was heated at 100°C for 20 h. The mixture was concentrated and the residue was dissolved in DCM (10 mL) and H₂O (10 mL). The organic layer was dried over Na₂SO₄, filtered and concentrated to give the crude product. The crude product was washed with MeOH (10 mL) to give 7-(((3r,5r,7r)-adamantan-1-yl)methyl)-3-propyl-[1,2,4]triazolo[4,3a]pyrazin-8(7H)-one (51 mg, 17.43% yield). ¹H NMR (CDCI₃ 400MHz): δ 6.85 (d, J=5.6

Hz, 1 H), 6.59 (d, J=Q.Q Hz, 1 H), 3.68 (s, 2 H), 2.96 (t, J=7.2 Hz, 2 H), 2.00 (s, 3 H),

1.94 -1.89 (m, 2 H), 1.72 - 1.63 (m, 12 H), 1.07 (t, J=7.2 Hz, 3 H). LC-MS: t_R = 3.07 min (method 9), m/z = 327.1 [M + H]⁺.

7-((4,4-dimethyIcyclohexyl)methyI)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)one:

To a suspension of 3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (200 mg, 1.12 mmol) in DMF (5 mL) was added 4-(bromomethyl)-1,1-dimethylcyclohexane (276 mg,

1.35 mmol, 1.20 Eq) and K2CO3 (310 mg, 2.24 mmol, 2.00 Eq). The mixture was heated at 60°C for 12 h. The mixture was concentrated and the residue was dissolved in DCM (10 mL) and H₂O (10 mL). The organic layer was dried over Na₂SO₄, filtered and concentrated to give the crude product. The crude product was washed with MeOH (10 mL) to give 7-((4,4-dimethylcyclohexyl)methyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin8(7H)-one (102 mg, 30% yield). ¹H NMR (CDCI₃ 400MHz): δ 6.90 (d, J=6.0 Hz, 1 H),

6.62 (d, J=6.0 Hz, 1 H), 3.83 (d, J=7.2 Hz, 2 H), 2.95 (t, J=7.6 Hz, 2 H), 1.93 - 1.88 (m, 2 H), 1.80-1.70 (m, 1 H), 1.50 -1.42 (m, 2 H), 1.33-1.39 (m, 2 H), 1.25 -1.14 (m, 4 H), 1.06 (t, J=7.6 Hz, 3 H), 0.89 (s, 6 H). LC-MS: t_R = 2.84 min (METHOD 3), m/z =

303.2 [M + H]⁺.

3-propyl-7-(spiro[2.5]octan-6-ylmethyl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one:

Step 1 : To a cooled (0°C) solution of spiro[2.5]octan-6-ylmethanol (200 mg, 1.43 mmol) in DCM (10 mL) was added Et₃N (289 mg, 2.86 mmol) and MsCI (197 mg, 1.72 mmol). The mixture was stirred at 0°C for 1 hr. The reaction was checked by TLC. Water (5 mL) was added to the mixture. The organic layer was dried over Na2SO4, filtered and concentrated to give spiro[2.5]octan-6-ylmethyl methanesulfonate (310 mg, 99.3% yield) as a light yellow oil.

Step 2: To a suspension of 3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (200 mg,

1.12 mmol) in DMF (5 mL) was added spiro[2.5]octan-6-ylmethyl methanesulfonate (293 mg, 1.34 mmol) and K₂CO₃ (310 mg, 2.24 mmol). The mixture was heated at 60°C for 12 h. The mixture was concentrated and the residue was dissolved in DCM (10 mL) and H₂O (10 mL). The organic layer was dried over Na₂SO4, filtered and concentrated to give the crude product. The crude product was washed with MeOH (10 mL) to give 3propyl-7-(spiro[2.5]octan-6-ylmethyl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (90 mg, 27% yield). ¹H NMR (CDCI3 400MHz): δ 6.91 (d, J=6.0 Hz, 1 H), 6.63 (d, J=6.0 Hz, 1 H), 3.84 (d, J=7.6 Hz, 2 H), 2.95 (t, J=7.6 Hz, 2 H), 1.93 -1.88 (m, 3 H), 1.69 - 1.65 (m, 4 H), 1.25 -1.43 (m, 2 H), 1.06 (t, J=7.6 Hz, 3 H), 0.92 - 0.88 (m, 2 H), 0.29 - 0.26 (m, 2 H), 0.20 - 0.18 (m, 2 H). LC-MS: f_R = 2.71 min (METHOD 3), m/z = 301.2 [M + H]⁺.

Example 72

O

7-((4-methylcyclohexyl)methyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one:

Step 1 : To a cooled (0°C) solution of (4-methylcyclohexyl)methanol (250 mg, 1.95 mmol) in DCM (10 mL) was added TEA (395 mg, 3.90 mmol) and MsCI (268.05 mg, 2.34 mmol). The mixture was stirred at 0°C for 1 hr.. Water (5 mL) was added to the mixture. The organic layer was dried over Na₂SO₄, filtered and concentrated to give (4methylcyclohexyl)methyl methanesulfonate (400 mg, 99% yield) as a light yellow oil.

Step 2: To a suspension of 3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (250 mg, 1.40 mmol) in DMF (5 mL) was added (4-methylcyclohexyl)methyl methanesulfonate (376 mg, 1.82 mmol) and K₂CO₃ (388 mg, 2.81 mmol). The mixture was heated at 60°C for 12 h. The mixture was concentrated and the residue was dissolved in DCM (10 mL) and H₂O (10 mL). The organic layer was dried over Na₂SO₄, filtered and concentrated to give the crude product. The crude product was washed with MeOH (10 mL) to give 7((4-methylcyclohexyl)methyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (69 mg, 17.09% yield). ¹H NMR (CDCI3 400MHz): δ 6.90 (dd, J=6.0, 2.0 Hz, 1 H), 6.62 (t, J=6.0 Hz, 1 H), 3.90 (d, 7=7.6 Hz, 1 H), 3.80 (d, 7=7.2 Hz, 1 H), 2.95 (t, J=7.6 Hz, 2 H), 1.93 -

1.88 (m, 2 H), 1.72 -1.69 (m, 2 H), 1.49 -1.47 (m, 2 H), 1.45 -1.30 (m, 2 H), 1.08 1.04 (m, 5 H), 0.96 - 0.86 (m, 5 H). LC-MS: t_R = 2.70 min (METHOD 3), m/z = 289.2 [M + H]⁺.

The two diastereoisomers, cis and trans, was separated by SFC, to yield 7-(((1 s,4s)-4methylcyclohexyl)methyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one and 7(((1r,4r)-4-methylcyclohexyl)methyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one.

Example 73 o

7-((3-methylcyclohexyl)methyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one:

Step 1: Borane-tetrahydrofuran complex (1 M, 7.03 mL, 2.00 Eq) was added dropwise to a solution of 3-methylcyclohexane-1-carboxylic acid (500 mg, 3.52 mmol) in THF (15 mL) at 0 °C. Then the mixture was heated at 60°C for 12 h. The mixture was cooled to 0°C and MeOH (3 mL) was added dropwise to the mixture. The mixture was concentrated and the residue was purified by flash chromatography on silica gel (petroleumsether/ethyl acetate =50/1-10/1) to give (3-methylcyclohexyl)methanol (440 mg, 97.50% yield) as a colorless oil.

Step 2: To a cooled (0°C) solution of (3-methylcyc)ohexyl)methanol (200 mg, 1.56 mmol) in DCM (10 mL) was added Et₃N (316 mg, 3.12 mmol) and MsCI (790 mg, 6.90 mmol). The mixture was stirred at 0°C for 1 h. The reaction was checked by TLC. Water (5 mL) was added to the mixture. The organic layer was dried over Na₂SO₄, filtered and concentrated to give (3-methylcyclohexyl)methyl methanesulfonate (320 mg, 99.43% yield) as a yellow oil.

1.12 mmol) in DMF (5 mL) was added (3-methylcyclohexyl)methyl methanesulfonate (278 mg, 1.35 mmol) and K₂CO₃ (310 mg, 2.24 mmol). The mixture was heated at 60°C ' 10 for 12 h. The mixture was concentrated and the residue was dissolved in DCM (10 mL) and H₂O (10 mL). The organic layer was dried over Na₂SO₄, filtered, concentrated and purified by prep. TLC (DCM/MeOH=50/1 ) to give 7-((3-methylcyclohexyl)methyl)-3propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one as a mixture of cis/trans isomers (119.20 mg, 413 micromol, 36% yield). ¹H NMR (CDCI3 varian 400): δ 6.90 (d, J=5.6 Hz, 1 H),

6.61 (d, J=6.0 Hz, 1 H), 3.91 - 3.84 (m, 0.48 H), 3.76 (d, J=7.6 Hz, 1.52 H), 2.95 (t,

J=7.6 Hz, 2 H), 2.21 - 2.05 (m, 0.2 H), 1.92 -1.84 (m, 3 H), 1.77 -1.70 (m, 1.3 H), 1.62 -

1.45 (m, 1.7 H), 1.41 -1.15 (m, 3 H), 1.04 (t, J=7.6 Hz, 3 H), 0.95-0.85 (m, 5 H), 0.680.65 (m, 0.8 H). LC-MS: f_R = 2.70 min (METHOD 3), m/z = 289.2 [M + H]⁺.

Example 74 o

7-((2-methylcyclohexyl)methyl)-3-propyl-[1,2_J4]triazolo[4,3-a]pyrazin-8(7H)-one:

Step 1 : Borane-tetrahydrofuran complex (1 M, 7.03 mL, 2.00 Eq) was added dropwise to a solution of 3-methylcyclohexane-1 -carboxylic acid (500.00 mg, 3.52 mmol, 1.00

Eq) in THF (15 mL) at 0 °C. Then the mixture was heated at 60°C for 12 h. The mixture 25 was cooled to 0°C and MeOH (3 mL) was added dropwise to the mixture. The mixture was concentrated and the residue was purified by flash chromatography on silica gel (PE/EA=50/1~10/1) to give (3-methylcyclohexyl)methanol (440 mg, 97% yield).

Step 2: To a cooled (0°C) solution of (3-methylcyclohexyl)methanol (200 mg, 1.56 mmol) in DCM (5 mL) was added Et₃N (316 mg, 3.12 mmol) and methanesulfonyl chloride (214 mg, 1.87 mmol). The mixture was stirred at 0°C for 1 h. The reaction was checked by TLC. Water (5 mL) was added to the mixture. The organic layer was dried over Na₂SO4, filtered and concentrated to give (2-methylcyclohexyl)methyl methanesulfonate (320 mg, 99% yield).

1.12 mmol) in DMF (5 mL) was added (2-methylcyclohexyl)methyl methanesulfonate (277 mg, 1.34 mmol) and K₂CO₃ (310 mg, 2.24 mmol). The mixture was heated at 60°C for 12 h. The mixture was concentrated and the residue was dissolved in DCM (10 mL) and H₂O (10 mL). The organic layer was dried over Na₂SO₄, filtered, concentrated and purified by prep-TLC (DCM/MeOH=50/1) to give 7-((2-methylcyclohexyl)methyl)-3propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one as a mixture of cis/trans isomers (89 mg, 27.68% yield). ¹H NMR (CDCI3 varian 400): δ 6.87 - 6.83 (m, 1 H), 6.60 - 6.53 (m, 1 H),

4.12 - 4.07 (m, 0.3 H), 3.92 - 3.85 (m, 0.1 H), 3.81 - 3.77 (m, 1.3 H), 3.68 - 3.64 (m, 0.3 H), 2.89 (t, J=7.2 Hz, 2 H), 1.96 - 0.91 (m, 18 H). LC-MS: f_R = 2.66 min (METHOD 3), m/z = 289.2 [M + H]⁺.

Example 75:

7-((1-methylcyclohexyl)methyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one:

To a suspension of 3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (200 mg, 1.12 mmol) in DMF (5 mL) was added 1-(bromomethyl)-1-methylcyclohexane (257 mg, 1.34 mmol) and K₂CO₃ (310 mg, 2.24 mmol). The mixture was heated at 100°C for 20 h. The mixture was concentrated and the residue was dissolved in DCM (10 mL) and H₂O (10 mL). The organic layer was dried over Na₂SO4, filtered and concentrated to give the crude product. The crude product was washed with MeOH (10 mL) to give 7-((1methylcyclohexyl)methyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (36 mg, 10.99% yield). ¹H NMR (CDCI3 400MHz): δ 6.86 (d, J=6.4 Hz, 1 H), 6.63 (d, J=6.0 Hz,

H), 3.84 (s, 2 H), 2.95 (t, J=7.6 Hz, 2 H), 1.94 -1.88 (m, 2 H), 1.60 - 1.56 (m, 5 H),

1.46 - 1.38 (m, 5 H), 1.06 (t, J=7.6 Hz, 3 H), 0.99 (s, 3 H). LC-MS: f_R = 2.66 min (METHOD 3), m/z = 289.2 [M + H]⁺.

7-((4-fluorocyclohexyl)methyl)-3-propyI-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one:

Step 1: Borane-tetrahydrofuran complex (1 M, 4.11 mL, 2.00 Eq) was added dropwise to a solution of 4-fluorocyclohexane-1 -carboxylic acid (300 mg, 2.05 mmol) in THF (15 mL) at 0°C. Then the mixture was heated at 60°C for 12 h. The mixture was cooled to 0°C and MeOH (3 mL) was added dropwise to the mixture. The mixture was concentrated and the residue was purified by flash chromatography on silica gel (PE/EA=50/1 ~5/1 ) to give (4-fluorocyclohexyl)methanol (200 mg, 73.81% yield) as a colorless oil.

Step 2: To a cooled (0°C) solution of (4-fluorocyclohexyl)methanol 2 (200 mg, 1.51 mmol) in DCM (10 mL) was added TEA (306 mg, 3.03 mmol) and MsCI (208 mg, 1.82 mmol). The mixture was stirred at 0°C for 1 h. The reaction was checked by TLC. Water (5 mL) was added to the mixture. The organic layer was dried over Na₂SO₄, filtered and concentrated to give (4-fluorocyclohexyl)methyl methanesulfonate (310 mg, 97.64% yield) as a yellow oil.

Step 3: To a suspension of 3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (190 mg, 1.07 mmol) in DMF (10 mL) was added (4-fluorocyclohexyl)methyl methanesulfonate (269 mg, 1.28 mmol) and K₂CO₃ (295 mg, 2.13 mmol). The mixture was heated at 60°C for 12 h. The mixture was concentrated and the residue was dissolved in DCM (10 mL) and H₂O (10 mL). The organic layer was dried over Na₂SO₄, filtered and concentrated to give the crude product. The crude product was washed with MeOH (10 mL) to give 7((4-fluorocyclohexyl)methyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one as a mixture of cis/trans isomers (62 mg, 19.88% yield). ¹H NMR (CDCI3 400MHz): δ 6.92

100 (app. dd, J=6.0, 8.8 Hz, 1 H), 6.61 (app. dd, J=4.0, 6.0 Hz, 1 H), 4.90 - 4.78 (m, 0.5 H),

4.58 - 4.40 (m, 0.5 H), 3.81 (t, J=7.2 Hz, 2 H), 2.96 (t, J=7.6 Hz, 2 H), 2.18 -1.75 (m, 4 H), 1.63 -1.41 (m, 6 H), 1.20 -1.09 (m, 1 H), 1.06 (t, J=7.2 Hz, 3 H). LC-MS: f_R = 2.26 min (METHOD 3), m/z = 293.2 [M + H]⁺.

Example 77 o

7-((4,4-difluorocyclohexyl)methyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one:

Step 1 : To a cooled (0°C) solution of (4,4-difluorocyclohexyl)methanol (200 mg, 1.33 mmol) in DCM (10 mL) was added TEA (270 mg, 2.66 mmol) and MsCI (183 mg, 1.60 mmol). The mixture was stirred at 0°C for 1 h. The reaction was checked by TLC. Water (5 mL) was added to the mixture. The organic layer was dried over Na₂SO₄, filtered and concentrated to give (4,4-difluorocyclohexyl)methyl methanesulfonate (300 mg, 98.82% yield).

1.12 mmol) in DMF (5 mL) was added (4,4-difluorocyclohexyl)methyl methanesulfonate (307 mg, 1.35 mmol) and K₂CO₃ (310 mg, 2.24 mmol). The mixture was heated at 60°C for 12 h. The mixture was concentrated and the residue was dissolved in DCM (10 mL) and H₂O (10 mL). The organic layer was dried over Na₂SO₄, filtered and concentrated to give the crude product. The crude product was washed with MeOH (10 mL) to give 7((4,4-difluorocyclohexyl)methyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (28 mg, 7.94% yield). ¹H NMR (CDCI3 400MHz): δ 6.93 (d, J=6.0 Hz, 1 H), 6.62 (d, J=6.0 Hz, 1 H), 3.85 (d, J=7.6 Hz, 2 H), 2.96 (t, J=7.6 Hz, 2 H), 2.16 - 2.11 (m, 3 H), 1.93 -

1.88 (m, 2 H), 1.79 - 1.62 (m, 4 H), 1.42 -1.38 (m, 2 H), 1.06 (t, J=7.6 Hz, 3 H). LC-MS: t_R = 2.83 min (method 8), m/z = 311.0 [M + H]⁺.

Example 78

101 ο

6-([1,r-biphenyl]-4-ylmethyl)-7-(cyclohexylmethyl)-3-(tetrahydro-2H-pyran-4-yl)- [1.2.4] triazolo[4,3-a]pyrazin-8(7H)-one:

Step 1: 6-bromo-8-methoxy-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3-a]pyrazine (225 mg, 0.719 mmol) and Bis(di-tert-butyl(4dimethylaminophenyl)phosphine)dichloropalladium(ll) (A-taPhos)₂PdCl2 (90 mg, 0.127 mmol) was dissolved in anhydrous THF (8800 mg, 10 ml, 122 mmol) under argon and degassed for 20 min. ([1,T-biphenyl]-4-ylmethyl)zinc(ll) chloride (4.31 ml, 2.156 mmol, 0.5 molar, THF) was added dropwise and the reaction was stirred ovemight. The reaction mixture was poured into aq. sat. NH4CI (10 mL) and extracted with ethyl acetate (20 mL). The water phase was re-extracted with ethyl acetate (10 mL), and the combined organic phases were washed with brine and evaporated to dryness. The crude product was purified with column chromatography (heptane to ethyl acetate) to yield 6-([1 ,T-biphenyl]-4-ylmethyl)-8-methoxy-3-(tetrahydro-2H-pyran-4-yl)- [1.2.4] triazolo[4,3-a]pyrazine (232 mg, 0.579 mmol, 81%) as a solid. LC-MS: t_R = 0.79 min (méthode 5), m/z = 401.1 [M + H]⁺.

Step 2: 6-([1,T-biphenyl]-4-ylmethyl)-8-methoxy-3-(tetrahydro-2H-pyran-4-yl)- [1,2,4]triazolo[4,3-a]pyrazine (248 mg, 0.619 mmol) was mixed with HCl (2.333 ml, 4.67 mmol, 2 molar, H₂O) and MeOH (5544 mg, 7 ml, 173 mmol). The reaction was heated in microwave-oven at 100°C for 20 min. The reaction was concentrated in vacuo. To give crude 6-([1 ,T-biphenyl]-4-ylmethyl)-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3a]pyrazin-8(7H)-one hydrochloride (233 mg, 0.540 mmol, 87 % yield) which was used for next step without further purification.

Step 3: 6-([1 ,T-biphenyl]-4-ylmethyi)-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3a]pyrazin-8(7H)-one hydrochloride (233 mg, 0.540 mmol, 98 %),

102 (bromomethyl)cyclohexane (220 mg, 0.174 ml, 1.244 mmol), Sodium iodide (8.09 mg, 0.054 mmol) and K₂CO₃ (336 mg, 2.428 mmol) was dissolved in DMF (6608 mg, 7 ml, 90 mmol) and stirred at 60°C overnight. The reaction was poured into water, and extracted with ethyl acetate (2two times 10 ml), and concentrated. The crude product was purified by column chromatography (heptane to ethyl acetate) to give 6-([1 ,Tbiphenyl]-4-ylmethyl)-7-(cyclohexylmethyl)-3-(tetrahydro-2H-pyran-4-yl)- [1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (80 mg, 0.164 mmol, 30%). ¹H NMR (600 MHz, CDCI₃) δ 7.61 - 7.55 (m, 4 H), 7.46 (t, J = 7.7 Hz, 2 H), 7.37 (s, 1 H), 7.23 (d, J = 8.3 Hz, 2 H), 6.85 (s, 1 H), 4.13 - 4.07 (m, 2 H), 4.00 (s, 2 H), 3.78 (bs, 2 H), 3.55 (td, J =

11.6,2.2 Hz, 2 H), 3.19 (m, 1 H), 2.23-2.14 (m, 2 H), 1.95 (m, 3 H), 1.81 -1.75 (m, 2 H), 1.75 - 1.70 (m, 3 H), 1.65 (d, J = 12.0 Hz, 2 H), 1.16 (d, J = 8.3 Hz, 2 H), 1.06 (s, 1H). LC-MS: t_R = 0.89 min (méthode 5), m/z = 483.3 [M + H]⁺.

Example 79

6-methyl-7-((4-methylcyclohexyl)methyl)-3-(tetrahydro-2H-pyran-4-yl)- [1,2,4]ίπ3ζοΙο[4,3-3]ρνΓ3ζΙη-8(7Η)-οηβ, stereoisomer 1 and 2.:

To a suspension of 3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (250 mg, 1.40 mmol) in DMF (5 mL) will be added (4-methylcyclohexyl)methyl methanesulfonate (376 mg, 1.82 mmol) and K₂CO₃ (388 mg, 2.81 mmol). The mixture will be heated at 60°C for 12 h. The mixture will be concentrated and the residue will be dissolved in DCM (10 mL) and H₂O (10 mL). The organic layer will be dried over Na₂SO4, filtered and concentrated to give the crude product. The crude product will be washed with MeOH (10 mL) to give 6-methyl-7-((4-methylcyclohexyl)methyl)-3(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one. The two stereoisomers will be separated by SFC.

Example 80

103

7-((4>methoxycyclohexyl)methyl)-6-methyl-3-(tetrahydro-2H-pyran-4-yl)- [1₅2,4]triazolo[4₅3-a]pyrazin-8(7H)-one, stereoisomer 1 and 2:

To a suspension of 3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (250 mg, 1.40 mmol) in DMF (5 mL) will be added (4-methoxycyclohexyl)methyl methanesulfonate (376 mg, 1.82 mmol) and K2CO3 (388 mg, 2.81 mmol). The mixture will be heated at 60°C for 12 h. The mixture will be concentrated and the residue will be dissolved in DCM (10 mL) and H₂O (10 mL). The organic layer will be dried over Na₂SO4, filtered and concentrated to give the crude product. The crude product will be washed with MeOH (10 mL) to give 6-methyl-7-((4-methylcyclohexyl)methyl)-3(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one. The two stereoisomers will be separated by SFC.

6-methyl-7-((4-methylcyclohexyl)methyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin8(7H)-one, stereoisomer 1 and 2.:

To a suspension of 3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (250 mg, 1.40 mmol) in DMF (5 mL) will be added (4-methylcyclohexyl)methyl methanesulfonate (376 mg, 1.82 mmol) and K₂CO₃ (388 mg, 2.81 mmol). The mixture will be heated at 60°C for

h. The mixture will be concentrated and the residue will be dissolved in DCM (10 mL) and H₂O (10 mL). The organic layer will be dried over Na₂SO4, filtered and concentrated to give the crude product. The crude product will be washed with MeOH (10 mL) to give

104

6-methyl-7-((4-methylcyclohexyl)methyl)-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3a]pyrazin-8(7H)-one. The two stereoisomers will be separated by SFC.

Example 82

7-((4-methoxycyclohexyl)methyl)-6-methyl-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-

8(7H)-one, stereoisomer 1 and 2:

To a suspension of 3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (250 mg, 1.40 mmol) in DMF (5 mL) will be added (4-methoxycyclohexyl)methyl methanesulfonate (376 mg, 1.82 mmol) and K₂CO₃ (388 mg, 2.81 mmol). The mixture will be heated at 60°C for 12 h. The mixture will be concentrated and the residue will be dissolved in

DCM (10 mL) and H₂O (10 mL). The organic layer will be dried over Na₂SO4, filtered and concentrated to give the crude product. The crude product will be washed with MeOH (10 mL)to give 6-methyl-7-((4-methylcyclohexyl)methyl)-3-(tetrahydro-2H-pyran-

4-yl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one. The two stereoisomers will be separated by SFC.

105

7-(4-methoxybenzyl)-6-methyl-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one:

Step 1: To a solution of (4-methoxyphenyl)methanamine (30.00 g, 218.69 mmol) and Et₃N (26.56 g, 262.43mmol) in dry DCM (500 mL) was added ethyl 2-chloro-2oxoacetate (32.84 g, 240.56 mmol) dropwise at 0°C. The mixture was stirred at 0°C for 40 min. The mixture was quenched with H₂O (15 mL), extracted with DCM (10 mL, three times). The combined organics were dried over Na₂SO₄ and concentrated. ethyl

2-((4-methoxybenzyl)amino)-2-oxoacetate (50.00 g, 96% yield) was obtained.

Step 2: To a solution of ethyl 2-((4-methoxybenzyl)amino)-2-oxoacetate (10.00 g, 42.15 mmol) in EtOH (200 mL) was added 1-aminopropan-2-ol (3.80 g, 50.58 mmol). The mixture was heated at 75 °C for 2 hours. The mixture was concentrated under vacuum, washed with n-hexane (150 mL, two times), filtered and dried under vacuum. Λ/1 -(2hydroxypropyl)-A/2-(4-methoxybenzyl)oxalamide (8.70 g, 77% yield) was obtained.

Step 3: To a solution of N1-(2-hydroxypropyl)-N2-(4-methoxybenzyl)oxalamide (5.00 g, 18.78 mmol) in CH₃CN (100 mL) was added trichlororuthenium hydrate (42.33 mg, 187.80 micromol) in H₂O (7.5 mL) and NaBrO₃ (3.12 g, 20.66 mmol) in water (15 mL). The mixture was stirred at 25 °C for 16 hours. Water (250 mL) was added to the mixture and stirred at 25 °C for 2 hours. The mixture was filtered, washed with H₂O (200 mL, three times) and dried under vacuum. /V1-(4-methoxybenzyl)-/V2-(2oxopropyl)oxalamide (3.16 g, 43% yield, 67.67% purity) was obtained.

Step 4: To a solution of N1-(4-methoxybenzyI)-N2-(2-oxopropyl)oxaIamide (3.00 g,

11.35 mmol) in CH₃COOH (10 mL) was added TFA (1.29 g, 11.35 mmol). The mixture was stirred at 140 °C for 4 hours. The mixture was concentrated under vacuum. Brown solid was obtained. H₂O (2 mL) was added to the solid. The mixture was adjusted to pH = 7 by saturated aq. NaHCO₃. The mixture was filtered. The filter cake was washed with

106 water (30 mL, three times) and dried under vacuum. 1-(4-methoxybenzyl)-6-methyl-1,4dihydropyrazine-2,3-dione (2.10 g, 75% yield) was obtained.

Step 5:1-(4-methoxybenzyl)-6-methyl-1,4-dihydropyrazine-2,3-dione (4.50 g, 18.27 mmol) was added to POCl₃ (49.50 g, 322.83 mmol). The mixture was stirred at 26°C for 16 hr. The mixture was concentrated and the residue was poured into water (50 mL). The mixture was adjusted to pH = 7 by sat. aq. NaHCO₃ and extracted with DCM (200 mL, two times). The combined organic layer was washed with H₂O (200 mL), dried over Na₂SO₄, filtered and concentrated. The crude product was purified by flash chromatography on silica gel (5%~50% ethyl acetate in petroleumsether). 3-chloro-1-(4methoxybenzyl)-6-methylpyrazin-2(1 H)-one (3.78 g, 78% yield) was obtained.

Step 6: To a solution of 3-chloro-1-(4-methoxybenzyl)-6-methylpyrazin-2(1H)-one (970.00 mg, 3.66 mmol) in EtOH (15 mL) was added NH₂NH₂ H₂O (1.83 g, 36.60 mmol). The mixture was stirred at 40°C for 16 hours. The mixture was filtered. The filter cake was washed with cold EtOH (10 mL, three times) and dried under vacuum. 3hydrazinyl-1-(4-methoxybenzyl)-6-methylpyrazin-2(1H)-one (760 mg, 79% yield) was obtained.

Step 7: To a solution of 3-hydrazinyl-1-(4-methoxybenzyl)-6-methylpyrazin-2(1H)-one (100 mg, 384.19 micromol) in dry DCM (5 mL) was added butanal (29 mg, 403.40 micromol). The mixture was stirred at 40 °C for 2 hours. The reaction mixture was cooled to 25°C and directly used for the next step.

Step 8: To the solution of crude (E)-3-(2-butylidenehydrazinyl)-1-(4-methoxybenzyl)-6methy)pyrazin-2(1H)-one obtained above was added Phl(OAc)₂ (142 mg, 441.81 micromol). The mixture was stirred at 25 °C for 2 hours. Sat. aq. NaHCO₃ (2 mL) and H₂O (5 mL) was added to the mixture. The mixture was extracted with DCM (10 mL, three times). The combined organic was concentrated under vacuum. The residue was purified by CombiFlash (silica gel, 100% ethyl acetate ). 7-(4-methoxybenzyl)-6methyl-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (47 mg, 38% yield, 97% purity) was obtained. ¹H NMR (CDCI₃ 400MHz): δ 7.18 (d, J = 8.4 Hz, 2H), 6.85 (d, J = 8.0 Hz, 2H), 6.72 (s, 1H), 5.25 (s, 2H), 3.78 (s, 3H), 2.93 (t, J= 7.6 Hz, 2H), 2.27 (s, 3H), 1.92-1.87 (m, 2H), 1.05 (t, J = 7.6 Hz, 3H). LC-MS: f_R = 1.844 min (method 6), m!z = 313.1 [M + H]⁺.

107

Example 84

7-(4-methoxybenzyl)-6-methyI-3-(tetrahydro-2H-pyran-4-yI)-[1,2,4]triazolo[4,3a]pyrazin-8(7H)-one:

Step 1: To a solution of 3-hydrazinyl-1-(4-methoxybenzyl)-6-methylpyrazin-2(1H)-one (600 mg, 2.31 mmol) in DCM (20 mL) was added tetrahydro-2H-pyran-4-carbaldehyde (276 mg, 2.43 mmol). The mixture was stirred at 40 °C for 1.5 hours. The mixture was directly used to the next step.

Step 2: To the reaction mixture obtained above was added Phl(OAc)₂ (71 mg, 220 micromol). The mixture was stirred at 25 °C for 2 hours. H₂O (5 mL) was added to the mixture. The mixture was extracted with DCM (10 mL, three times). The combined organic phases were concentrated under vacuum. The residue was purified by CombiFlash (silica gel, 10% MeOH in DCM ). 7-(4-methoxybenzyl)-6-methyl-3(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one (17.00 mg, 24.69% yield, 98.87% purity) was obtwained. ¹H NMR (CDCI3 400MHz): δ 7.17 (d, J = 8.4 Hz, 2H), 6.84 (d, J = 8.8 Hz, 2H), 6.77 (s, 1H), 5.24 (s, 2H), 4.13 (d, J = 11.6 Hz, 2H), 3.78 (s, 3H), 3.61-3.55 (m, 2H), 2.21-3.16 (m, 1H), 2.27 (s, 3H), 2.20-2.14 (m, 2H), 1.961.93 (m, 2H). LC-MS: t_R = 1.984 min (method 3), m/z = 355.1 [M + H]⁺.

PDE1 INHIBITION ASSAY

PDE1A, PDE1B and PDE1C assays were performed as follows: the assays were performed in 60 pL samples containing a fixed amount ofthe PDE1 enzyml (sufficient to convert 20-25% ofthe cyclic nucléotide substrate), a buffer (50 mM HEPES pH 7.6;

mM MgCI₂; 0.02% Tween20), 0.1 mg/ml BSA, 15 nM tritium labelled cAMP and varying amounts of inhibitors. Reactions were initiated by addition of the cyclic nucléotide substrate, and reactions were allowed to proceed for 1 h at room température before being terminated through mixing with 20 pL (0.2 mg) yttrium silicate

SPA beads (PerkinElmer). The beads were allowed to settle for 1 h in the dark before

108 the plates were counted in a Wallac 1450 Microbeta counter. The measured signais were converted to activity relative to an uninhibited control (100%) and lC₅₀ values were calculated using XIFit (model 205, IDBS).

Claims

Claims

1. A compound having the structure

Ri

Compound (I) wherein n is 0 or 1 ;

Ri is selected from the group consisting of linear or branched C-|-C₈ alkyl, oxetanyl, tetrahydrofuranyl, tetrathydropyranyl and saturated monocyclic C₃-C₈cycloalkyl; or

R! is selected from the group consisting of oxetanyl substituted one or two times with methyl or hydroxy; tetrahydrofuranyl substituted one or two times with methyl or hydroxy; tetrathydropyranyl substituted one or two times with methyl or hydroxy; saturated monocyclic C₃-C₈ cycloalkyl substituted one or two times with methyl or hydroxy; and linear or branched Ci-C₈ alkyl substituted one, two or three times with fluorine; and

R₂ is selected from the group consisting of linear or branched Ci-C₈ alkyl, phenyl, saturated monocyclic C₃-C₈ cycloalkyl, saturated bicyclic C₄-C₁₀cycloalkyl, saturated tricyclic C7-C10 cycloalkyl, oxetanyl, tetrahydrofuranyl and tetrahydropyranyl; or

R₂ is selected from the group consisting of phenyl substituted with a substituent selected from the group consisting of halogen, methyl, difluoromethyl, trifluoromethyl and methoxy; saturated monocyclic C₃-C₈ cycloalkyl, substituted one or two times with substituents selected from the group consisting of fluorine and methyl; and oxetanyl, tetrahydrofuranyl and tetrahydropyranyl, each

110 substituted one or two times with substituents selected from the group consisting of fluorine and methyl;

R₃ is selected from the group consisting of linear or branched C-|-C₄ alkyl, phenyl, substituted phenyl, halogen and tetrahydrofuranyl;

R₄ is selected from the group consisting of linear or branched C-|-C₄ alkyl, halogen, and tetrahydrofuranyl;

and pharmaceutically acceptable acid addition salts of Compound I, racemic mixtures of Compound I, or the corresponding enantiomer and/or optical isomer of Compound I, and polymorphie forms of Compound I as weil as tautomeric forms of Compound I;

with the proviso that compound I is not 1,2,4-Triazolo[4,3-a]pyrazin-8(7H)-one, 7[(4-chlorophenyl)methyl]-3-methyl- (CAS Registry Number: 946270-18-4) or

1,2,4-Triazolo[4,3-a]pyrazin-8(7H)-one, 7-[(4-chlorophenyl)methyl]-3-propyl(CAS Registry Number: 946237-23-6).
2. The compound of claim 1, wherein R-ι is selected from methyl, ethyl, propyl and isopropyl.
3. The compound of claim 1, wherein R₂ is methyl.
4. The compound of claim 1, wherein when R₂ is substituted phenyl, then the substituent is selected from the group consisting of fluorine, chlorine and methoxy.
5. The compound of claim 1 wherein R₂ is phenyl substituted with difluoromethyl or trifluoromethyl.
6. The compound of claim 1, wherein R₂ is adamantyl.
7. The compound of claim 1 wherein R₂ is phenyl substituted with phenyl, fluorine or methyl.
8. The compound of claim 1, wherein the compound is selected from the group consisting of:

3-Propyl-7-((tetrahydro-2H-pyran-3-yl)methyl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)- one, stereoisomer 1

111

3-Propyl-7-((tetrahydro-2H-pyran-3-yl)methyl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)one, stereoîsomer 2

7-(Cyclohexylmethyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one

7-(Cyclopentylmethyl)-3-propyl-[1_!2,4]triazolo[4,3-a]pyrazin-8(7H)-one

3-Propyl-7-((tetrahydro-2H-pyran-4-yl)methyl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)one

7-lsobutyl-3-propyl-[1,2,4]triazoIo[4,3-a]pyrazin-8(7H)-one

7-(Cyclopropylmethyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one

7-Ethyl-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one

7-(Oxetan-3-ylmethyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one

7-(Cycloheptylmethyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one

3-Propyl-7-((tetrahydrofuran-3-yl)methyl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one, stereisomer 1

3-Propyl-7-((tetrahydrofuran-3-yl)methyl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one, stereisomer 2

7-Benzyl-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one

7-(2-Fluorobenzyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one

7-(3-Fluorobenzyl)-3-(tetrahydro-2H-pyran-4-yl)-[1,2_l4]triazolo[4,3-a]pyrazin-8(7H)one

7-(3-Fluorobenzyl)-3-propyl-[1,2_l4]triazolo[4,3-a]pyrazin-8(7H)-one

7-(3-Methylbenzyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one

3-Propyl-7-(4-(trifluoromethyl)benzyl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one

7-(3-Fluorobenzyl)-3-((tetrahydrofuran-3-yl)methyl)-[1,2,4]triazolo[4,3-a]pyrazin8(7H)-one

3-Propyl-7-(2-(trifluoromethyl)benzyl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one

7-(2-Chlorobenzyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one

112

7-(4-Chlorobenzyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one

7-(4-Chlorobenzyl)-3-(tetrahydrofuran-3-yl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one

7-Hexyl-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one

7-(4-Fluorobenzyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one

7-(4-Chlorobenzyl)-3-ethyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one

7-(3-Chlorobenzyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one

7-(4-Methyibenzyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one

7-(2-Methylbenzyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one

3-Cyclopentyl-7-(3-fluorobenzyl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one

7-lsopentyl-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one

3-Cyclopropyl-7-(3-fluorobenzyl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one

3-Cyclohexyl-7-(3-fluorobenzyl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one

7-(3-Fluorobenzyl)-3-(tetrahydro-2H-pyran-2-yl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)one, stereoisomer 1

7-(3-Fluorobenzyl)-3-(tetrahydro-2H-pyran-2-yl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)one, stereoisomer2

7-(3-Fluorobenzyl)-3-(tetrahydrofuran-3-yl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one, stereoisomer 1

7-(3-Fluorobenzyl)-3-(tetrahydrofuran-3-yl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one, stereoisomer 2

7-(3-Fluorobenzyl)-3-(2-fluoroethyl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one

3-(1,1-Difluoroethyl)-7-(3-fluorobenzyl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one

7-(3-Fluorobenzyl)-3-(tetrahydro-2H-pyran-3-yl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)one, stereoisomer 1

7-(3-Fluorobenzyl)-3-(tetrahydro-2H-pyran-3-yl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)one, stereoisomer 2

7-(3-Fluorobenzyl)-3-(tetrahydrofuran-2-yl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one

Stereoisomer 1

113

7-(3-Fluorobenzyl)-3-(tetrahydrofuran-2-yl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one

Stereoisomer 2

7-(3-Fluorobenzyl)-3-((tetrahydrofuran-2-yl)methyl)-[1,2,4]triazolo[4,3-a]pyrazin8(7H)-one, stereoisomer 1

7-(3-Fluorobenzyl)-3-((tetrahydrofuran-2-yl)methyl)-[1,2,4]triazolo[4,3-a]pyrazin8(7H)-one, stereoisomer 2

7-(3-Fluorobenzyl)-3-(2,2,2-trifluoroethyl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one

7-(3-Fluorobenzyl)-3-(oxetan-3-yl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one

7-(3-Fluorobenzyl)-3-(1-fluoroethyl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one, stereoisomer 2

7-(3-Fluorobenzyl)-3-(1-fluoroethyl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one, stereoisomer 1

7-(3-Fluorobenzyl)-3-(heptan-3-yl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one,

7-(3-Fluorobenzyl)-3-((tetrahydrofuran-3-yl)methyl)-[1,2,4]triazolo[4,3-a]pyrazin8(7H)-one, stereoisomer 1

7-(3-Fluorobenzyl)-3-((tetrahydrofuran-3-yl)methyl)-[1,2,4]triazolo[4,3-a]pyrazin8(7H)-one, stereoisomer 2

7-((4,4-Dimethylcyclohexyl)methyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one

7-(Cycloheptylmethyl)-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3-a]pyrazin8(7H)-one

7-(((3r,5r,7r)-Adamantan-1-yl)methyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)one

7-((4-Methylcyclohexyl)methyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one

7-((1-Methylcyclohexyl)methyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one

7-((4,4-Difluorocyclohexyl)methyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one

7-(Cyclopentylmethyl)-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3-a]pyrazin8(7H)-one

7-(Cyclohexylmethyl)-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3-a]pyrazin8(7H)-one

3-Propyl-7-(spiro[2.5]octan-6-ylmethyl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one

114

7-((3-Methylcyclohexyl)methyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one

7-((2-Methylcyclohexyl)methyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one

7-(((1 r,3r,5r,7r)-Adamantan-2-yl)methyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin8(7H)-one

7-((4-Fluorocyclohexyl)methyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one

7-(3-Fluorobenzyl)-3-((1s,4s)-4-hydroxycyclohexyl)-[1,2,4]triazolo[4,3-a]pyrazin8(7H)-one

7-(3-Fluorobenzyl)-3-((1r,4r)-4-hydroxycyclohexyl)-[1,2,4]triazolo[4,3-a]pyrazin8(7H)-one

7-(((1 s,4s)-4-methylcyclohexyl)methyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)one

7-(((1 r,4r)-4-methylcyclohexyl)methyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)one

6-bromo-7-(3-fluorobenzyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one

6-brorno-7-(3-fluorobenzyl)-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3a]pyrazin-8(7H)-one

6-bromo-7-(cyclopentylmethyl)-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3a]pyrazin-8(7H)-one

6-bromo-7-(cyclohexylmethyl)-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3a]pyrazin-8(7H)-one

6-bromo-7-(cycloheptylmethyl)-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3a]pyrazin-8(7H)-one

6- benzyl-7-methyl-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)one

7- (4-methoxybenzyl)-6-methyl-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3a]pyrazin-8(7H)-one

7-(4-methoxybenzyl)-6-methyl-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one

7-((4-methoxycyclohexyl)methyl)-6-methyl-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin8(7H)-one (cis)

7-((4-methoxycyclohexyl)methyl)-6-methyl-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin8(7H)-one (trans)

115

Cis

6-rnethyl-7-((4-rnethylcyclohexyl)rnethyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin8(7H)-one

Trans

6-methyl-7-((4-methylcyclohexyl)methyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin8(7H)-one

Cis-7-((4-methoxycyclohexyl)methyl)-6-methyl-3-(tetrahydro-2H-pyran-4-yl)- [1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one

Trans-7-((4-methoxycyclohexyl)methyl)-6-methyl-3-(tetrahydro-2H-pyran-4-yl)- [1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one

Cis-6-methyl-7-((4-methylcyclohexyl)methyl)-3-(tetrahydro-2H-pyran-4-yl)- [1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one

Trans-6-methyl-7-((4-methylcyclohexyl)methyl)-3-(tetrahydro-2H-pyran-4-yl)- [1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one

6- ([1,T-biphenyl]-4-ylmethyl)-7-(cyclohexylmethyl)-3-(tetrahydro-2H-pyran-4-yl)- [1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one

7- (3-fluorobenzyl)-6-(3-methylbenzyl)-3-(tetrahydro-2H-pyran-4-yl)- [1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one

7-(cyclohexylmethyl)-6-(3-methylbenzyl)-3-(tetrahydro-2H-pyran-4-yl)- [1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one

7-(cyclopentylmethyl)-6-(3-methylbenzyl)-3-(tetrahydro-2H-pyran-4-yl)- [1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one

7-(cycloheptylmethyl)-6-(4-fluorobenzyl)-3-(tetrahydro-2H-pyran-4-yl)- [1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one

6- benzyl-7-(cycloheptylmethyl)-3-(tetrahydro-2H-pyran-4-yl)~[1,2,4]triazolo[4,3a]pyrazin-8(7H)-one

6,7-bis(3-fluorobenzyl)-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3-a]pyrazin8(7H)-one

7- (cyclohexylmethyl)-6-(3-fluorobenzyl)-3-(tetrahydro-2H-pyran-4-yl)- [1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one

7-(cyclopentylmethyl)-6-(3-fluorobenzyl)-3-(tetrahydro-2H-pyran-4-yl)- [1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one

116

7-(3-fluorobenzyl)-6-(4-fluorobenzyl)-3-(tetrahydro-2H-pyran-4-yl)- [1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one

7-(cyclohexylmethyl)-6-(4-fluorobenzyl)-3-(tetrahydro-2H-pyran-4-yl)- [1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one

7-(cyclopentylmethyl)-6-(4-fluorobenzyl)-3-(tetrahydro-2H-pyran-4-yl)- [1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one

7-(cycloheptylmethyl)-6-(2-methylbenzyl)-3-(tetrahydro-2H-pyran-4-yl)- [1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one

7-(cycloheptylmethyl)-6-(4-methylbenzyl)-3-(tetrahydro-2H-pyran-4-yl)- [1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one

7-(cyclohexylmethyl)-6-(4-methylbenzyl)-3-(tetrahydro-2H-pyran-4-yl)- [1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one

7-(cyclopentylmethyl)-6-(4-methylbenzyl)-3-(tetrahydro-2H-pyran-4-yl)- [1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one

7-(cyclohexylmethyl)-6-(2-methylbenzyl)-3-(tetrahydro-2H-pyran-4-yl)- [1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one

7-(cyclopentylmethyl)-6-(2-methylbenzyl)-3-(tetrahydro-2H-pyran-4-yl)[I^AjtriazoIoIRS-aJpyrazin-SCyHj-one

6-benzyl-7-(cyclopentylmethyl)-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3a]pyrazin-8(7H)-one

6- benzyl-7-(cyclohexylmethyl)-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3-

a]pyrazin-8(7H)-one

7- (3-fluorobenzyl)-6-(4-methylbenzyl)-3-(tetrahydro-2H-pyran-4-yl)- [1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one

7-(3-fluorobenzyl)-6-(2-methylbenzyl)-3-(tetrahydro-2H-pyran-4-yl)- [1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one

6- benzyl-7-(4-fluorobenzyl)-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3-

a]pyrazin-8(7H)-one (R)-7-(3-fluorobenzyl)-3-propyl-6-(tetrahydrofuran-3-yl)-[1,2,4]triazolo[4,3a]pyrazin-8(7H)-one (SLy-ÎS-fluorobenzyO-S-propyl-G^tetrahydrofuran-S-ylXI^AltriazoloIRSa]pyrazin-8(7H)-one

7- (3-fluorobenzyl)-6-methyl-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one

117

7-(3-fluorobenzyl)-6-ethyl-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one

6- benzyl-7-(3-fluorobenzyl)-3-(tetrahydro-2H-pyran-4-yl)-[1,2,4]triazolo[4,3a]pyrazin-8(7H)-one (R) -7-(3-fluorobenzyl)-3-propyl-5-(tetrahydrofuran-3-yl)-[1,2,4]triazolo[4,3a]pyrazin-8(7H)-one (S) -7-(3-fluorobenzyl)-3-propyl-5-(tetrahydrofuran-3-yl)-[1,2,4]triazolo[4,3a]pyrazin-8(7H)-one

7- (3-fluorobenzyl)-3-propyl-5-methyl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one

7-(3-fluorobenzyl)-3-propyl-5-ethyl)-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one

5- bromo-7-(3-fluorobenzyl)-3-propyl-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one

6- ([1,T-biphenyl]-4-ylmethyl)-7-(cyclohexylmethyl)-3-(tetrahydro-2H-pyran-4-yl)- [1,2,4]triazolo[4,3-a]pyrazin-8(7H)-one and pharmaceutically acceptable salts thereof.
9. A compound of any one of claims 1 to 8 for use as a medicine.
10. A compound of any one of claims 1 to 8 for use in the treatment of a disease selected from the group consisting of attention-deficit/hyperactivity disorder

5 (ADHD), schizophrenia, cognitive impairment, dépréssion, Parkinson’s disease and Alzheimers disease.
11. A compound of any one of claims 1 to 8 for the préparation of a médicament for use in the treatment of a disease selected from the group consisting of attentiondeficit/hyperactivity disorder (ADHD), schizophrenia, cognitive impairment,

10 dépréssion, Parkinson’s disease and Alzheimers disease.
12. A pharmaceutical composition comprising a therapeutically effective amount of a compound of any one of claims 1 to 8 and one or more pharmaceutically acceptable carriers, diluents and excipients.
13. The pharmaceutical composition of claim 12 for the treatment of a disease

15 selected from the group consisting of attention-deficit/hyperactivity disorder (ADHD), schizophrenia, cognitive impairment, dépréssion, Parkinson’s disease and Alzheimers disease.

118
14. Use of a compound of any of claims 1-8 in the manufacture of a médicament for the treatment of a neurodegenerative disorder, including Alzheimer's Disease, Parkinson’s Disease and Huntington's Disease or for the treatment of a psychiatrie disorder including Attention Déficit hyperactivity Disorder (ADHD), 5 dépréssion, narcolepsy, cognitive impairment and cognitive impairment associated with schizophrenia (CIAS) or a brain disease including restless leg syndrome.